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Abstract 
 
The nuclear matrix (NM) is a fibrogranular network of ribonucleoproteins upon 
which transcriptional complexes and regulatory genomic sequences are 
organized. A hallmark of cancer is the disorganization of nuclear architecture; 
however, the extent to which the NM is involved in malignancy is not well studied. 
 
The RUNX1 and RUNX2 proteins form complexes within the NM to promote 
hematopoiesis and osteoblastogenesis, respectively at the transcriptional level. 
RUNX1 and RUNX2 are both expressed in breast cancer cells (BrCCs); 
however, their genome-wide BrCC functions are unknown. RUNX1 and RUNX2 
activate many tumor suppressor pathways in blood and bone lineages, 
respectively, including attenuation of protein synthesis and cell growth via 
suppression of ribosomal RNA (rRNA) transcription, which appears contrary to 
Runx-expression in highly proliferative BrCCs. To define roles for RUNX1 and 
RUNX2 in BrCC phenotype, we examined the involvement of RUNX1 and 
RUNX2 in rRNA transcription and generated a genome-wide model for RUNX1 
and RUNX2-binding and transcriptional regulation. To validate gene expression 
patterns identified in our screen, we developed a Real-Time qPCR primer design 
program, which allows rapid, high-throughput design of primer pairs (FoxPrimer). 
In BrCCs, RUNX1 and RUNX2 regulate genes that promote invasiveness and do 
vi 
 
not affect rRNA transcription, protein synthesis, or cell growth. We have 
characterized in vitro functions of Runx proteins in BrCCs; however, the 
relationships between Runx expression and diagnostic/prognostic markers of 
breast cancer (BrCa) in patients are not well studied. Immunohistochemical 
detection of RUNX1 and RUNX2 in BrCa tissue microarrays reveals RUNX1 
expression is associated with early, smaller tumors that are ER+ (estrogen 
receptor), HER2+, p53-, and correlated with androgen receptor (AR) expression; 
RUNX2 expression is associated with late-stage, larger tumors that are HER2+. 
These results show that the functions and expression patterns of NM-associated 
RUNX1 and RUNX2 are context-sensitive, which suggests potential disease-
specific roles. 
 
Two functionally disparate genomic sequence types bind to the NM: matrix 
associated regions (MARs) are functionally associated with transcriptional 
repression and scaffold associated regions (SARs) are functionally associated 
with actively expressed genes. It is unknown whether malignant nuclear 
disorganization affects the functions of MARs/SARs in BrCC. We have refined a 
method to isolate nuclear matrix associated DNA (NM-DNA) from a structurally 
preserved NM and applied this protocol to normal mammary epithelial cells and 
BrCCs. To define transcriptional functions for NM-DNA, we developed a 
computational algorithm (PeaksToGenes), which statistically tests the 
vii 
 
associations of experimentally-defined NM-DNA regions and ChIP-seq-defined 
positional enrichment of several histone marks with transcriptome-wide gene 
expression data. In normal mammary epithelial cells, NM-DNA is enriched in both 
MARs and SARs, and the positional enrichment patterns of MARs and SARs are 
strongly associated with gene expression patterns, suggesting functional roles. In 
contrast, the BrCCs are significantly enriched in the silencing mark H3K27me3, 
and the NM-DNA is enriched in MARs and depleted of SARs. The MARs/SARs in 
the BrCCs are only weakly associated with gene expression patterns, suggesting 
that loss of normal DNA-matrix associations accompanies the disease state. Our 
results show that structural preservation of the in situ NM allows isolation of both 
MARs and SARs, and further demonstrate that in a disorganized, cancerous 
nucleus, normal transcriptional functions of NM-DNA are disrupted. 
 
Our studies on nuclear organization in BrCC, show that the disorganized 
phenotype of the cancer cell nucleus is accompanied by deregulated 
transcriptional functions of two constituents of the NM. These results reinforce 
the role of the NM as an important structure-function component of gene 
expression regulation.  
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Research Chapters 
 
CHAPTER 1 INTRODUCTION 
 
General background 
 
The nucleus is the eukaryotic organelle in which genomic DNA is stored, 
replicated, and transcribed (Alberts et al. 2002). Many factors collectively 
regulate the transcription of specific genes, the precise temporal expression of 
which is required for cellular functions such as cell cycle progression, cellular 
homeostasis, and lineage commitment (Lanctôt et al. 2007, Hager et al. 2009). A 
critical mechanism for gene expression regulation is the facultative spatial 
organization of regulatory genomic sequences and transcriptional complexes 
(Zaidi et al. 2007). In diseases such as breast cancer, many of the regulatory 
mechanisms controlling gene expression are impaired, which results from and 
potentiates the disease state (Meaburn et al. 2009, Misteli 2010). In cancer, 
malformed or irregular nuclei are used as diagnostic and prognostic parameters 
of disease. Cancer cell nuclei are often characterized as having “folds” or 
“indentations”. The distribution of heterochromatin is often markedly disrupted in 
cancer cells as compared to normal cells (Zink et al. 2004b). We hypothesize 
that these grossly observed nuclear changes correspond to changes in the 
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spatial organization of transcriptional regulatory complexes and genomic 
sequences. This study is focused on two components that contribute to nuclear 
organization, the nuclear matrix and RUNX proteins, and their functional 
associations with gene expression in breast cancer cells. 
 
Nuclear domains associated with transcription 
 
The diameter of the average human nucleus is approximately 6µm (Alberts et al. 
2002). However, the human genome is approximately 2 meters in length (Lander 
et al. 2001). The length of the genome in relation to the size of the nucleus 
creates a non-trivial space restriction issue. In order to attain sufficient 
compaction to fit into the nucleus, DNA is wrapped around histone octamers and 
further folded into higher-order structures (Li et al. 2007). Genes are 
subsequences of DNA that can be transcribed into RNA and comprise roughly 
1% of the human genome (ENCODE Project Consortium 2011). The small 
percentage of genomic sequence that encodes genes, combined with nuclear 
volume limitations necessitates the organization of genomic DNA such that 
genes are accessible to transcriptional regulators. Further compounding the 
spatial problem, while all cells within an organism have approximately the same 
genomic sequence, not all genes within the genome are expressed in every cell. 
Specific genes, herein referred to as phenotypic genes, are only expressed 
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within certain developmental time frames and in defined cellular lineages (Zaidi 
et al. 2005). Therefore, of the 1% of the human genome encoding genes, only a 
subset of genes are transcriptionally active in a given cell type. One mechanism 
for specification of phenotypic gene expression is coordinated spatial 
organization of genomic sequences and regulatory complexes (Stein et al. 2003, 
Misteli 2007, Hager et al. 2009). Disruption of key components of nuclear 
organization and gene expression regulation often results in developmental 
abnormalities, indicating the importance of nuclear organization as a mechanism 
for cellular phenotype (Alvarez et al. 2000, Melillo et al. 2001, De Sandre-
Giovannoli et al. 2002, Alsheimer et al. 2004, Roshon and Ruley 2005, Frock et 
al. 2006).  
 
At a gross scale, expression of genes can be bisected into two groups based on 
the chromatin environment within and surrounding the genes. Genes organized 
within more compact chromatin structures, referred to as heterochromatin, are 
unlikely to be expressed as these regions are mostly inaccessible to 
transcriptional complexes. Genic regions organized within less compact 
structures, or euchromatin, are permissive for interaction with transcriptional 
complexes and therefore have the potential to be transcribed (Li et al. 2007). 
Heterochromatin and euchromatin occupy spatially distinct regions of the 
nucleus. Light microscopy imaging of cells reveals the nucleus as being 
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organized into three regions: 1) the peripheral heterochromatin, 2) the nucleolus 
(sometimes more than one, depending on cell type), and 3) the euchromatic 
space between the nucleolus and peripheral heterochromatin (Berezney et al. 
1995, Nickerson et al. 1995). Even at this broad scale, patterns in gene 
expression form based on whether a particular gene is localized to the 
euchromatic space, the peripheral heterochromatin, or the nucleolus (Nickerson 
2001). While it is convenient to discuss these nuclear areas as if they are 
separated by a physical barrier, similar to cytoplasmic organelles, it is important 
to make the critical distinction that nuclear organelles, or compartments, are not 
separated by a membrane. Nuclear organelles are defined by the concentration 
of similar structural or functional bodies within the nucleus, not by physical 
separation via a membrane (Dundr and Misteli 2010). 
 
The nucleolus is a specialized nuclear compartment within which the short arms 
of human chromosomes 13, 14, 15, 21, and 22 are localized (Sullivan et al. 
2001). These chromosomal regions contain tandem-arrayed repeats of the gene 
encoding ribosomal RNA (rRNA), which, once processed, forms the major 
catalytic subunit of the ribosome. Specialized proteins, such as RNA Polymerase 
I (Pol I), are concentrated within the nucleolus to drive the transcription of 
ribosomal DNA (rDNA) and processing of pre-rRNA into mature ribosomes 
(McStay and Grummt 2008). The dense concentration of these regulatory factors 
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and ribosomal RNAs causes the visually distinct appearance of the nucleolus, 
which can be observed via light microscopy or staining techniques that 
distinguish between RNA and DNA, such as Papanicolaou stain (Papanicolaou 
and Traut 1997). Ribosomal RNA transcription is the rate limiting step for cellular 
growth and accounts for the majority of a cell’s transcriptional activity (Grummt 
and Voit 2010). Organization and concentration of regulatory factors within the 
nucleolus is essential for the precise regulation of rRNA transcription (Grummt 
2010). 
 
The nucleolus is not the only place where compartmentalization of transcriptional 
functions is observed in the nucleus. Typically, RNA Polymerase II (Pol II) 
transcription of phenotypic genes occurs between the nucleolus and the 
peripheral heterochromatin in the euchromatic space (Herman et al. 1978, 
Jackson and Cook 1985, Jackson et al. 1993, Wansink et al. 1993, Niedojadlo et 
al. 2011). Peripheral heterochromatin is generally transcriptionally silent, with the 
exception of genes within the peripheral heterochromatin proximal to nuclear 
pores that are sometimes observed to be highly expressed in specific instances 
(Mateos-Langerak et al. 2007, Papantonis and Cook 2010). The transcription of 
most phenotypic genes is executed by Pol II in coordination with a multitude of 
regulatory factors, which can be cell cycle, cell type, or developmentally specific 
(Stein et al. 2011). Pol II transcription occurs at a defined number of sites, 
6 
 
primarily within the euchromatic space, which are referred to as transcription 
factories (Jackson et al. 1998, Cook 1999). These transcription factories are 
relatively static in position, and contain a high concentration of transcription 
factors and RNA processing factors (Ghamari et al. 2013). The inclusion of RNA 
processing factors is likely due to the observation that RNA splicing occurs co-
transcriptionally (Xu and Cook 2008).  
 
Similar to the transcription factories, the chromosomes themselves are not free-
floating entities within the nucleus. Chromosomes occupy distinct territories 
relative to one another, which are preserved throughout multiple cell divisions 
(Lanctôt et al. 2007, Geyer et al. 2011). Transcriptionally silent chromosomal 
regions are largely localized to the peripheral regions of the nucleus, while 
transcriptionally active regions of chromosomes are found within the euchromatic 
space (Andrulis et al. 1998). Live cell imaging of genes has demonstrated that 
silent, or non-expressed genes, are quite static within the chromosome territory; 
in contrast, expressed genes are dynamic in their range of movement within the 
chromosome territory (Kosak et al. 2002, Zink et al. 2004a, Hewitt et al. 2004). 
This freedom of motion observed for expressed genes is thought to arise from 
the transient nature of transcription. Genes are typically not constitutively 
expressed; rather they are transcribed in bursts. It has been hypothesized that 
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these transient events occur concurrently with the movement of a gene into a 
transcription factory (Deng et al. 2012).  
 
It is thought that transcription factors regulate genes by binding to cis-elements 
such as promoters and enhancers (Ong and Corces 2011, Spitz and Furlong 
2012). Yet, this model may not fully explain how genes are recruited to 
transcription factories. The average gene length in the human genome is 
approximately 3,000 base pairs, which is similar to the average length of a gene 
in a simpler organism like Drosophila melanogaster (modENCODE Consortium 
et al. 2010, ENCODE Project Consortium 2011). A major difference between 
less-complex organisms and humans is the variance in gene length. Human 
genes (and many other mammals) can be tens to hundreds of kilobase pairs in 
length. Transcription factors typically bind a sequence of DNA that is roughly 10 
bases in length (Wang et al. 2012). It seems unlikely that a single binding event 
would be sufficient to drive a stable interaction between a gene that may be 
several kilobase pairs in length and a transcription factory. It is therefore more 
likely that a combination of binding events, driven by multiple DNA-binding 
factors, promotes the recruitment of a gene to the transcription factory. This idea 
is consistent with the observations that gene promoters can be occupied by 
multiple DNA-binding proteins and their cognate co-factors to regulate gene 
transcription (Lian et al. 2006). One recent study has demonstrated that, in the 
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case of longer genes, multiple interactions can be observed between the gene 
body and the transcription factory. These binding events result in multiple sub-
loop structures forming while the gene is being actively transcribed (Larkin et al. 
2012). How these DNA-binding proteins are concentrated within transcription 
factories and the binding events required for recruitment of a genic sequence to 
transcription factories are active areas of research that are likely to provide key 
insight into the regulation phenotypic gene expression.  
 
Observation and isolation of the nuclear matrix 
 
Early light microscopic images of mammalian cells defined the nucleus as dense 
chromatin and nucleoli suspended in transparent “nuclear sap” or karyolymph 
(Fawcett 1966). Use of the term karylomph implied that everything within that 
area was randomly diffusing throughout the nucleus. Thin sectioning of cells 
combined with electron microscopy allowed observation of two distinct nuclear 
structures containing genomic DNA: the previously observed densely-stained 
compacted heterochromatin and the less compact euchromatin (Nickerson et al. 
1995). Electron microscopic imaging of regressive EDTA-stained embedded thin 
sections revealed a fibrogranular network of RNPs between the densely-stained 
heterochromatin (Monneron and Bernhard 1969, Bernhard 1969, Fakan and 
Bernhard 1971). This fibrogranular network of RNPs is highly associated with 
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active transcription, as it is largely comprised of newly-synthesized pre-mRNAs 
(Bachellerie et al. 1975, Fakan and Nobis 1978, Fakan and Hughes 1989). This 
observed network of perichromatin fibrils has been defined as the “in situ nuclear 
matrix” (Berezney 1984). 
 
Berezney and Coffey isolated and characterized the nuclear matrix from rat liver 
tissue (Berezney and Coffey 1974, 1977). The previously observed in situ 
nuclear matrix can be isolated from nuclei through nuclease digestion followed by 
high salt and detergent extraction. The residual fraction maintains the 
ultrastructural and biochemical properties of the intact perichromatin fibrils. When 
histones are extracted from chromosomes, genomic DNA extends outward from 
the nuclear matrix in long (up to 100Kbp) loops (Cook and Brazell 1975, 1980, 
Benyajati and Worcel 1976, Paulson and Laemmli 1977, Marsden and Laemmli 
1979, Vogelstein et al. 1980). These observations of genomic DNA being 
tethered to the nuclear matrix at the bases of loops were very exciting and 
suggested that the nuclear matrix may play a major role in the architectural 
organization of nuclear bodies. Experimental approaches centered on the 
nuclear matrix found that many critical nuclear activities and the factors executing 
these functions are associated with the nuclear matrix. These functions include 
but are not limited to replication (Dijkwel et al. 1986, Velden and Wanka 1987, 
Tubo and Berezney 1987), DNA looping attachment sites (Gasser and Laemmli 
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1987), and transcription (Feldman and Nevins 1983, Lewis and Lebkowski 1984, 
Zehnbauer and Vogelstein 1985, van Wijnen et al. 1993). In the case of 
transcription, the number of nuclear matrix fibrils correlates with transcriptional 
activity, which supports the idea that the nuclear matrix plays a major role in 
transcriptional regulation (Petrov and Sekeris 1971). 
 
DNA associated with the nuclear matrix 
 
To understand the mechanisms by which the nuclear matrix organizes DNA into 
loops and how these binding events are associated with nuclear functions, many 
experimental approaches were designed to isolate and characterize DNA 
sequences associated with the nuclear matrix. The two most commonly used 
techniques for isolation of matrix-associated DNA rely upon similar approaches in 
which histones are extracted and non-matrix-associated DNA is removed via 
nuclease digestion (Nickerson et al. 1995). Histones are solubilized and removed 
via high concentrations of sodium chloride or the chaotropic agent and detergent 
lithium 3,5-diiodosalicylate (LiS); the residual structures after extraction are 
referred to as the nuclear matrix and the nuclear scaffold, respectively (Berezney 
and Coffey 1977, Mirkovitch et al. 1984). DNA regions isolated via sodium 
chloride or LiS are therefore referred to as matrix-associated regions (MARs) and 
scaffold-associated regions (SARs), respectively. However, because the 
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experimental approach and residual structure are similar, these approaches were 
considered interchangeable and the matrix-associated sequences were referred 
to as S/MARs (Boulikas 1995). These genomic regions attached to the nuclear 
matrix have been observed in the introns of genes, as well as within both 
proximal and distal regions flanking gene bodies (Mirkovitch et al. 1987, 
Georgiev et al. 1991, Boulikas 1995). Both cell-type and developmental time 
point differences in matrix-associated DNA near genes have been observed 
(Dworetzky et al. 1992, Bidwell et al. 1993, 1994, van Wijnen et al. 1993), so it is 
therefore critical to understand how these matrix-attachment events are 
regulated and how these genomic regions contribute to phenotypic gene 
expression regulation when associated with the nuclear matrix. 
 
S/MARs are proposed to have common sequence-based elements. There is not 
a consensus sequence motif for S/MARs in the traditional sense of a 
transcription factor motif; rather S/MARs share a set of biophysical features. Most 
commonly, S/MARs are characterized by sequences that allow for bending or 
curving of DNA, inverted repeat regions, and stretches of AT bases (Boulikas 
1995). The AT-rich S/MARs are well-characterized in terms of how frequently 
these sequences are experimentally observed to be associated with the nuclear 
matrix and in terms of the identification of proteins that preferentially bind to AT-
rich sequences. These AT-rich regions also have a unique physical property in 
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their ability to unwind under torsional stress, and have been referred to as base 
unpairing regions (BURs) (Bode et al. 1992). Proteins such as: heterogeneous 
nuclear ribonucleoprotein U (HNRNPU) (also known as scaffold attachment 
factor A (SAF-A)), special AT-rich sequence binding protein 1 (SATB1), and high 
mobility group AT-hook 1 (HMGIY) are localized within the nuclear matrix and 
bind to AT-rich S/MARs (Bode et al. 1992, Dickinson et al. 1992, Fackelmayer et 
al. 1994, Belle et al. 1998, Liu et al. 1999). These proteins bind S/MARs and 
organize genomic DNA to promote the expression of genes. SATB1 is 
particularly interesting in that it normally functions to organize and regulate the 
expression of cytokine genes in thymocytes (Cai et al. 2006). However, when 
ectopically expressed in breast cancer cells, SATB1 promotes tumor 
progression, invasion and metastasis (Han et al. 2008). The observation that the 
transcriptional role of a S/MAR-binding protein, such as SATB1, can be cell-type 
dependent suggests that unknown factors may contribute to which S/MARs are 
available for binding. 
 
RUNX proteins in development and breast cancer 
 
Runt-related transcription factors (RUNX1, RUNX2, and RUNX3) are a family of 
proteins that share a DNA-binding domain (Runt), which is highly conserved in 
Homo sapiens, Mus musculus, Rattus norvegicus, Caenorhabditis elegans, and 
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Drosophila melanogaster (Kagoshima et al. 1993, van Wijnen et al. 2004). Runx1 
is required for definitive hematopoiesis (Wang et al. 1996) and Runx2 is required 
for osseous development (Komori et al. 1997). Genetic ablation of either Runx1 
or Runx2 results in embryonic or post-natal death, respectively (Wang et al. 
1996, Komori et al. 1997). Runx3 appears to play roles in gut and neuronal 
development. However, due to conflicting phenotypes for independently 
developed Runx3-null mouse models of development, the predominant 
developmental role of Runx3 is unclear (Levanon et al. 2003). This dissertation is 
focused on the transcriptional roles of RUNX1 and RUNX2 in breast cancer, and 
will not focus on the functions of RUNX3. 
 
While the DNA-binding domain of RUNX proteins is found near the N-terminus, 
RUNX proteins also share a unique C-terminal domain called the nuclear matrix 
targeting sequence (NMTS), which is conserved in mammals (Zeng et al. 1997, 
1998, Tang et al. 1999). Runx2 (previously known as NMP-2) was identified as a 
nuclear matrix-specific protein that binds to and regulates the osteocalcin 
(Bglap2) promoter during osteoblast differentiation, which suggested that nuclear 
matrix targeting of RUNX proteins may be important for function (Bidwell et al. 
1993, Merriman et al. 1995). Genetic insertion of a stop codon in Runx1 or 
Runx2, before the C-terminal portion containing the NMTS results in 
developmental phenocopies of the corresponding null models (Choi et al. 2001, 
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Dowdy et al. 2010). Cell-based studies have further demonstrated the 
importance of RUNX protein targeting to the nuclear matrix in the transcriptional 
regulation of phenotypic genes (Zaidi et al. 2001, 2006, Vradii et al. 2005). The 
functional and developmental abnormalities observed when RUNX proteins lack 
the NMTS domain indicate that targeting to the nuclear matrix is essential for the 
fidelity of RUNX protein function. 
 
RUNX proteins have been described as both oncogenes and tumor suppressors, 
depending on the cellular context (Cameron and Neil 2004, Pratap et al. 2010, 
Chimge and Frenkel 2012). Traditionally, RUNX1 has been classified as a tumor 
suppressor due to the frequency of mutations and translocations of RUNX1 in 
lymphomas (Song et al. 1999, Li et al. 1999, Miething et al. 2007, De Braekeleer 
et al. 2009, Mangan and Speck 2011). There is also evidence to suggest that 
ectopic or increased RUNX1 protein expression promotes the development of 
certain cancers such as epithelial tumors, endometrial cancer, and acute 
lymphoid leukemia (Niini et al. 2000, Harewood et al. 2003, Planagumà et al. 
2004, 2011, Abal et al. 2006, Planaguma et al. 2006, Doll et al. 2009, Hoi et al. 
2010). RUNX1 is expressed in the epithelial cells of normal mammary glands 
(Blyth et al. 2010, Wang et al. 2011a, Janes 2011). In breast cancer, RUNX1: 1) 
appears to function primarily as a tumor suppressor protein as mutations in 
RUNX1 are frequently observed in patients (The Cancer Genome Atlas Network 
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2012), 2) RUNX1 transcript levels are significantly decreased in patients with 
metastatic breast cancer (Ramaswamy et al. 2003), and 3) in cell-based models 
of breast cancer development, the RUNX1 gene locus is deleted during 
oncogenic transformation (Kadota et al. 2010). RUNX2 suppresses the growth of 
proliferating osteoblasts, and it has been suggested that in this context, RUNX2 
can function as a tumor suppressor (Pratap et al. 2003, Galindo et al. 2005, 
Young et al. 2007b). Similarly, RUNX1 regulates the growth of hematopoietic 
cells (Bakshi et al. 2008); RUNX proteins bind to rDNA repeats and regulate the 
transcription of rRNA, which is the rate-limiting step in protein synthesis and cell 
growth (Grummt and Voit 2010). Although RUNX2 appears to inhibit osteoblastic 
cell growth, in multiple cancer types such as lymphoma, osteosarcoma, colon, 
pancreatic and prostate, increased RUNX2 levels are associated with the 
disease state, indicating that RUNX2 is likely functioning in an oncogenic manner 
within these cellular lineages (Stewart et al. 1997, Vaillant et al. 1999, Blyth et al. 
2006, Kayed et al. 2007, Kuo et al. 2009, Akech et al. 2010, Sase et al. 2012). In 
normal mammary epithelial cells, low levels of RUNX2 can be detected, and a 
role for regulating milk production has been proposed (Inman and Shore 2003, 
Shore 2005). In breast cancer patients, detection of RUNX2 is associated with 
poor prognosis and clinical outcome, and in cell-based experiments, RUNX2 
promotes the invasive and osteolytic properties of bone metastatic breast cancer 
cells (Pratap et al. 2008, Das et al. 2009, Onodera et al. 2010). These 
observations, taken together, suggest that RUNX1 may function as a breast 
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cancer tumor suppressor, while RUNX2 may function as a breast cancer 
oncogene; however, the roles of RUNX1 and RUNX2 in breast cancer 
development have not been directly compared. 
 
In breast cancer cells, RUNX2 is associated with the nuclear matrix. Runx2 
targeting to the nuclear matrix is required for the Runx2-dependent transcription 
of genes responsible for the osteomimetic and bone resorptive phenotype of the 
MDA-MB-231 breast cancer cells (Barnes et al. 2004, Javed et al. 2005). A 
commonly observed translocation event in acute myeloid leukemia between 
chromosome 8 and 21, t(8;21), results in a fusion protein with the N-terminus of 
RUNX1 (including the Runt DNA-binding domain) and ETO. The AML-ETO 
fusion protein interacts with the nuclear matrix, however, the subnuclear 
distribution of AML-ETO is distinct from the distribution of normal RUNX1 
expressed from the wild-type RUNX1 allele (Barseguian et al. 2002).Although the 
predominant roles for RUNX1 and RUNX2 in tumorigenesis appear to differ, 
these observations demonstrate the importance of proper subnuclear targeting to 
the nuclear matrix for the execution of these RUNX-dependent functions. 
 
Expression of a nuclear matrix-associated protein in cancer cells is often 
clinically relevant, and is not unique to RUNX proteins. For example, B23 is a 
nucleolar protein associated with the nuclear matrix that is highly expressed in 
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prostate cancer (Subong et al. 1999). A nuclear matrix-specific variant of Ciz1, 
which normally interacts with and regulates the localization of p21, promotes cell 
growth in vitro, and is sufficient to identify early stage lung cancer (Higgins et al. 
2012). NMP-22 is expressed in bladder cancer and is used to detect bladder 
cancer in patients (Soloway et al. 1996, Shariat et al. 2004, Zink et al. 2004b). 
Understanding the functions of nuclear matrix-associated proteins that are 
expressed in cancer cells, such as RUNX proteins, may lead to novel means of 
diagnosis and/or treatment. 
 
There have been no studies to date analyzing the functions of ectopically-
expressed RUNX proteins in breast cancer cells on a genome-wide scale. This is 
a critical point, as most of the previous studies that have focused on the role of 
RUNX2 in human breast cancer cells have relied on overexpression of wild-type 
or mutant Mus musculus Runx2 (Barnes et al. 2004, Javed et al. 2005, Pratap et 
al. 2008, Chimge et al. 2011). We are primarily interested in defining the native 
relationships between matrix-associated factors like RUNX proteins and the 
regulation of gene expression. Therefore, an approach in which RUNX proteins 
are depleted via RNAi was deemed preferable to overexpression for studying the 
functional contributions of RUNX proteins to the invasive phenotype of breast 
cancer cells. 
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In studies of Asian breast cancer patients, expression of RUNX2 was found to be 
associated with poor clinical outcome and estrogen receptor (ER) negative 
hormone status (Das et al. 2009, Onodera et al. 2010). To date, RUNX1 
expression in breast cancer patients has not been examined histologically on a 
broad scale. Detection of RUNX1 has been characterized by The Human Protein 
Atlas in limited samples where no clinical inferences can be drawn; in these 
studies, RUNX1 is observed to be strongly expressed in both normal and tumor 
samples (Uhlén et al. 2005, Pontèn et al. 2008, Uhlen et al. 2010). It is therefore 
of great interest to understand the functions of ectopic RUNX proteins in breast 
cancer cells and the extent to which RUNX expression is associated with breast 
cancer patient tissue samples. 
 
Controversial transcriptional associations of matrix-associated DNA 
 
Many studies investigating the transcriptional role of DNA associated with the 
insoluble matrix/scaffold have experimentally prepared “nuclear halos” before 
digestion of looped (or non-matrix-associated) DNA (Adachi et al. 1989, Gerdes 
et al. 1994, Maya-Mendoza and Aranda-Anzaldo 2003, Ostermeier et al. 2003, 
Heng et al. 2004, Keaton et al. 2011). While SARs and MARs have previously 
been described interchangeably, some recent studies have begun to make 
functional distinctions between these two classes of matrix-associated DNA and 
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their associations with transcription. Technical improvements in the ability to 
quantitatively measure specific sequences of nucleic acids in a high-throughput 
manner appear to be driving a reinvestment of effort into understanding the 
transcriptional associations of matrix-associated DNA. Isolation of the matrix-
associated DNA using LiS buffer reveals a positive correlation between gene 
expression and association of upstream genomic elements with the nuclear 
matrix (Linnemann et al. 2007, Keaton et al. 2011). These observations are 
similar to what was previously observed in smaller-scale or non-gene-specific 
experiments (Herman et al. 1978, Ciejek et al. 1983, Jost and Seldran 1984, 
Jackson and Cook 1985, Cook 1989, Ogata 1990, Jackson et al. 1993, Wansink 
et al. 1993). In contrast, when high concentrations of sodium chloride are used to 
extract chromatin prior to nuclease digestion, a strong correlation between 
proximity to the nuclear matrix and gene silencing can be observed (Maya-
Mendoza and Aranda-Anzaldo 2003, Rivera-Mulia and Aranda-Anzaldo 2010, 
Trevilla-García and Aranda-Anzaldo 2011). In these studies, proximity to the 
nuclear matrix is measured by site-specific PCR of DNA associated with the 
nuclear matrix following timed digestion with DNAse I. These observations that 
proximity to the nuclear matrix correlates with gene silencing are in stark contrast 
with many previous studies demonstrating that the nuclear matrix is the site of 
active transcription. In an attempt to reconcile these observed transcriptional 
associations for matrix-associated DNA isolated via LiS or sodium chloride, 
Linnemann and colleagues performed both isolation methods in parallel, followed 
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by hybridization of matrix-associated sequences to a chromosome-wide 
oligonucleotide array (Linnemann et al. 2008). In this study, to differentiate 
between the two extraction methods, sequences isolated via sodium chloride or 
LiS were referred to by the original descriptions of the structures isolated, MARs 
and SARs, respectively. Genome-wide transcript levels were measured by an 
Affymetrix cDNA array, and compared to the chromosome-wide profile of matrix-
associated DNA isolated by sodium chloride or LiS. Here, it was observed that 
enrichment of sodium chloride-isolated MARs within genes is negatively 
correlated with gene expression, while enrichment of LiS-isolated SARs in 
upstream genomic elements is positively correlated with gene expression. The 
positions of MARs and SARs were also different; SARs were typically observed 
5’ of genes and in gene-rich regions, while MARs were typically in gene-poor 
regions or within a silenced gene body. The Linnemann study is the only large-
scale study comparing quantitative positional measurements of matrix-associated 
DNA and gene expression between the two isolation methods. It is, however, not 
the first study to compare the isolation methods. Belgrader and colleagues 
performed a rigorous analysis of the structural and biochemical differences 
between nuclear matrices isolated via sodium chloride and LiS (Belgrader et al. 
1991). This comparative study also included the more gentle isolation of the 
nuclear matrix using low concentrations of ammonium sulfate. They observed 
gross differences in the ultrastructural preservation of the residual nuclear matrix 
following extraction via these three methods. Matrices isolated via sodium 
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chloride had non-apparent nucleoli and a high degree of aggregate-like 
structures bound to the fibrogranular nuclear matrix. When the nuclear matrix 
was isolated using LiS, the nucleolus was visible, but diffuse in appearance; LiS-
isolated nuclear matrices had fewer aggregates than sodium chloride-isolated 
nuclear matrices, but these aggregates were still frequently observed. Nuclear 
matrices isolated via ammonium sulfate, have extremely well-preserved nucleoli, 
and very few, if any, aggregates form on the filamentous matrix structure. It has 
been proposed the studying structural components of the nucleus requires the 
preservation of structure to the highest degree possible (Jackson and Cook 
1995, Nickerson 2001). The generation of data via approaches that best 
recapitulate the physiological states of intact biological systems is critical for our 
understanding of changes in phenotypic gene expression regulation. It is 
possible that the matrix-associated DNA may contain artifacts or may be missing 
information when isolated via techniques that do not preserve the structural 
integrity of the nuclear matrix. We hypothesize that isolation of matrix-associated 
DNA in a manner that preserves the architectural integrity of the nuclear matrix 
will provide a high level of insight into the native interactions between 
chromosomes and the nuclear matrix. Applying this approach at a genome-wide 
scale to compare gene expression profiles and matrix-associated DNA profiles 
from normal and cancer cells will therefore allow for quantitative investigation into 
the role of the nuclear matrix in transcriptional regulation of phenotypic gene 
expression. 
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General question to be addressed 
 
Cancer cell nuclei are generally disorganized. Are components of the nuclear 
matrix and associated DNA segments similarly disorganized? If so how do these 
observations relate to transcriptional functions? 
 
Specific questions to be experimentally addressed 
 
Is genomic DNA associated with the nuclear matrix enriched in particular 
sequences or regions? Does the pattern of matrix-associated DNA correlate with 
the enrichment of euchromatin or heterochromatin? How does enrichment of 
matrix-associated DNA compare to gene expression patterns? Are there 
differences in matrix-associated DNA between a normal mammary epithelial cell 
and a malignant metastatic breast cancer cell? 
 
In blood and bone cells, RUNX proteins control cell growth and proliferation 
through the attenuation of protein synthesis via transcriptional regulation of 
ribosomal RNA (Young et al. 2007a, Bakshi et al. 2008, Ali et al. 2010, 2012). 
Breast cancer cells are highly proliferative in the presence of RUNX1 and 
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RUNX2 proteins. Are the mechanisms of Runx-mediated growth regulation 
operative in breast cancer cells? What genes are regulated by RUNX proteins in 
a breast cancer cell? Where, in the genome, are RUNX proteins binding in breast 
cancer cells? To what extent are these binding events associated with gene 
expression regulation? 
 
RUNX1 and RUNX2 are expressed in breast cancer cell lines, what is their 
expression pattern in tumor tissue from breast cancer patients? Is the expression 
level of RUNX1 or RUNX2 in human breast cancer tissue associated with any 
particular type, grade, or stage of breast cancer? Does the presence of growth 
factor or hormone receptors such as HER2, estrogen receptor (ER), 
progesterone receptor (PR), or androgen receptor (AR) affect the expression 
intensity of RUNX1 or RUNX2 in tissue from human breast cancer? 
 
Experimental design 
 
To understand functional relationships between parameters of nuclear 
organization and gene expression regulation, we examined DNA sequences 
associated with the nuclear matrix in normal breast epithelial cells compared to 
metastatic breast cancer cells. To address this question we developed and 
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describe a method for the isolation of nuclear matrix-associated DNA (NM-Seq) 
that preserves nuclear integrity. NM-seq utilizes next-generation sequencing to 
facilitate a genome-wide unbiased comparison between matrix-associated DNA 
in normal mammary epithelial cells (MCF10a) and malignant metastatic breast 
cancer cells (MDA-MB-231). Structure-function relationships between gene 
expression patterns and nuclear organization are defined by comparing the 
profiles of matrix-associated DNA in MCF10a and MDA-MB-231 cells with the 
binding profiles of several histone modifications (H3K4me3, H3K27me3, and 
H3K9me2) and with genome-wide transcriptome data. 
 
In this study, we also examine the phenotypic roles of the nuclear matrix-
associated proteins RUNX1 and RUNX2 in MDA-MB-231 malignant metastatic 
breast cancer cells. We examine the extent to which RUNX proteins regulate cell 
growth through the transcriptional regulation of ribosomal RNA. On a genome-
wide scale, we define the genes responsive to RUNX protein levels by knocking 
down endogenous RUNX proteins. We further characterize RUNX proteins in 
breast cancer cells by comparing RUNX binding on a genome-wide scale with 
gene expression patterns to establish positional relationships for functional 
binding of RUNX proteins. To understand potential clinical impacts of these in 
vitro findings, we examine the expression of RUNX1 and RUNX2 in tumor tissue 
from more than 125 North American breast cancer patients using 
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immunohistochemistry and compare the detected levels of RUNX proteins with 
several histopathological markers of breast cancer as well as the 
growth/hormone receptors HER2, ER, PR, and AR. 
 
We describe two open-source software packages that were specifically 
developed to assist in the understanding of general parameters of nuclear 
organization. FoxPrimer is a Real-Time qPCR primer design tool and database 
with a web interface. FoxPrimer is designed for high-throughput creation, 
storage, and retrieval of high quality primers for the validation of omics-type 
datasets. FoxPrimer was used to validate gene expression data for Runx-
regulated genes in breast cancer cells. PeaksToGenes is a command-line 
interface program designed to create average gene plots and run statistical tests 
to define associative patterns in binding of nuclear features near genes. 
PeaksToGenes was used to model regulatory binding events for both matrix-
associated DNA and Runx proteins. 
  
26 
 
 
 
 
 
 
 
 
CHAPTER 2 ISOLATION AND CHARACTERIZATION OF NUCLEAR MATRIX 
ASSOCIATED DNA IN BREAST CANCER CELL LINES 
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Introduction 
 
Our understanding of how genomic DNA is organized within the nucleus of a 
eukaryotic cell has increased dramatically in recent years with the advent of deep 
sequencing technologies and research consortia such as ENCODE (ENCODE 
Project Consortium 2011). One of the most fundamental questions under 
investigation is addressing how higher-order structure of genomic DNA 
participates in gene regulation. 
  
The concept of nuclear organization has evolved through many observations of 
non-random localization of functional regulatory factors in the nucleus (Lanctôt et 
al. 2007, Misteli 2007, Zaidi et al. 2007, Stein et al. 2011). Many critical functional 
activities such as splicing, transcription, replication, DNA repair and RNA 
processing are associated with a nuclear structural scaffold comprised of a 
fibrogranular network of RNPs, the ‘nuclear matrix’ (Berezney et al. 1995, 
Nickerson 2001). While the nuclear matrix is associated with many nuclear 
functions, this study is focused on transcription and the spatial relationships of 
genes and transcription with the nuclear matrix. 
 
The nuclear matrix is a filamentous structure of RNPs (Fey et al. 1986). Using 
regressive EDTA staining, this network of RNPs can be observed in intact cells 
by electron microscopy (Monneron and Bernhard 1969, Bernhard 1969). The 
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nuclear matrix, associated proteins and DNA can be biochemically isolated using 
a variety of methods such as high salt extraction and nuclease digestion 
(Berezney and Coffey 1977), low salt 3,5-diiodosalicylic acid, lithium salt (LiS) 
buffer extraction followed by nuclease digestion (Mirkovitch et al. 1984), 
electroelution of intact nuclei (Jackson and Cook 1988), or a more “gentle” 
nuclease digestion and salt extraction procedure (Fey et al. 1986, He et al. 
1990). Common to all approaches is the digestion of DNA and extraction of 
soluble chromatin resulting in the isolation of a residual nuclear matrix.  
 
Transcription occurs at distinct foci or transcription factories within the nucleus, 
which are associated with the nuclear matrix (Jackson and Cook 1985, Jackson 
et al. 1993, 1998). Transcription factors such as RNA Pol II, co-factors, or lineage 
specific transcriptional regulators are similarly organized into transcription 
factories within which actively transcribed genes are localized (Stein et al. 2011). 
DNA-bound proteins such as topoisomerase or transcription factors such as 
hormone receptors or SATB1 recruit DNA to the nuclear matrix in a sequence-
specific manner (Van Steensel et al. 1991, Dworetzky et al. 1992, Dickinson et 
al. 1992, van Wijnen et al. 1993). Identifying genomic sequencing enriched in 
these transcription factories may provide insight into novel matrix-associated 
proteins functioning to recruit genes to transcription factories. It was 
hypothesized that computational methods may be able to predict DNA 
associated with the nuclear matrix based on a consensus sequence (Boulikas 
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1995, Singh et al. 1997), however, recent experimental approaches have 
demonstrated that the sequences of DNA associated with the nuclear matrix do 
not appear to have a conserved sequence motif (Wilson and Coverley 2013). 
These experimental observations are concordant with the growing database of 
specific sequences that are recognized by transcription factors (Heinemeyer et 
al. 1998, Bryne et al. 2008). In the absence of a predictive model for matrix-
associated DNA, these sequences must therefore be experimentally defined for a 
given cell population or physiological state. 
 
To study DNA associated with the nuclear matrix, two common approaches have 
been taken to isolate and identify matrix-associated DNA. Isolation is achieved 
through a step-wise process. First, chromatin is extracted via high salt or LiS 
buffer. This extraction step results in an intermediate “nucleoid” or “nuclear halo” 
structure in which DNA is observed to form loops emanating from a residual 
structure (Keaton et al. 2011, Trevilla-García and Aranda-Anzaldo 2011). It is 
thought that DNA at the base of these loops is matrix-associated DNA (Gasser 
and Laemmli 1987), therefore loop DNA is separated from matrix DNA by cutting 
DNA near the base of the loops with either DNAse I or restriction endonucleases. 
Regions of DNA enriched in association with the nuclear matrix can be measured 
by fluorescent in situ hybridization (FISH) (Gerdes et al. 1994), polymerase chain 
reaction (PCR) (Maya-Mendoza and Aranda-Anzaldo 2003) or more recently by 
hybridization to an oligonucleotide tiling array (Heng et al. 2004). 
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A confusing nomenclature was developed to describe the types of DNA regions 
associated with the nuclear matrix based on the experimental approach used to 
extract chromatin. Isolation via high salt or LiS buffer was described as isolating 
the nuclear matrix or the nuclear scaffold, respectively. Therefore, DNA 
sequences isolated from the nuclear matrix or the nuclear scaffold were referred 
to as matrix associated regions (MARs) and scaffold associated regions (SARs), 
respectively. Initial studies on transcriptional roles for matrix-associated DNA 
were typically focused on a single gene or cluster of genes, and DNA isolated via 
either of these approaches appeared to similarly enriched for transcriptionally 
active genes (Ciejek et al. 1983, Jost and Seldran 1984, Ogata 1990, Gerdes et 
al. 1994). Therefore, the MARs and SARs were considered reasonably 
interchangeable and led to the convention of referring to matrix-associated DNA 
sequences as S/MARs (Nickerson et al. 1995).  
 
Recent PCR-based quantification of matrix-associated DNA of broad gene loci 
such as the albumin locus led Aranda-Anzaldo and colleagues to propose that 
matrix-associated DNA is a transcriptionally repressive element rather than a 
transcriptionally activating element (Maya-Mendoza and Aranda-Anzaldo 2003, 
Rivera-Mulia and Aranda-Anzaldo 2010, Trevilla-García and Aranda-Anzaldo 
2011). These proposed repressive functions for matrix-associated DNA conflict 
with many previous studies indicating that the nuclear matrix-associated DNA is 
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enriched in actively transcribed genes (Herman et al. 1978, Ciejek et al. 1983, 
Jost and Seldran 1984, Jackson and Cook 1985, Cook 1989, Ogata 1990, 
Jackson et al. 1993, Wansink et al. 1993, Gerdes et al. 1994). The advent of 
genomic tiling microarrays allowed for identification of S/MARs on a broad 
chromosome-wide scale (Linnemann et al. 2007, Keaton et al. 2011) and later 
allowed Krawetz and colleagues to make a direct comparison between the 
positions of MARs (isolated via high salt) and SARs (isolated via LiS) and gene 
expression patterns on a broad scale (Linnemann et al. 2008). We are inclined to 
emphasize the results of this approach as this is the only study in which the 
chromosome-wide quantification of matrix-associated DNA isolated via high salt 
or LiS buffer has been compared. Linnemann et al. demonstrate that matrix-
associated DNA sequences isolated via high salt (MARs) are located within the 
gene bodies of poorly or non-expressed genes. In contrast, matrix-associated 
sequences isolated via LiS (SARs) are located 5’ of actively transcribed genes. 
This study suggests that the type of DNA (in relation to transcription) is 
dependent on the isolation method employed. Belgrader et al. examining the 
fibrogranular structure of the nuclear matrix via electron microscopy follow 
multiple extraction methods (Belgrader et al. 1991). High salt extraction resulted 
in a non-apparent nucleolus and a high degree of aggregate structures on the 
matrix fibrils; LiS extraction causes a diffuse nucleolar structure to form and a 
moderate level of aggregate structures. Using a gentler extraction of chromatin 
via ammonium sulfate, Belgrader et al. observed a high degree of nucleolar 
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preservation and few, if any, aggregates on the matrix fibrils. It has been argued 
that methods used to isolate the nuclear matrix should be evaluated by the 
protocol’s ability to preserve the integrity of structures, such as the RNP fibrils, 
which can be observed in the intact nucleus (Nickerson 2001), and we 
hypothesize that characterization of DNA sequences isolated from a structurally 
intact nuclear matrix will allow for a high degree of insight into the functional 
properties of matrix-associated DNA.  
 
To study the association of genomic DNA with the nuclear matrix under 
conditions in which structural integrity is preserved, we have optimized an 
experimental approach for biochemical isolation of the nuclear matrix based on 
the Penman (He et al. 1990, Nickerson et al. 1997, Wan et al. 1999) approach for 
nuclear matrix isolation. The Penman method, as demonstrated by Belgrader et 
al., better preserves the structural organization of the nuclear matrix as 
compared to the high salt and LiS extraction methods. To improve upon previous 
approaches, which quantified matrix-associated DNA via hybridization-based 
arrays, we employed recent technological advances in deep sequencing to study 
the genome-wide patterns of nuclear matrix-associated DNA utilizing long 
(100bp) paired-end sequencing. This method of sequencing gives us a high 
volume of reads as well as a high degree of confidence in the positional mapping 
of reads to the genome. Thus, we can more accurately identify specific 
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sequences enriched in association with the nuclear matrix. We have named this 
method nuclear matrix sequencing (NM-seq). 
 
In cancers, proteins that are specific to the disease state have been identified to 
associate with the nuclear matrix, however, it is not known if genomic sequences 
associated with the nuclear matrix are similarly altered (Getzenberg et al. 1991, 
1996, Partin et al. 1993, Samuel et al. 1997). To understand how matrix-
associated DNA might be involved with a disease such as breast cancer and to 
demonstrate a potential application of NM-seq, we applied our technique of 
isolating nuclear matrix-associated DNA to two breast cell lines: MCF10a 
immortalized normal mammary epithelial cells and MDA-MB-231 mesenchymal-
like metastatic breast cancer cells. 
  
Considering first the non-tumorigenic MCF10a cells, our results demonstrate that 
NM-seq can identify matrix-associated DNA in both gene-rich/actively-transcribed 
regions and gene-poor/weakly-transcribed regions, which suggests we have 
preserved both repressive (MAR) and active (SAR) interactions with the nuclear 
matrix. When comparing the normal and cancer cells, we observed disparate 
patterns of nuclear matrix-associated DNA between the MCF10a and MDA-MB-
231 cells with respect to gene-rich versus gene-poor association and GC content 
of matrix-associated DNA. Integrating gene expression data with matrix-
associated DNA enrichment patterns, we found that matrix-associated DNA is 
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enriched in regions flanking transcribed genes in MCF10a cells, while in MDA-
MB-231 cells poorly or non-expressed gene regions are more associated with the 
nuclear matrix. These results suggest that the malignant metastatic breast 
cancer cell line MDA-MB-231 has major differences in the functional association 
of genomic DNA with the nuclear matrix and in gene expression regulation when 
compared to the normal mammary epithelial cell line MCF10a. 
 
Results 
 
Preparation of nuclear matrix fraction while preserving nuclear structure 
 
Isolation of the nuclear matrix fraction is typically achieved through step-wise 
nuclease digestion and salt extraction (Nickerson 2001). Recent approaches 
used to study matrix-associated DNA (NM-DNA) have biochemically extracted 
the matrix by salt extracting nuclei, making so-called "halo" preparations, 
followed by nuclease digestion (Maya-Mendoza and Aranda-Anzaldo 2003, Heng 
et al. 2004, Linnemann et al. 2007, Rivera-Mulia and Aranda-Anzaldo 2010, 
Keaton et al. 2011, Trevilla-García and Aranda-Anzaldo 2011). Biochemically, 
these types of preparations do isolate the nuclear matrix fraction, but they also 
disrupt nuclear integrity (Belgrader et al. 1991). Structural integrity of the nucleus 
is critical for maintenance of proper DNA-matrix interactions. DNA sequences 
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associated with the nuclear matrix are highly dynamic and subject to dramatic 
changes when nuclei are salt extracted (Craig et al. 1997). Using a stabilization 
reagent, such as copper ion, prevents these salt-induced shifts in matrix-
associated DNA (Belgrader et al. 1991). 
 
Given the highly sensitive nature of DNA-matrix interactions, in an attempt to 
preserve native DNA-matrix interactions we designed a protocol based on 
previous approaches demonstrating a high degree of structural preservation of 
the nuclear matrix. The nuclear matrix can be purified while preserving nuclear 
structure using formaldehyde stabilization prior to nuclease digestion and salt 
extraction (Nickerson et al. 1997). We used this experimental approach as the 
starting point in our experimental optimization to isolate NM-DNA. The procedure 
we developed for isolating the nuclear matrix uses formaldehyde-stabilized 
nuclei, restriction enzyme digestion and high salt extraction (Figure 2.1), and 
preserves both nuclear structure and functional domain localization (Figure 2.2).  
 
After nuclear matrix isolation, formaldehyde stabilization is reversed via 
incubation at 55°C for 16 hours in elution buffer (1% SDS, 100mM Sodium 
bicarbonate), DNA is isolated and randomly sheared via sonication, and finally, 
libraries are prepared for deep sequencing (Figure 2.1 A). To control for biases 
in chromosome copy number, restriction enzyme cut sites, sample preparation 
(size selection and PCR) and sequencing, DNA isolated from digested nuclei 
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prior to salt extraction was used as “Input” control to define enrichment regions 
for NM-DNA. Applying this novel approach to our model cell lines resulted in 
166,861,270 mapped reads and 255,049,970 mapped reads for the MCF10a and 
the MDA-MB-231 NM-DNA samples, respectively. Each mapped read pair 
represents a high-confidence region as it is mapped from long (100bp) paired-
end reads. 
 
During the nuclear matrix isolation procedure, we see a significant extraction 
(>90%) of genomic DNA as measured by DAPI incorporation (Figure 2.2 A). 
Further validating the effectiveness of this protocol to preserve nuclear integrity, 
we also observe that the spatial distribution and staining intensity of several 
matrix-associated proteins (Coilin, NPAT, PML, SC-35, UBF, and Pol II) are 
maintained throughout nuclear matrix isolation (Figure 2.2 B).  
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Figure 2.1 Diagram of nuclear matrix-associated DNA isolation 
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Figure 2.1 Diagram of nuclear matrix-associated DNA isolation 
 
(A) Diagram depicting the workflow of nuclear matrix isolation. (B) 
Representation of matrix-DNA interactions in whole cell/CSK extracted nuclei, 
digested nuclei, and after salt extraction. (C) Legend for symbols/drawings used 
in (B) to represent key components of nuclear organization during isolation of the 
nuclear matrix fraction. 
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Figure 2.2 Nuclear integrity and functional domains remain intact during isolation 
of the nuclear matrix fraction. 
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Figure 2.2 Nuclear integrity and functional domains remain intact during isolation 
of the nuclear matrix fraction. 
 
(A) DIC III phase contrast images and DAPI staining of MDA-MB-231 cells at 
three stages of isolation of nuclear matrix: whole cell, CSK-extracted nuclei 
digested with restriction enzymes, and nuclear matrix. (B) Confocal 
immunofluorescence micrographs of critical nuclear proteins in MCF10a and 
MDA-MB-231 cells after CSK extraction or following full nuclear matrix isolation 
(NMIF). Proteins examined include: Coilin (Cajal bodies / modification of small 
nuclear/nucleolar RNAs), NPAT (nuclear protein, ataxia-telangiectasia locus - 
histone gene transcription), PML (promyelocytic leukemia - PML bodies), SC-35 
(serine/arginine-rich splicing factor 2 - pre-mRNA splicing), UBF (upstream 
binding transcription factor, RNA polymerase I - rRNA transcription), and Pol II 
(RNA polymerase II – mRNA synthesis).  
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Defining enriched regions for nuclear matrix-associated DNA 
 
When performing deep-sequencing for chromatin immunoprecipitation (ChIP-
seq), it is common protocol to define enriched regions for a given pulldown using 
some form of “peak calling” algorithm (Landt et al. 2012). Many of the most 
popular “peak calling” algorithms (MACS (Zhang et al. 2008), SPP (Kharchenko 
et al. 2008), PeakSeq (Rozowsky et al. 2009)) operate on a major assumption: 
enrichment of a single protein will produce a defined genomic interval width from 
which to build a peak-shift model for defining the peak regions. This assumption 
cannot be made when trying to define enriched regions from matrix-associated 
DNA, as isolation of the nuclear matrix enriches for an unknown number of 
proteins associated with DNA in widths of unknown length (Davie 1995, Samuel 
et al. 1997). To address this issue we developed a more direct method of 
defining genomic regions enriched (or depleted) in association with the nuclear 
matrix. At the most basic level, we are examining the ratio of NM-DNA over the 
DNA isolated from the digested nuclei fraction (DigNuc) in specific genomic 
regions defined below. This method of measuring NM-DNA enrichment as the 
ratio of matrix-associated DNA over non-extract DNA is similar to methods 
applied when using genomic-tiling arrays (Linnemann et al. 2007, 2008, Keaton 
et al. 2011). Due to the advantageous genome-wide nature of our approach, the 
DigNuc fraction provides information about regions where genomic sequences 
are over- and under-represented; using this information we can therefore 
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determine how to best scale the ratio of NM-DNA over DigNuc when defining 
enriched regions. We used the sequence enrichment scaling (SES) algorithm, as 
it empirically determines an appropriate scaling factor to be applied to the input 
(DigNuc) channel based on the sorting statistic (Diaz et al. 2012). Briefly, SES 
compares the input (DigNuc) and IP (NM-DNA) reads across the entire genome 
to identify systematic biases caused by the processing samples and deep 
sequencing. These genome-wide biases are weighted and converted into a 
scaling factor, which is then applied when calculating the enrichment of the IP 
(NM-DNA) sample over the input (DigNuc) in a specific region of the genome. 
 
Sequence complexity of nuclear matrix-associated DNA is different between 
MCF10a and MDA-MB-231 cells 
 
Structural matrix-associated DNA elements such as matrix-attachment regions 
(MARs) and scaffold-attachment regions (SARs) are procedurally isolated using 
salt conditions quite different than those we have used in our nuclear matrix 
isolation protocol (Berezney and Coffey 1977, Mirkovitch et al. 1984). Based on a 
comparative study by Linnemann et al. these sequence elements have distinct 
associations with nuclear functions (Linnemann et al. 2008). MARs appear to be 
highly enriched in gene-poor or transcriptionally silent regions, while SARs are 
highly associated with gene-rich, actively-transcribed genomic regions. It is 
thought that each of these element types can be defined by sequence motifs; 
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however, computational efforts have proven not to predict sequences isolated 
from cells (Wilson and Coverley 2013). While the order of operations (salt 
extraction, nuclease digestion) and detergents/salts used affects which type of 
DNA element will be enriched in the matrix fraction, the procedures used to 
isolate the aforementioned sequence elements significantly disrupt nuclear 
structure and organization.  
 
NM-seq preserves the integrity of nuclear organization; we therefore feel it is 
critical to report the sequence complexity of enriched sequences isolated from 
our model cell lines. By partitioning the genome into 200bp non-overlapping 
windows, we calculated the ratio of NM-DNA to DigNuc input (NM-DNA 
enrichment) and the corresponding percent of G plus C bases (GC content) in 
each window. Plotting the pairs of NM-DNA enrichment versus GC content in a 
scatterplot and calculating the Pearson correlation coefficient (r), we observe that 
in MDA-MB-231 cells the regions most associated with the nuclear matrix are 
AT-rich and that GC-content and NM-enrichment are slightly negatively 
correlated (r = -0.24). In the MCF10a cells, we observe that AT/GC content is 
relatively evenly spread across NM-DNA-enriched and NM-DNA-depleted 
regions, with a very weak positive correlation trend (r = 0.12) (Figure 2.3). These 
trends can be further visualized by separating the 200bp non-overlapping 
genomic regions into ten groups based on the rank of the NM-DNA enrichment in 
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the region (1 = most enriched, 10 = least enriched) and plotting the distribution of 
GC percentages for the regions in each group (Figure 2.4). 
 
In the MDA-MB-231 cells (breast cancer cell line), NM-DNA is enriched in AT-
sequences, while for the MCF10a (normal mammary epithelial) cell line, NM-
DNA appears to be AT/GC neutral. In the human genome, genic regions are GC-
rich or GC-neutral, while gene-poor regions are AT-rich (Lander et al. 2001). The 
observed associations of NM-DNA sequence complexity combined with the 
distributions of AT-rich and GC-neutral regions in the human genome suggests 
that NM-DNA may be enriched in different genomic regions within normal cells 
and malignant metastatic cells. 
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Figure 2.3 Nuclear matrix-associated DNA weakly correlates with AT-rich 
sequence in MDA-MB-231 cells, but not in MCF10a cells 
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Figure 2.3 Nuclear matrix associated DNA weakly correlates with AT-rich 
sequence in MDA-MB-231 cells, but not in MCF10a cells 
 
(A and B) Using genome-wide non-overlapping 200bp intervals, nuclear matrix-
associated DNA (NM-DNA) enrichment (NM-DNA / Digested Nuclei) was 
measured in MCF10a cells (A) and MDA-MB-231 cells (B) and is represented on 
the x-axis. For each 200bp interval, the corresponding percent of G plus C bases 
within the interval is plotted as the dependent variable on the y-axis. These x-y 
pairs are plotted for the entire genome using a hexagonal density scatterplot 
where an increased number of shared x-y observations are represented as 
darker hexagons (right panels). Pearson r and p-value were calculated for each 
cell line with the correlation line plotted in red; the Pearson r and p-value are 
indicated in the upper right of the scatterplot for each cell line. 
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Figure 2.4 GC content as a function of nuclear matrix-associated DNA 
enrichment rank shows a similar trend as the scatter plot; matrix-associated DNA 
in GC-neutral in MCF10a cells, and AT-rich in MDA-MB-231 cells. 
 
49 
 
Figure 2.4 GC content as a function of nuclear matrix-associated DNA 
enrichment rank shows a similar trend as the scatter plot; matrix-associated DNA 
in GC-neutral in MCF10a cells, and AT-rich in MDA-MB-231 cells. 
 
(A and B) For each cell line (MCF10a (A) and MDA-MB-231 (B)), the NM-DNA 
enrichment ratios in 200bp genome-wide non-overlapping intervals were 
measured and subdivided into 10 approximately equal groups based on ranks 
(rank 1 = top ~10% NM-DNA enrichment ratios, rank 10 = bottom ~10% NM-DNA 
enrichment ratio). For each of these ranks, the GC content was measured for the 
intervals in each rank (defined by NM-DNA enrichment) and the resultant GC 
distribution was plotted (y-axis) in box and whiskers format. Because there were 
some ties in NM-DNA enrichment ratios, the number of observations of NM-DNA 
enrichment/GC content was slightly different in each column therefore the width 
of the box and whiskers plot reflects the number of observations made. 
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Nuclear matrix-associated DNA is enriched in gene-poor regions in MDA-MB-231 
cells and gene-rich regions in MCF10a cells 
 
We next wanted to understand the positions of NM-DNA isolated from NM-seq 
compare to gene positions. Using the same 200bp windows for measuring GC-
content and NM-DNA, we measured the number of RefSeq genes that are found 
in each 200bp window (Pruitt et al. 2009). This is a greedy definition in which we 
are defining a gene as being within a given 200bp interval if any portion of the 
gene body overlaps with the 200bp interval. In these 200bp non-overlapping 
intervals, we find there are up to three genes within the interval and will refer to 
the number of genes per interval as a class of 200bp intervals. Instead of plotting 
this data as a scatterplot, we instead plotted box and whisker plots of the 
distribution of NM-DNA enrichment values found in each class of 200bp intervals 
for each cell line (Figure 2.5 A). As there are very few regions in the genome in 
which there are two or three genes per 200bp interval, the width of the box and 
whisker plots correlates with the number of 200bp intervals containing 0, 1, 2 or 3 
genes. These box and whisker plots are cropped to show the slight differences in 
the median (horizontal line) NM-DNA enrichment for each class of 200bp interval. 
The tables to the right of each box and whisker plot show the mean NM-DNA 
enrichment value per class of 200bp interval (Figure 2.5 A right).  
 
51 
 
To further investigate where in the genome NM-DNA isolated via NM-seq is 
enriched relative to genes, we used cytologically-defined chromosomal band 
coordinates as regions of interest (Meyer et al. 2013). These bands are 
visualized by Giemsa staining, where the density of genes within each cytological 
band is inversely correlates with the observed intensity of staining, and have 
been used for comparison of hybridization of matrix-associated DNA in a 
previous study (Craig et al. 1997). For each cytological band, we calculated the 
enrichment ratio of NM-DNA to digested nuclei as well as the percentage of the 
cytological band that is defined as a gene by RefSeq (Pruitt et al. 2009). By 
plotting these paired observations per cytological band in a scatter plot and 
calculating the Pearson r, we observe that in MCF10a cells NM-DNA enrichment 
is correlative with gene-dense regions, while in MDA-MB-231 cells NM-DNA 
enrichment is correlated with gene-poor regions (Figure 2.5 B). When the 
relationships between gene-rich and gene-poor are viewed at the resolution of 
cytological bands, there are strong relationships between NM-DNA enrichment 
and gene density, however, when viewed in finer detail (200bp), these trends are 
not readily apparent. This observation suggests that NM-DNA-enrichment 
associations with gene-density are broad and may be involved in mediating 
large-scale organization of genomic DNA. These observations suggest that our 
hypothesis based on differences in sequence complexity that matrix-associated 
DNA in each cell line would be enriched in different genomic locations is correct. 
Observed differences in both sequence complexity and gene-rich versus gene-
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poor association lead us to hypothesize that NM-DNA is likely to be differentially 
associated with transcriptional activities between normal and cancer cell lines. 
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Figure 2.5 Nuclear matrix-associated DNA is broadly associated with gene-rich 
regions in MCF10a cells and with gene-poor regions in MDA-MB-231 cells. On a 
small (200bp) scale, these associations are not observed. 
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Figure 2.5 Nuclear matrix associated DNA is broadly associated with gene-rich 
regions in MCF10a cells and with gene-poor regions in MDA-MB-231 cells. On a 
small (200bp) scale, these associations are not observed. 
 
(A) Box and whisker plots of the distributions of nuclear matrix associated DNA 
(NM-DNA) enrichment (NM-DNA / Digested Nuclei) values (y-axis) plotted based 
on the number of genes found within the corresponding 200bp intervals (x-axis) 
for MCF10a cells (upper panel) and MDA-MB-231 cells (lower panel). The width 
of the box and whisker plots corresponds to the number of times X number of 
genes are found within 200bp intervals in the human genome. Plots are cropped 
on the y-axis to show weak trends for the median values of NM-DNA enrichment 
based on the number of genes in each interval. (B) Scatterplots of percent of 
gene coverage per chromosome band (y-axis) and NM-DNA enrichment per 
chromosome band (x-axis) in MCF10a cells (left panel) and MDA-MB-231 cells 
(middle panel). These x-y pairs are plotted for the entire genome using a 
hexagonal density scatterplot in which an increased number of shared x-y 
observations are represented as darker hexagons (right panel). Pearson r and p-
value was calculated for each cell line with the correlation line plotted in red and 
the Pearson r and p-value in the upper right of the scatterplot for each cell line.  
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Genome-wide associations of nuclear matrix-associated DNA and chromatin 
modifications appears to be different in MDA-MB-231 and MCF10a cells 
 
It is not clear whether NM-DNA is associated with transcription repression or 
transcriptional association (Maya-Mendoza and Aranda-Anzaldo 2003, 
Linnemann et al. 2007, 2008, Alva-Medina et al. 2011, Keaton et al. 2011, 
Trevilla-García and Aranda-Anzaldo 2011). Modifications of histone 3 are 
strongly associated with transcriptional states (Greer and Shi 2012). We 
therefore sought to investigate how NM-DNA isolated via NM-seq is associated 
with several modifications of histone 3 on a genome-wide scale. Positional 
comparison of NM-DNA enrichment and histone enrichment has never been 
executed at genomic resolution, and NM-seq allows for this type of interrogation 
of nuclear architecture. In both the MCF10a and MDA-MB-231 cells, we 
performed ChIP-seq for the histone modifications histone 3 lysine 4 tri-
methylation (H3K4me3), histone 3 lysine 27 tri-methylation (H3K27me3) and 
histone 3 lysine 9 di-methylation (H3K9me2) and compared the genome-wide 
enrichment profiles of these histone modifications to NM-DNA enrichment 
patterns. This approach is designed to give us some idea of the extent to which 
matrix-associated DNA is associated with functionally diverse histone 
modifications using our novel isolation methods. 
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We took two unbiased approaches, k-means clustering and Pearson r 
correlation, to discover potential relationships between genomic enrichment of 
NM-DNA and of these chromatin modifications (Figure 2.6). The enrichment of 
NM-DNA, H3K4me3, H4K27me3, and H3K9me2 in 200bp, non-overlapping 
genome-wide coordinates was measured in both MCF10a and MDA-MB-231 
cells. In (Figure 2.6 A), each row is a 200bp non-overlapping interval in which we 
have measured the enrichment of NM-DNA, H3K9me2, H3K27me3, and 
H3K4me3 in each cell line. The columns correspond to the histone mark or NM-
DNA in each cell line. Once this matrix is constructed, k-means clustering is 
applied to identify patterns in the enrichment of these marks. While clustering of 
the enrichment of the histone marks appears to segregate nicely, it does not 
appear that NM-DNA enrichment patterns are affected by the patterns of 
enrichment of histone 3 modifications (Figure 2.6 A). 
 
We then performed pairwise comparisons between each histone 3 modification 
and NM-DNA enrichment, and present these data as a scatter plot correlation 
matrix (Figure 2.6 B). Along the diagonal from bottom left to top right are the 
names for cell line and sample. The left half of the matrix shows density scatter 
plots of enrichment between the pairs of samples, and the right half of the matrix 
contains the Pearson correlation coefficient (r) between the sample pairs. Here 
we observed that NM-DNA did not correlate with histone 3 modifications within 
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either cell line nor did NM-DNA in MCF10a cells correlate with NM-DNA in MDA-
MB-231 cells. 
 
Combining the observations from both approaches, we find that the enrichment 
patterns of H3K4me3, H3K27me3, and H3K9me2 are very similar across the two 
cell lines (Figure 2.6 A) and each modification is mildly correlated across cell 
lines (Figure 2.6 B). Given previous reports that matrix-associated DNA 
generally lacks nucleosomes (Boulikas 1995), we were surprised to not find 
negative correlations between NM-DNA enrichment and these chromatin marks. 
We observe essentially no correlation (positive or negative) between NM-DNA 
enrichment and these histone marks. This study is the first in which the positional 
enrichment of histone modifications has been directly compared to the positional 
enrichment of matrix-associated DNA on a genome-wide scale, so we suggest 
that, as compared to previous studies, the scale of NM-seq allows for a more 
accurate representation of the positional relationships between histone 3 
modifications and NM-DNA. If matrix-associated DNA were nucleosome-free, 
any location in which a core histone (histone 3) is found should be depleted of 
matrix-associated DNA. This analysis uncovers many locations where a histone 
protein and NM-DNA are enriched, which suggests that NM-DNA is not, as a 
rule, nucleosome-free. We cannot rule out mutual exclusivity in a shared location. 
ChIP-seq and NM-seq are measuring frequencies of interaction between a 
protein and genomic sequence or a genomic sequence and the nuclear matrix, 
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respectively. This analysis demonstrates that there is not a clear relationship 
between the positional enrichments of nuclear matrix and modifications of 
histone 3. 
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Figure 2.6 On a genome-wide scale, nuclear matrix-associated DNA is not 
negatively-correlated with the histone modifications H3K4me3, H3K27me3 and 
H3K9me2 in MDA-MB-231 or MCF10a cells. 
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Figure 2.6 On a genome-wide scale, nuclear matrix-associated DNA is not 
negatively-correlated with the histone modifications H3K4me3, H3K27me3 and 
H3K9me2 in MDA-MB-231 or MCF10a cells 
 
(A) Using genome-wide non-overlapping 200bp intervals, the enrichment of NM-
DNA (NM-DNA / Digested Nuclei), and the enrichment of the histone 
modifications H3K4me3, H3K27me3, and H3K9me2 (IP / Input) were measured 
and plotted as a heat map. Each horizontal row is the same 200bp interval. For 
each nuclear feature measured (columns), the log2 of the enrichment values was 
plotted and then clustered using the k-means expectation-maximization 
algorithm. The color scale for log2(enrichment) is found below the heat map. (B) 
Pairwise matrix of scatterplots comparing the enrichment of each nuclear mark in 
each cell line. Scatterplots (upper left panels) are hexagonal density scatter plots 
where darker dots indicate an increased number of paired x-y observations. 
Pearson r values and p-values were calculated for each pairwise comparison. 
The line of best fit is plotted in red on the scatterplots and the Pearson r and p-
values are displayed in the mirrored panels (bottom left panels). 
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Discriminative motif discovery suggests DNA-binding proteins may participate in 
the context-dependent functions of nuclear matrix-associated DNA 
 
While NM-DNA enrichment in MCF10a and MDA-MB-231 patterns may be 
similar in terms of non-correlation with the histone marks examined, the direct 
comparison of NM-DNA enrichment between MCF10a and MDA-MB-231 cells 
shows no correlation (r = -0.09) (Figure 2.6 B). Although the general trends of 
sequence complexity and correlations between gene-rich versus gene-poor 
enrichment are different between these two cell lines, direct comparison of 
positional enrichment of NM-DNA between these two cell lines shows that there 
are some genomic sequences that are associated with the matrix in both cell 
lines as well as some matrix-associated sequences that are unique to each cell 
line. This observation, combined with our comparative analyses between NM-
DNA enrichment and sequence complexity, as well as associations with gene-
rich versus gene-poor regions, leads us to hypothesize that in each cell line there 
may be different proteins responsible for recruiting DNA to the nuclear matrix. To 
determine what DNA-binding proteins may be responsible for recruitment of DNA 
to the nuclear matrix, we looked at sequence motifs enriched in nuclear matrix-
associated DNA. We defined four types of sequence regions to perform motif 
discovery: most associated with the nuclear matrix in MDA-MB-231 cells and 
least associated with the nuclear matrix in MCF10a cells, most associated with 
the nuclear matrix in MCF10a cells and least associated with the nuclear matrix 
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in MDA-MB-231 cells, least associated with the nuclear matrix in both cell lines, 
and most enriched in both cell lines. We then performed discriminative motif 
discovery on these four sets of genomic intervals to determine which types or 
families of proteins may be responsible for the disparate enrichment patterns of 
matrix-associated DNA between these two cell lines (Figure 2.7). Discriminative 
motif discover takes a set of sequences and compares against a background of 
sequences to discover sequence motifs that are significantly overrepresented in 
the set of target sequences (Heinz et al. 2010). For each category of genomic 
regions, a different set of motifs were found. This suggests that the expression of 
certain DNA-binding proteins may result in the observed differences in NM-DNA. 
It is interesting that a motif similar to the RUNX motif is discovered in the regions 
enriched in NM-DNA in both cell lines, as RUNX proteins are dependent on 
interaction with the nuclear matrix for many functions and have been reported to 
be expressed and functional in both cell lines (Zeng et al. 1997, 1998, Barnes et 
al. 2004, Shore 2005, Kadota et al. 2010). Breast cancer associated 1 (BRCA1), 
whose motif is enriched in MCF10a NM-DNA, associates with the nuclear matrix 
and participates in DNA repair, which takes place on the nuclear matrix (Huber 
and Chodosh 2005). It is not clear what function the v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog (avian) (MAF) family of proteins, a motif 
enriched in NM-DNA-enrichment regions in MDA-MB-231 cells, may have. 
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Figure 2.7 Discriminative motif discovery for sequences most associated with the 
nuclear matrix in MCF10a and MDA-MB-231 cells suggests that cell-type-specific 
proteins may participate in differences in matrix-DNA associations. 
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Figure 2.7 Discriminative motif discovery for sequences most associated with the 
nuclear matrix in MCF10a and MDA-MB-231 cells suggests that cell-type-specific 
proteins may participate in differences in matrix-DNA associations. 
 
Four classes of sequences were defined empirically based on NM-DNA 
enrichment percentiles within MCF10a and MDA-MB-231 cells. Using the paired 
NM-DNA enrichment values and genomic coordinates for the previously defined 
genome-wide non-overlapping 200bp intervals, four categories were defined: 
enriched in both (intervals where NM-DNA enrichment is in the top 10% of each 
cell line), enriched in MCF10a (intervals where NM-DNA enrichment is in the top 
10% in MCF10a cells and bottom 10% in MDA-MB-231 cells), enriched in MDA-
MB-231 (intervals where NM-DNA enrichment is in the top 10% in MDA-MB-231 
cells and bottom 10% in MCF10a cells), and depleted in both (intervals where 
NM-DNA enrichment is in the bottom 10% in both cell lines). The sequence logo 
for each de novo motif and the known motifs to which each discovered motif is 
similar are presented for each of the four classes of NM-DNA enrichment. 
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NM-DNA in MCF10a cells is associated with higher gene expression, while in 
MDA-MB-231 cells NM-DNA is associated with lower gene expression 
 
In MDA-MB-231 and MCF10a cells, we observe opposite trends in NM-DNA 
enrichment with sequence complexity and gene-rich versus gene-poor regions. 
These observations lead us to hypothesize that NM-DNA may be differentially 
associated with gene expression patterns between the normal and cancer cell 
lines. Therefore, we examined the relationships between gene expression and 
NM-DNA enrichment. RNA isolated from each cell line was subjected to 
Affymetrix Human Gene 1.0ST arrays to obtain a quantitative signature of gene 
expression in each cell line. Transcript detection levels were normalized across 
arrays using the robust means algorithm (RMA) (for more details, please see 
methods) (Irizarry et al. 2003). We began with the cytological band level, and 
measured the mean RMA-normalized transcript level for all genes within the 
cytological band and compared these values to the mean NM-DNA enrichment in 
the cytological band. Again, we observed opposite results for the MCF10a and 
MDA-MB-231 cells: in MCF10a cells NM-DNA enrichment is somewhat 
correlated (Pearson r = 0.32) with transcript levels, while in MDA-MB-231 cells 
NM-DNA enrichment is somewhat negatively correlated (Pearson r = -0.32) with 
transcript levels (Figure 2.8). 
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Figure 2.8 Nuclear matrix-associated DNA enrichment correlates with higher 
levels of gene expression in MCF10a cells and with lower levels of genes 
expression in MDA-MB-231 cells. 
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Figure 2.8 Nuclear matrix associated DNA enrichment correlates with higher 
levels of gene expression in MCF10a cells and with lower levels of genes 
expression in MDA-MB-231 cells. 
 
(A and B) For each chromosomal band, the mean RMA-normalized transcript 
detection value (extracted from Affymetrix Human Gene 1.0ST arrays) for all 
genes found within the given chromosomal band was plotted as the y-coordinate 
and the corresponding enrichment of NM-DNA was plotted as the x-coordinate. 
These x-y coordinates were plotted as hexagonal density scatterplots where the 
darker hexagons represent an increased number of shared x-y observations. The 
Pearson r and p-value for MCF10a (A) and MDA-MB-231 (B) were calculated 
and the line was plotted in red over the scatter plots; the Pearson r and p-value 
are indicated in the bottom-right corner of the scatterplot in (A) and the top-right 
corner of the scatterplot in (B).  
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Using a gene-centric approach, NM-DNA is differentially associated with gene 
expression and chromatin states between MCF10a and MDA-MB-231 cells. 
 
As shown in Figure 2.8, NM-DNA is differentially associated with active gene 
expression in the MCF10a and MDA-MB-231 cells. In order to understand how 
NM-DNA enrichment differs at the gene level, we measured the enrichment of 
NM-DNA within 10Kb of all genes in the hg19 RefSeq genome (Pruitt et al. 
2009). We initially clustered these binding patterns to see if genes that are 
differentially expressed between MCF10a and MDA-MB-231 cells have a 
particular pattern of NM-DNA-enrichment, however, no meaningful clusters were 
identified (data not shown). To further define parameters of nuclear organization, 
we performed ChIP-seq for histone H3K9me2, H3K27me3, and H3K4me3. The 
enrichment ratios of these chromatin modifications were combined with the NM-
DNA enrichment data and k-means clustering was performed (Figure 2.9 A). 
 
Given our previous observations, it is expected that we observe very little NM-
DNA enrichment near gene bodies in MDA-MB-231 cells. Similar to the 
observations made in Figure 4.6, the patterns of the chromatin modifications 
(H3K4me3, H3K27me3, and H3K9me2) are even more uniform across cell lines 
at the single gene level. As observed in (Figure 2.6), H3K27me3 is detected at a 
significantly higher level in MDA-MB-231 cells as compared to MCF10a cells at 
both the genome-wide and gene-centric scales. An in vitro comparison of 
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H3K27me3 enrichment in normal (human mammary epithelial cells (HMEC)) and 
breast cancer cells (HCC1954) revealed that H3K27me3 is significantly enriched 
in the cancer cell line as compared to the normal cell line in both genic and 
intergenic regions (Hon et al. 2012). These observations are similar to the 
observations presented here where MDA-MB-231 cells are significantly more 
enriched for H3K27me3 as compared to MCF10a cells in both genic and 
intergenic regions. These cell line studies are in contrast with data observed from 
patient samples where reduction of H3K27me3 is associated with poor patient 
survival (Greer and Shi 2012).  These disparate observations of H3K27me3 
enrichment between patients and derived cell lines may be due to either 
detection methods or cell line derivation, and are not examined in this study.  
 
To investigate whether NM-DNA enrichment near genes may be involved the 
phenotypic differences between MCF10a and MDA-MB-231 cells, we defined 
genes that are differentially expressed between MCF10a and MDA-MB-231 cells. 
The genes that are significantly more or less expressed in each cell line are likely 
to be related to these phenotypic differences between these two cell lines. To 
test whether the genomic regions within and surrounding these differentially 
expressed genes are more or less associated with a pattern of chromatin marks 
and NM-DNA enrichment we used a chi-squared test. For each cluster identified 
by k-means clustering (colors on left of Figure 2.9 A), this test determines the 
extent to which these genes are over or underrepresented. This is done by 
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defining an expected value (based on the distribution (represented as a 
percentage) of all genes within each cluster) and comparing these expected 
values to the observed distribution of genes defined as more expressed in each 
cell line. We can see that the genes more expressed in MCF10a cells are 
primarily found in the purple, pink and brown clusters, while the genes more 
expressed in MDA-MB-231 cells are primarily found in the yellow, red and blue 
clusters. In the MCF10a cells, the yellow, red and blue clusters have increased 
H3K9me2 enrichment compared to the purple, pink and brown clusters, while in 
the MDA-MB-231 cells, the opposite is observed (Figure 2.9 B). In the case of 
NM-DNA, the MCF10a cells show more enrichment flanking the gene bodies in 
the purple, pink and brown clusters compared to the yellow, red and blue 
clusters. However, in the MDA-MB-231 cells there does not appear to be any 
difference in the enrichment pattern of NM-DNA between these groups of 
clusters. In MCF10a cells, the observation that the enrichment pattern of NM-
DNA near genes is related to gene expression suggests that NM-DNA may have 
a functional role in gene expression regulation. In MDA-MB-231 cells, NM-DNA 
enrichment patterns do not appear to be a strongly associated with gene 
expression patterns. These observations lead us to hypothesize that the 
functional role of NM-DNA in gene expression regulation is somehow disrupted in 
the cancer cell line. 
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Figure 2.9 Distinct patterns in the enrichment of NM-DNA and H3K27me3 for 
genes differentially expressed between MDA-MB-231 and MCF10a cells. 
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Figure 2.9 Distinct patterns in the enrichment of NM-DNA and H3K27me3 for 
genes differentially expressed between MDA-MB-231 and MCF10a cells. 
 
(A) For each annotated transcript in RefSeq, the enrichment (NM-DNA / Digested 
Nuclei or IP / Input) of NM-DNA, H3K4me3 (K4me3), H3K27me3 (K27me3) and 
H3K9me2 (K9me2) was measured in 30 defined relative genomic regions: 10Kb 
5’-transcriptional start site (TSS) to the TSS in 1Kb steps, transcription 
termination site (TTS) to 10Kb 3’-TTS in 1Kb steps, and TSS to TTS. These 
enrichment ratios for the relative genomic coordinates were concatenated 
horizontally to combine each nuclear feature from both cell lines so that each 
horizontal row in the heat map represents one RefSeq transcript. The colors on 
the left side of the heat map correspond to clusters discovered by k-means 
expectation maximization. The enrichment ratios were log2-transformed and the 
colors corresponding to the log2-transformed enrichment ratios are found below 
the heat map. (B) Distributions are presented as a percent of total number of 
genes for each of the three gene lists for each cluster identified by k-mean 
clustering. Chi-squared table of the distribution of all genes in RefSeq 
(Expected), genes more expressed in MDA-MB-231 cells (MDA-MB-231 
Observed) and genes more expressed in MCF10a cells (MCF10a Observed).   
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Direct comparison of matrix-associated DNA enrichment with gene expression 
patterns 
 
Because we observed some differences in how NM-DNA and H3K27me3 are 
associated with gene expression patterns between MCF10a and MDA-MB-231 
cells, we directly tested whether these binding profiles are significantly different 
near gene bodies using PeaksToGenes (please see chapter 5 for more complete 
methods description). 
 
Using the internal spike-in controls defined by Affymetrix as negative controls, we 
separated the RefSeq genes in the array into two categories: expressed (greater 
than the mean of the RMA-normalized expression values of the negative control 
probes) and non-expressed (less than or equal to the mean of the RMA-
normalized expression values of the negative control probes). Then, we 
performed the Wilcoxon Rank Sum Test for the observed signal enrichment of 
H3K4me3, H3K27me3, H3K9me2, and NM-DNA in each relative genomic 
window, comparing the expressed genes versus the non-expressed genes.  
 
The histone modification H3K4me3 is associated with transcriptional initiation (Li 
et al. 2007), and in both MCF10a and MDA-MB-231 cells the genes defined as 
expressed are significantly more associated with H3K4me3 in regions proximal to 
the TSS as compared to genes defined as non-expressed (Figure 2.10 A). The 
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repressive histone modification H3K27me3 (Li et al. 2007) is significantly more 
associated with genes defined as non-expressed in both MCF10a and MDA-MB-
231 cells when compared to expressed genes (Figure 2.10 B).  
 
The widely observed functions of H3K4me3 and H3K27me3 combined with their 
strong associations near expressed and non-expressed genes in both cell lines 
suggest that our defining of expressed versus non-expressed genes is valid.  
 
H3K9me2 is thought to be associated with repression (Hawkins et al. 2010), and 
in both MCF10a and MDA-MB-231 cells, enrichment of this chromatin 
modification within the gene body is very strongly associated with non-expressed 
genes (Figure 2.10 C). There is one slight difference, however, in the regions 
flanking the gene bodies: in MDA-MB-231 cells, non-expressed genes are 
significantly more associated with H3K9me2 enrichment, while in MCF10a cells 
there is a much weaker association of H3K9me2 enrichment. This analysis 
provides evidence to suggest that H3K9me2 may be differentially associated with 
gene expression between MCF10a and MDA-MB-231 cells.  
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Figure 2.10 Histone marks linked to transcriptional activation or repression are 
appropriately associated with expressed or non-expressed genes, respectively. 
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Figure 2.10 Histone marks linked to transcriptional activation or repression are 
appropriately associated with expressed or non-expressed genes, respectively. 
 
(A, B, and C) For each annotated transcript in RefSeq, the enrichment (IP / 
Input) of H3K4me3 (A), H3K27me3 (B) and H3K9me2 (C) was measured in 30 
defined relative genomic regions: 10Kb 5’-transcriptional start site (TSS) to the 
TSS in 1Kb steps, transcription termination site (TTS) to 10Kb 3’-TTS in 1Kb 
steps, and TSS to TTS in 10 approximately equal intervals (scaled to 1Kb in 
length). Using a Wilcoxon Rank Sum Test, contrast test types were run to 
contrast genes expressed in a cell line versus genes not expressed in a cell line. 
Lines represent the mean enrichment of the nuclear mark being measured (left y-
axis) in the relative genomic region (x-coordinate) for the set of genes being 
contrasted (color-coded and defined below graphs). Triangles correspond to the 
approximate p-value (95% CI) for the Wilcoxon Rank Sum Test run at each 
relative interval (right y-axis). All panels: MDA-MB-231 (left) and MCF10a (right). 
Error bars are SEM.  
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Comparing NM-DNA enrichment in MCF10a cells near expressed versus non-
expressed genes, we observed that NM-DNA is significantly enriched flanking 
the gene bodies of actively expressed genes (green line) and within the gene 
bodies of non-expressed genes (pink line) (Figure 2.11 A – right). The 
magnitudes of the mean differences between NM-DNA enrichment within 
MCF10a expressed (green) and MCF10a non-expressed (pink) were quite high. 
In regions flanking gene bodies (especially 5’-TSS), the magnitude of the mean 
differences of NM-DNA enrichment near MCF10a expressed (green) and 
MCF10a non-expressed (pink) were not large. However, using p-values 
approximated from the Wilcoxon Rank Sum Test (triangles), we observed that 
these small differences in flanking regions were highly reproducible, and we think 
it is therefore important to understand what these types of matrix-DNA 
interactions may mean.  
 
In MDA-MB-231 cells, NM-DNA was enriched near the TSS of expressed genes 
(blue) and near the TTS and 3’-end of non-expressed (red) genes (Figure 2.11 A 
– left). Compared to the enrichment patterns observed in MCF10a cells (Figure 
2.11 A – right), the mean magnitudes of MDA-MB-231 expressed (blue) and 
MDA-MB-231 non-expressed (red) genes were lower than their respective 
expression counterparts in the MCF10a cells. This is expected given the gene-
poor preferences for NM-DNA enrichment observed in MDA-MB-231 cells. 
Further comparison of these two plots revealed very different patterns in the 
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mean enrichment positions of NM-DNA relative to expressed and non-expressed 
genes. While the magnitude of the mean NM-DNA enrichment within MDA-MB-
231 non-expressed (red line) genes was greater than expressed genes (blue 
line), the p-values associated with these differences were much higher when 
compared to the plots for MCF10a cells. Further inspection revealed differences 
in NM-DNA enrichment within the 5’-end of gene bodies of expressed and non-
expressed genes between MDA-MB-231 and MCF10a cells. In MCF10a cells, 
there was a clear distinction between NM-DNA enrichment within and outside of 
the gene bodies of non-expressed genes (pink line), while in MDA-MB-231 cells 
NM-DNA was only statistically significantly enriched in the 3’-half of gene bodies 
of non-expressed genes (red line). Another major difference between these two 
cell lines was the differences in how NM-DNA was enriched in regions flanking 
expressed and non-expressed genes. In MCF10a cells, some of the most 
significant differences in the enrichment patterns of NM-DNA are observed in 
intergenic regions 5’ of the TSS, in contrast NM-DNA in MDA-MB-231 cells is 
similarly enriched near expressed and non-expressed genes. The one 
consistency between these two cell lines is that NM-DNA enrichment within the 
gene body is associated with lower expression levels, but even that observation 
is weakly conserved in the MDA-MB-231 cells. 
 
When considering genes that are differentially expressed between MCF10a and 
MDA-MB-231 cells for either H3K9me2 (Figure 2.11 B) or NM-DNA (Figure 2.11 
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C), we observe that the trends in association of NM-DNA and H3K9me2 with 
gene expression are even more exaggerated. The genes used for comparison 
were defined using expression data from Affymetrix and a contrast test was 
performed to define genes that are differentially expressed between MCF10a and 
MDA-MB-231 cells. From this test two lists of genes were defined: genes more 
expressed in MCF10a (orange line) cells and genes more expressed in MDA-
MB-231 cells (purple line). When performing the Wilcoxon Rank-Sum Test using 
PeaksToGenes, the background list of genes is the rest of the RefSeq mRNAs 
for each respective list in each cell line (brown line – MDA-MB-231, cyan line – 
MCF10a). In MCF10a, regions flanking the genes expressed more in MCF10a 
cells as compared to MDA-MB-231 (orange line) are significantly enriched in NM-
DNA (Figure 2.11 B – right), and weakly associated with H3K9me2 (Figure 2.11 
C – right) as compared to the rest of the MCF10a transcriptome (cyan line). Both 
H3K9me2 and NM-DNA are enriched within the gene bodies of the rest of the 
MCF10a transcriptome (cyan line) as compared to genes more expressed in 
MCF10a compared to MDA-MB-231 cells (orange line). Comparing the MCF10a 
NM-DNA profiles in (Figure 2.11 C – right) to (Figure 2.11 A – right), we 
observed the p-values associated with the differences in NM-DNA enrichment 
within gene bodies and flanking gene bodies are higher when comparing genes 
more expressed in MCF10a cells to the rest of the MCF10a transcriptome as 
compared to MCF10a expressed versus MCF10a non-expressed genes. Of note 
is the observed magnitude of NM-DNA enrichment in regions flanking genes 
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more expressed in MCF10a cells (orange line) being increased as compared to 
the rest of the MCF10a transcriptome (cyan line) (Figure 2.11 C – right). This 
suggests that in normal cells, regions flanking highly expressed genes have 
increased association with the nuclear matrix. 
 
In MDA-MB-231, the entire region near genes more expressed in MDA-MB-231 
cells as compared to MCF10a (purple line) is significantly depleted in association 
of H3K9me2 as compared to the rest of the MDA-MB-231 transcriptome (brown 
line) (Figure 2.11 B – left). This is different from what is observed in MCF10a 
cells (Figure 2.11 B – right) where we observed that NM-DNA enrichment in 
regions flanking gene bodies of MCF10a more expressed genes (orange line) is 
not significantly different from the enrichment near the rest of the MCF10a 
transcriptome (cyan line). Interestingly, the pattern of 5’ gene body enrichment of 
NM-DNA for MDA-MB-231 expressed genes (blue line) (Figure 2.11 A – left), is 
not observed when comparing genes more expressed in MDA-MB-231 cells 
(purple line) to the rest of the MDA-MB-231 transcriptome (brown line) (Figure 
2.11 C – left). 
 
Consistently observed in both cell lines are the strong associations of both 
H3K9me2 and NM-DNA within the gene bodies of either non-expressed or less-
expressed genes. In terms of matrix-associated DNA, these types of sequences 
would be functionally characterized as MARs (Linnemann et al. 2008). In both 
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cell lines, NM-DNA enrichment near the TSS is associated with expressed 
genes. These types of sequences would be functionally characterized as SARs 
(Linnemann et al. 2008). It is interesting that SARs are also found in regions 
flanking gene bodies of expressed genes, however, this association between 
NM-DNA and gene expression is only observed in the normal mammary 
epithelial cell line MCF10a. These analyses demonstrate the ability of our 
protocol to isolate and enrich for two functional species of DNA associated with 
the nuclear matrix. While these types of matrix-associated DNA have different 
roles in gene expression regulation, analyzing enrichment patterns of matrix-
associated DNA from our protocol in a gene-centric manner allows for unbiased 
categorization of both MARs and SARs. 
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Figure 2.11 Meta-gene analysis reveals significant differences in the associations 
between NM-DNA enrichment and H3K9me2 enrichment and gene expression 
patterns in MDA-MB-231 and MCF10a cells. 
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Figure 2.11 Meta-gene analysis reveals significant differences in the associations 
between NM-DNA enrichment and H3K9me2 enrichment and gene expression 
patterns in MDA-MB-231 and MCF10a cells. 
 
(A, B and C) For each transcript annotated in RefSeq, the enrichment (NM-DNA 
/ Digested Nuclei or IP / Input) of NM-DNA, or H3K9me2 was measured in 30 
defined relative genomic regions: 10Kb 5’-transcriptional start site (TSS) to the 
TSS in 1Kb steps, transcription termination site (TTS) to 10Kb 3’-TTS in 1Kb 
steps, and TSS to TTS in 10 approximately equal intervals (scaled to 1Kb in 
length). Using a Wilcoxon Rank Sum Test, several contrast test types were 
performed: (A) genes expressed in a cell line versus genes not expressed in a 
cell line, (B & C) more expressed in one cell line versus the rest of the 
transcriptome. Lines represent the mean enrichment of the nuclear mark being 
measured (left y-axis) in the relative genomic region (x-coordinate) for the set of 
genes being contrasted (color-coded and defined below graphs). Triangles 
correspond to the approximate p-value (95% CI) for the Wilcoxon Rank Sum Test 
run at each relative interval (right y-axis). All panels: MDA-MB-231 (left) and 
MCF10a (right). Error bars are SEM. 
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Discussion 
 
Here we describe NM-seq, which is a method for the isolation of genomic DNA 
associated with the nuclear matrix in a manner that preserves nuclear integrity. 
When applied to a normal mammary epithelial cell (MCF10a) and a malignant 
metastatic breast cancer cell (MDA-MB-231), we demonstrated that NM-seq was 
capable of isolating sequences that can be characterized as either SARs or 
MARs, based on the positions of these sequences relative to gene expression 
patterns. When viewing the enrichment pattern of NM-DNA on a whole 
chromosome for both MCF10a and MDA-MB-231 cells, we observed that there 
was a somewhat inverse pattern of enrichment (Figure 2.12 A). However, it is 
important to note that the most enriched regions in MDA-MB-231 cells were 
similarly enriched in MCF10a cells (although significantly less than other 
enriched regions in MCF10a cells). This observation, combined with the 
observed massive increases in H3K27me3 enrichment, suggests that MDA-MB-
231 cells are deficient in normal structure-function relationships.  
  
85 
 
Figure 2.12 Chromosome-wide pattern of NM-DNA enrichment in MCF10a and 
MDA-MB-231 cells and model for transcriptional associations in each cell line 
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Figure 2.12 Chromosome-wide pattern of NM-DNA enrichment in MCF10a and 
MDA-MB-231 cells and model for transcriptional associations in each cell line 
 
(A) Circos histogram plot of chromosome 11 NM-DNA enrichment in MDA-MB-
231 cells (blue) and MCF10a cells (orange). Outer ring depicts ranges of Giemsa 
stain positivity per chromosomal band; red = centromeres and telomeres, white 
to black (and intermediate grays) indicate intensity of Giemsa staining (Meyer et 
al. 2013). Inner bars represent gene bodies. (B) Cartoon showing less frequent 
DNA-matrix interactions in MDA-MB-231 cells leading to alterations in gene 
expression.  
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Our results demonstrate that there are major differences in the structure-function 
relationships between a normal mammary epithelial cell line (MCF10a) and a 
malignant metastatic breast cancer cell line (MDA-MB-231). Marked 
reorganization of nuclear heterochromatin is a “hallmark of cancer”, and indicates 
that the cancer cells are fundamentally different from their normal counterparts in 
terms of nuclear organization (Hanahan and Weinberg 2000). While this study is 
limited to two immortalized breast lines, the observed correlations between 
expression of matrix-associated proteins and cancer progression suggests that 
changes in DNA associated with the nuclear matrix would follow suit (Samuel et 
al. 1997, He et al. 2008). We suggest that this study is limited in terms the 
inference of general roles for the associations between nuclear matrix-associated 
DNA and transcriptional states because we have only used two cell lines. This 
study demonstrates a potential application of NM-seq in understanding 
differences between the transcriptional associations of NM-DNA in normal and 
disease-state cells. Integrative combinations of NM-seq with ChIP-seq for 
modifications of histone H3 further demonstrates how NM-seq can be used to 
investigate the relationships between chromatin states and matrix-associated 
DNA.  
 
To further study how matrix-associated DNA may be involved with nuclear 
organization, we propose that the application of NM-seq to several tier 1 
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ENCODE cell lines (ENCODE Project Consortium 2011) would yield great 
insight. There are many nuclear functions known to be enriched in association 
with the nuclear matrix such as replication, transcription, RNA splicing, and DNA 
repair (Nickerson 2001). Because it is likely infeasible for one research group to 
perform the required experiments to investigate all these parameters in one cell 
line, using ENCODE cell lines allows for incorporation of these data without 
having to execute these experiments in house. This same logic can be applied to 
non-ENCODE datasets that are publicly available such as lamin-associated 
domains (LADs) (Guelen et al. 2008, Peric-Hupkes et al. 2010). LADs are 
defined using Lamin B1 that is modified to methylate adenine bases where Lamin 
B1 is bound (Guelen et al. 2008), which utilizes an approach called DNA adenine 
methylation identification (DamID) (Germann and Gaudin 2011). We hypothesize 
that LADs may have a significant overlap with NM-DNA in the same cell line 
because Lamin B1 is a matrix-associated protein and is known to bind S/MARs 
(Ludérus et al. 1992). However, it remains to be seen where these overlaps will 
occur and how the enrichment of NM-DNA within these regions compares to the 
global NM-DNA enrichment profile. 
 
Our motif discovery results suggest that multiple transcription factors may be 
involved in NM-DNA interactions with the nuclear matrix. Runx1 and Runx2 are 
required for definitive hematopoiesis and osteoblast maturation respectively 
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(Wang et al. 1996, Komori et al. 1997). Truncation of the C-terminus (required for 
matrix interaction) of Runx1 or Runx2 results in developmental phenocopies of 
the null phenotype (Choi et al. 2001, Dowdy et al. 2010). We therefore 
investigated the extent to which RUNX1 or RUNX2 (from ChIP-seq in Chapter 3) 
binding is enriched in NM-DNA enriched regions in the MDA-MB-231 cells. 
Although there is no overlap between the datasets beyond what can be 
considered random (data not shown), the development of these experimental 
approaches allows researchers to address these nuclear matrix-centric 
hypotheses in a rapid and thorough manner consistent with the types of -omics 
analyses currently being implemented in a variety of developmental and disease-
specific contexts. 
 
In this limited two cell line approach, we are considering MCF10a normal 
mammary epithelial cells as a model for normal associations between NM-DNA 
and transcriptional activity. In Figure 2.11 A, we observed large differences in 
the magnitude of the mean NM-DNA enrichment within the gene bodies of 
MCF10a expressed (green line) and MCF10a non-expressed (pink line) genes. 
Conversely, we observed small differences in the magnitude of the mean NM-
DNA enrichment in regions flanking the gene bodies of MCF10a expressed 
(green line) and MCF10a non-expressed (pink line) genes. While the observed 
differences in magnitude of NM-DNA enrichment in both gene-centric locations 
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(gene bodies and flanking regions), the p-values from the Wilcoxon Rank Sum 
Test were very similar across all regions. What these p-values are effectively 
saying is that the chances that these observed differences are some kind of 
outlier are very low. A potential mechanism that may explain why we observed 
highly reproducible differences in NM-DNA enrichment in both expressed and 
non-expressed genic regions is the dynamic movement of genes to and from 
transcription factories (Lanctôt et al. 2007, Ronneberger et al. 2008). We must 
first consider that when we are measuring enrichment of NM-DNA, what we are 
really measuring is the frequency with which sequences of DNA are interacting 
with the nuclear matrix. The more often a region interacts with the nuclear matrix, 
the more DNA will be sequenced from this region, and thus we will calculate this 
region to be more highly enriched in association with the nuclear matrix. 
Immunofluorescence studies of the movements of expressed versus non-
expressed genes demonstrated that expressed genes are highly dynamic in their 
range of motion within their chromosome territory, while non-expressed genes 
are relatively static in position (Andrulis et al. 1998, Kosak et al. 2002, Zink et al. 
2004a, Hewitt et al. 2004). Further, expressed genes are not constitutively 
expressed; rather they are thought to be transcribed in bursts when associated 
with transcription factories (Dundr and Misteli 2010, Deng et al. 2012). Given that 
the nuclear matrix is enriched in newly synthesized RNA and is localized within 
euchromatic regions, we expect actively transcribed genes to have some 
association with the nuclear matrix. We observed that expressed genes are 
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slightly enriched in association with the nuclear matrix in regions flanking gene 
bodies (Figure 2.11 A – right), however, the magnitude of these differences was 
weak. Considering that genes are only transiently associated with transcription 
factories, we propose that the nuclear matrix serves as a platform to organize 
actively transcribed sequences through interactions with sequences flanking the 
transcribed regions. The transient nature of genes with transcription factories 
explains the highly reproducible (low p-value), yet weak magnitude differences in 
NM-DNA enrichment observed for regions flanking expressed genes. These 
matrix-DNA interactions would therefore serve as an organizational platform for 
the recruitment of transcription and splicing factors to be spatially enriched in 
order to promote accurate and precise transcription in response to physiological 
demands. Conversely, the strong enrichment of NM-DNA within the gene bodies 
of non-expressed genes may be explained by the lack of movement of non-
expressed genes. Whereby lack of gene movement results in more stable 
interactions with the nuclear matrix (or NM-DNA enrichment). These non-
expressed genes would typically be observed in the regions of peripheral 
heterochromatin. While the nuclear matrix is less abundant in the peripheral 
heterochromatin regions, it is still present. These repressive regions may have 
more overlap with the previously discussed LADs; however, this is only 
speculation.  
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This study is the first to analyze matrix-associated DNA on a genome-wide scale 
at such a fine resolution (single base). It is also the only study that has made 
direct positional comparisons between matrix-associated DNA and histone 
modifications. These histone modifications (H3K4me3, H3K27me3, and 
H3K9me2) have not previously been analyzed on a genome-wide scale in either 
cell line. These advances, combined with the integration of transcriptome-wide 
gene expression analysis, make the impact of this study highly significant. Using 
a genome-wide unbiased approach, the results of this study reproduce and 
extend many of the seminal experiments demonstrating the functional 
associations between matrix-associated DNA and gene expression (Ciejek et al. 
1983, Jost and Seldran 1984, Jackson and Cook 1985, Cook 1989, Jackson et 
al. 1993, Linnemann et al. 2008, Rivera-Mulia and Aranda-Anzaldo 2010, 
Trevilla-García and Aranda-Anzaldo 2011). Rather than showing that the nuclear 
matrix is enriched for actively-transcribed loci, without knowing which loci are 
which, or showing that a single gene or small cohort of genes are associated with 
the nuclear matrix in a location-specific manner, we have shown that on a 
genone-wide scale there is are location-specific associations between the 
nuclear matrix and regions flanking transcribed genes. This is an important 
breakthrough in our ability to understand how the nuclear matrix is involved in the 
organization of transcriptional domains within the nucleus. We propose that NM-
seq can be utilized as a tool to study the functional contribution of the nuclear 
matrix to many nuclear functions, not only transcription. Because so many 
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groups are rapidly adopting genome-wide approaches for studying nuclear 
organization-based questions, we further propose that NM-seq should be 
considered as a complimentary tool for addressing these problems. 
 
Materials and Methods 
 
Cell Culture 
 
MCF10a cells were cultured in phenol-free DMEM/F12 media supplemented with 
EGF, insulin, cholera toxin and hydrocortisone and subcultured as described 
(Debnath et al. 2003). 
 
MDA-MB-231 cells were grown and subcultured as previously described (Pratap 
et al. 2008). 
 
Immunofluorescence microscopy 
 
Cells were grown on coverslips coated in 0.5% w/v gelatin as previously 
described prior to extraction (Ali et al. 2010, 2012). Fixed cells/nuclei/matrices 
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were then incubated with primary antibodies (NPAT, Coilin, PML, SC-35, UBF 
and Pol II) prior to incubation with AlexaFluor-conjugated secondary antibodies 
as previously described (Ghule et al. 2009, Ali et al. 2010, 2012). 
Immunofluorescence was executed in parallel to preparation of nuclear matrices 
for genomic DNA extract and deep-sequencing.  
 
ChIP-seq 
 
ChIP was performed on subconfluent cells as previously described (Lee et al. 
2006) with the following modification: after sonication, buffer C was exchanged 
for FA buffer (50mM HEPES-KOH, pH 7.5, 140mM Sodium Chloride, 1mM 
EDTA, 1% v/v Triton X-100, 0.1% w/v Sodium Deoxycholate, 0.1% w/v SDS, 1x 
Roche cOmplete EDTA-free protease inhibitor cocktail, 25nM MG132 in 
Nuclease-Free Water) prior to antibody pulldown using Amicon columns 
(10,000kDa MWCO). After genomic DNA was isolated for both specific IPs and 
Input DNA, libraries were prepared for paired-end multiplexed tag Solexa/Illumina 
sequencing using the Illumina DNA Sample Prep Kit v2.0 according to 
manufacturer instructions. 
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Isolation of nuclear matrix 
 
This section is not presented as methods, but rather in protocol format. 
 
Buffers: 
 
4x CSK Salts 
400mM Sodium Chloride, 4mM EGTA, 40mM PIPES pH 6.8 12mM Magnesium 
Chloride in Nuclease Free Water. This buffer is stable (maintains pH) at 4°C for 
approximately one month. 
 
4x Digestion Buffer 
200mM Sodium Chloride, 4mM EGTA, 40mM PIPES pH 6.8 12mM Magnesium 
Chloride in Nuclease Free Water. This buffer is stable (maintains pH) at 4°C for 
approximately one month. 
 
CSK Extraction Buffer 
1x CSK Salts, 300mM Sucrose, 0.5% v/v Triton X-100 in Nuclease Free Water. 
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CSK Crosslinking Buffer 
1x CSK Salts, 300mM Sucrose, 1%w/v Formaldehyde in Nuclease Free Water. 
 
CSK Wash Buffer 
1x CSK Salts, 1mM EDTA, 1mM EGTA, 300mM Sucrose in Nuclease Free 
Water 
 
Nuclear Matrix Digestion Buffer 
1x Digestion Buffer, 300mM Sucrose, 0.5%v/v Triton X-100, 600U/mL MspI, 
600U/mL HaeIII, 600U/mL RsaI, 600U/mL AluI, 600U/mL BamHI, 600U/mL PvuII 
in Nuclease Free Water. 
 
Digestion Wash Buffer 
1x Digestion Buffer, 300mM Sucrose, 10mM EDTA, 10mM EGTA in Nuclease 
Free Water. 
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Matrix Extraction Buffer 
1x Digestion Buffer, 300mM Sucrose, 10mM EDTA, 10mM EGTA, 250mM 
Ammonium Sulfate in Nuclease Free Water. 
 
Crosslink Reversal Buffer 
100mM Sodium Bicarbonate, 0.5%w/v SDS, 10mM EDTA, 10mM EGTA in 
Nuclease Free Water. 
 
Sonication Buffer 
10mM Tris-Cl, pH 8.0, 100mM Sodium Chloride, 1mM EDTA, 1mM EGTA, 
0.1%w/v Sodium Deoxycholate, 0.5%w/v N-Lauroylsarcosine in Nuclease Free 
Water. 
 
Day 1 
All buffers for this section should be prepared several hours prior to removing 
cells from the incubator. With the exception of the Crosslink Reversal Buffer, all 
buffers should be kept on ice in nuclease-free tubes/bottles. 
98 
 
It is important that the sucrose in the matrix buffer and the glycerol in the enzyme 
buffers are properly dissolved in solution before beginning. 
Add the formaldehyde to the CSK Crosslinking Buffer immediately before adding 
to cells. 
1. Grow adherent cells to passage (near confluence) density on a 100mM tissue 
culture plate. 
2. Remove plates from incubator and place on ice. Be sure that the plates are 
partially buried into the ice, and not just resting on top. Be careful not to push the 
plates in so far that ice will fall into the plates, and try to make the plate surface 
as level as possible for even buffer distribution. 
3. Aspirate media, gently wash cells twice with ice cold PBS to remove all media, 
serum, and non-adherent cells. 
4. Add 5mL CSK Extraction Buffer to each plate. Incubate on ice for 10 minutes. 
During incubation, gently rotate ice bucket in air to ensure the buffer is evenly 
dispersed across the cells. 
5. Aspirate CSK Extraction Buffer and discard. Wash cells gently twice with CSK 
Wash Buffer. 
6. Add 5mL CSK Crosslinking Buffer. Incubate on ice for 10 minutes. During 
incubation, gently rotate ice bucket in air to ensure the buffer is evenly dispersed 
across the cells. 
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7. Add 250µL freshly-prepared 2.5M Glycine to each plate, gently rotate to mix. 
Incubate for 10 minutes on ice to stop formaldehyde crosslinking, gently rocking 
ice bucket as before. 
8. Aspirate buffer from cells, and appropriately discard. Gently wash cells twice 
with CSK Wash Buffer. 
9. Add 1mL Nuclear Matrix Digestion Buffer to each plate. Place cells in 30°C 
incubator for 1 hour. Every 15 minutes, rotate the plates to ensure buffer is 
evenly distributed. 
10. For plates to be used for digested nuclei: 
(a) Scrape plates and all buffer into 50mL Amicon column with 10,000MWCO. 
(b) Add 10mL Digestion Wash Buffer to tube. 
(c) Spin at max speed for column until volume reaches approximately 400µL. 
(d) Add 10mL Crosslink Reversal Buffer. 
(e) Spin at max speed for column until volume reaches approximately 400µL. 
(f) Transfer top solution to 1.75mL Axygen tube. 
(g) Add 4µL of 20mg/mL Proteinase K to tube (final concentration of 200µg/mL). 
(h) Incubate in a 65°C water bath for 16 hours. 
For plates to be used for nuclear matrix preparation: 
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(a) Place plates back on ice. 
(b) Aspirate Nuclear Matrix Digestion Buffer. 
(c) Wash gently with Digestion Wash Buffer twice. 
(d) Add 5mL Matrix Extraction Buffer. Incubate on ice for 10 minutes. Gently rock 
ice bucket as described above. 
(e) Aspirate Matrix Extraction Buffer. Gently wash cells twice with Digestion 
Wash Buffer. 
(f) Scrape residual matrices on plates in 400µL Crosslink Reversal Buffer into 
50mL Amicon column with 10,000mwco. 
(g) Add 10mL Crosslink Reversal Buffer to tube. Spin at max speed for column 
until volume reaches approximately 400µL. Repeat. 
(h) Transfer top volume to 1.75mL Axygen tube. 
(i) Add 4µL of 20mg/mL Proteinase K to tube (final concentration of 200µg/mL). 
(j) Incubate tube in a 65°C water bath for 16 hours. 
Days 2: Genomic DNA Isolation 
Make a fresh preparation of phenol:chloroform:isoamyl alcohol (25:24:1) and 
chloroform:isoamyl alcohol (24:1). 
1. Pre-spin 2.0mL Phase-Lock Heavy (Qiagen) tubes. 
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2. Transfer solution from Axygen tube into Phase-Lock Heavy tube. 
3. Add 400µL phenol:chloroform:isoamyl alcohol. Vigorously mix for 15s. 
4. Spin at 10,000g for 10 minutes. 
5. Add 400µL chloroform:isoamyl alcohol. Vortex by tapping the bottom of the 
tube while holding the top for 30s. Spin again. 
6. Transfer supernatant into 1.75mL Axygen tube. 
7. Add 8µL 10mg/mL RNAse A to tube (final concentration of 200µg/mL). 
Incubate tube for 2 hours in 37°C water bath. 
8. Add 4µL 20mg/mL Proteinase K to tube (final concentration of 200µg/mL). 
Incubate tube for 2 hours in 55°C water bath. 
9. Pre-spin 2.0mL Phase-Lock Heavy tubes. 
10. Transfer solution from Axygen tube into Phase-Lock Heavy tube. 
11. Add 400µL phenol:chloroform:isoamyl alcohol. Vigorously mix for 15s. 
12. Spin at 10,000g for 10 minutes. 
13. Add 400µL chloroform:isoamyl alcohol. Vortex by tapping the bottom of the 
tube while holding the top for 30s. Spin again. 
14. Transfer supernatant into 1.75mL Axygen tube. Add 800µL ice-cold 100% 
Ethanol. Mix by inverting tube. 
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15. Place tube at -20°C overnight. 
Day 3: Sonication 
Freshly prepare Sonication Buffer and store on ice. 
Freshly prepare 80% Ethanol and store at -20°C for several hours before 
washing DNA pellet. 
Sonication conditions need to be empirically determined as not all sonicators are 
the same. Presented here is the methods used in our lab. 
1. Remove tubes from -20°C, spin at 4°C at full speed for 20 minutes. 
2. Gently remove and discard supernatant. 
3. Add 1mL ice cold 80% ethanol. Spin at 4°C at full speed for 10 minutes. 
Remove supernatant. Repeat. 
4. Add 500µL Sonication Buffer to tube, allow DNA to go into solution on ice. 
5. Suspend tube in ice water bath in sonication cabinet. 
6. Position tube so that the micro-tip is a few millimeters from the bottom of the 
tube and perfectly centered. 
7. Run the following sonication cycle 8 times: 
(a) Total sonication time of 20 seconds, oscillating between 1 second of 
sonication and 2 seconds of rest. 
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(b) 30 seconds of rest in between each cycle. 
8. Add 1mL ice-cold 100% Ethanol. Place tube at -20°C overnight. 
 
Gel Verification 
 
1. Cast a 2% TAE-agarose gel. 
2. Remove tubes from -20°C, spin at 4°C at full speed for 20 minutes. 
3. Gently remove and discard supernatant. 
4. Add 1mL ice cold 80% ethanol. Spin at 4°C at full speed for 10 minutes. 
Remove supernatant. Repeat. 
5. Add 100µL TE to pellet. 
6. Quantify DNA using Qubit dsDNA HS Assay (Invitrogen). 
7. Run a small (~200ng) amount of DNA (if you can spare it) for several hours at 
30V. Use a 100bp DNA ladder for a marker. Gel can be stained with ethidium 
bromide or other in-gel DNA visualizing reagent. Our lab used ethidium bromide. 
8. Visualize DNA using UV; if distribution is centered higher than 400bp, repeat 
sonication steps. A 400bp band will be selected from the gel during library 
preparation for sequencing. It is important that the distribution of band sizes is 
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centered at 400bp so that the slice selected will have a high probability to be 
representative of the entire population of DNA fragments. 
 
Library Preparation 
 
From this point, all DNA is treated as ChIP DNA for the preparation of genomic 
DNA libraries for deep-sequencing on the Illumina Hi-Seq 2000. All libraries are 
prepared according to the manual provided with the Illumina TruSeq DNA 
Sample Preparation v2 Guide. 
Buffers 
All buffers should be made fresh the day of the experiment unless otherwise 
noted, and are made with nuclease-free water in nuclease free tubes/bottles. All 
reasonable precautions to maintain a nuclease-free environment when 
preparing/using these buffers should be made. 
 
2.55M Sucrose 
Sucrose (g):    1710g  
Nuclease-free Water  900mL 
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Final Molarity   2.55M 
The following is from the Lamond lab protocol for sucrose buffer preparation 
http://www.lamondlab.com/f7nucleolarprotocol.htm: The stock solution is stable 
indefinitely at 4°C. This procedure can be carried out at RT. There is no need to 
heat up the solution to help disolve the sucrose. Heating up an incompletely 
dissolved sucrose solution can lead to charring of sucrose and affect the quality 
of the sucrose solution. 
Prepare the sucrose buffer as follows: 
1. Weigh out 1710 g sucrose. Keep it aside in a clean container. 
2. Put exactly 900ml water and a magnetic bar in a 5 liter beaker. Put the beaker 
on a stirrer and start stirring. 
3. Add 1/3 of the sucrose into the beaker. Make sure the magnetic bar is rotating 
freely. Stir for 1 hour. 
4. Add another 1/3 of the sucrose into the solution. Again make sure the rotation 
of the stir bar is not impaired. Stir for another 1 hour.. 
5. Add the remaining sucrose. Stir for another 1 hour, or until all the sucrose has 
gone into solution. The final volume should be exactly 2 liters. 
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Read Mapping 
 
100bp paired-end reads were mapped to the hg19 build of the human genome 
using Bowtie2 (Langmead and Salzberg 2012). 
 
Read Conversion 
 
Mapped reads were converted to BED-format reads for analysis using SAMTools 
(Li et al. 2009) and BedTools (Quinlan and Hall 2010) 
 
Discriminative Motif Discovery 
 
Homer (Heinz et al. 2010) motif discovery software was used to discover 
enriched motifs. For each set of test intervals, a GC/CpG/length-matched set of 
intervals was generated by Homer and used as background. 
 
GC Content 
 
107 
 
GC content was measured using custom Perl scripts reliant upon BioPerl (Stajich 
et al. 2002) to calculate GC content from FASTA-format sequence files. 
 
Giemsa Chromosome Bands 
 
Coordinates of Giemsa bands and RefSeq gene positions were extracted from 
the UCSC Genome Browser for hg19 (Meyer et al. 2013). 
 
Scatterplots and Correlation Coefficient Calculation 
 
Hexagonal plots and Pearson R correlation coefficient calculations were done in 
R using the “hexbin” package and the “cor.test” function. 
 
Heat Maps and Clustering 
 
K-means clustering and heat maps were generated in R. Heat maps were 
generated using the “heatmap.2” function from the “gplots” library. K-means 
clustering was performed using the “kmeans” function of the “stats” core 
package. 
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Affymetrix Arrays and Analysis 
 
Human Gene 1.0ST arrays from Affymetrix were used to measure gene 
expression levels in MCF10a and MDA-MB-231 cells. cRNA amplification and 
hybridization to the array was performed by the UMASS Medical School 
Genomic Core as previously described (Dowdy et al. 2010). 
 
Analysis was performed in R to execute normalization, quality control, transcript-
level reporting, annotation, and contrast tests. The “affy” (Gautier et al. 2004) 
package was used to read in raw fluorescent values from arrays; values were 
normalized across all arrays using quantile normalization (Bolstad et al. 2003), 
robust means average (RMA) background correction and median polish (Irizarry 
et al. 2003). Quality control plots were generated to ensure the arrays did not 
have any artifacts and post-processing values were in similar ranges. Transcripts 
were annotated using the “annotate” package, the 
“hugene10sttranscriptcluster.db” package. Contrast tests were generated and 
performed using the “limma” package. 
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Circos Plot 
 
Circos plot of NM-DNA-enrichment on human chromosome 11 was done using 
Circos  (Krzywinski et al. 2009). 
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CHAPTER 3 GENOME-WIDE ANALYSIS OF BINDING AND GENE 
EXPRESSION REGULATION OF RUNX1 AND RUNX2 IN MDA-MB-231 CELLS 
AND ASSOCIATION OF RUNX1 AND RUNX2 EXPRESSION WITH HORMONE 
RECEPTORS IN BREAST CANCER PATIENT SAMPLES 
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Introduction 
 
Transcription factors and their cognate coregulatory partners are critical for cell-
type specific expression of phenotypic genes. In cancer, many transcription 
factors with functions required for normal developmental processes function in 
tumor cells to promote cancer progression. For example, transcription factors 
that mediate signaling pathways for growth and tissue formation, including the 
TGF-beta, BMP, and WNT pathways, are highly active (Zaidi et al. 2007). Here, 
we address the functional activities of a transcription factor family that is required 
for developmental processes and whose expression is deregulated in breast 
cancer cells, though their distinct functional roles in contributing to the 
progression of tumor growth and later metastatic events are not clear. 
 
Runx1 and Runx2 are developmentally required for the emergence and 
maturation of the hematopoietic (Wang et al. 1996) and osseous (Komori et al. 
1997) lineages, respectively; they are also associated with tumor growth and 
metastasis (Pratap et al. 2006). In their native cellular context, RUNX proteins 
participate in multiple critical signaling pathways and regulate the expression of 
phenotypic genes and ribosomal RNA (Young et al. 2007a, 2007b, Bakshi et al. 
2008). Further, the result of RUNX binding to a gene promoter may be either 
activation or repression, depending on the co-regulatory proteins it recruits 
(Cameron and Neil 2004). These observations indicate that the presence of a 
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RUNX protein within a given cell does not necessarily predict the outcome on the 
transcriptional program. 
 
In breast and prostate cancer cell lines, both of which are predisposed to bone 
metastasis, RUNX2 plays a key transcriptional role in promoting both the 
osteomimetic and osteolytic activities of tumor cells (Barnes et al. 2004, Javed et 
al. 2005, Pratap et al. 2008, Akech et al. 2010). The mechanisms by which 
RUNX2 promotes metastatic bone disease have been well characterized in vitro 
and include the activation of bone/ECM-adhesion proteins (OP, BSP) and 
invasion-related factors (MMPs, VEGF), as well as mediating the TGF-
beta/SMAD signaling pathway and the vicious cycle of tumor growth and bone 
resorption (IHH/PTHRP) (Pratap et al. 2010, Chimge and Frenkel 2012). 
 
RUNX1, on the other hand, appears to function as a tumor suppressor in the 
MCF10a mammary epithelial cells and derived tumorigenic cell lines (Kadota et 
al. 2010, Wang et al. 2011a, Janes 2011). In MDA-MB-231 cells stably 
transfected with estrogen receptor alpha (ER-α), RUNX1 has been proposed to 
function as a tethering factor for ER-α to cooperatively promote estrogen 
stimulation (Stender et al. 2010). However, the functions of RUNX1 in the context 
of parental, ER-negative MDA-MB-231 cells are unknown. 
 
In Asian patients, RUNX2 expression is an independent predictor of disease and 
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is primarily associated with estrogen receptor negative (ER-) breast cancers (Das 
et al. 2009, Onodera et al. 2010). In a small scale study of European breast and 
breast cancer tissues, the Human Protein Atlas found that RUNX2 was not 
expressed in either normal or tumor tissues (Uhlén et al. 2005, Pontèn et al. 
2008, Uhlen et al. 2010). These observations lead us to hypothesize that due to 
the small sample size of the Human Protein Atlas study, the observation of 
RUNX2 not being expressed may not be representative of the expression profile 
of RUNX2 in all patients. An alternative explanation is that the expression of 
RUNX2 may be unique to Asian patients as a large scale study of the expression 
of RUNX2 in American or European patients of breast cancer has yet to occur. 
 
While the in vitro functions of RUNX1 in breast cells may not be well described, 
there is evidence to suggest that in breast cancer patients RUNX1 functions as a 
tumor suppressor. RUNX1 transcript is significantly lower in metastatic breast 
cancer cells as compared to primary tumors (Ramaswamy et al. 2003), and 
RUNX1 is significantly mutated in patients of breast cancer (The Cancer Genome 
Atlas Network 2012). In the Human Protein Atlas study mentioned above, 
RUNX1 was strongly detected in normal breast tissue and in tumor tissue, 
however, the sample size was small (Uhlén et al. 2005, Pontèn et al. 2008, Uhlen 
et al. 2010). These in vivo observations or RUNX1 expression patterns and 
mutational frequencies seemed counterintuitive to the observation that RUNX1 
was highly expressed in the malignant metastatic MDA-MB-231 cells, so it is 
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therefore necessary to examine both the functions of RUNX1 in MDA-MB-231 
cells and the expression pattern of RUNX1 in patient samples of breast cancer. 
 
To investigate the roles of RUNX1 and RUNX2 in breast cancer, we examined 
the extent to which RUNX expression is associated with breast cancer 
progression and transition into early metastatic disease. To accomplish this, we 
used cell line models of breast cancer as well as human breast cancer patient 
tissue. Using MDA-MB-231 cells as a model of metastatic breast cancer cells to 
define the functions of endogenously expressed RUNX proteins, we 
characterized the patterns of genome-wide RUNX1 and RUNX2 binding and 
genome-wide transcriptome response to RNAi-mediated knockdown of RUNX 
proteins. Here we report that while RUNX1 and RUNX2 both appear to play roles 
in transcriptionally regulating genes involved in the invasive phenotype of MDA-
MB-231 cells, only RUNX1 appears to be bound near the promoters of these 
genes. In human patients, while neither RUNX1 nor RUNX2 appear to be 
independent prognostic markers of disease, we do see RUNX1 expression as 
primarily associated with early stages of disease, while RUNX2 expression is 
primarily found in middle-late stage breast cancer. Integrating common markers 
of breast cancer prognosis (ER, PR, HER2, and AR), we find that RUNX1 
expression is correlated with AR expression, and association of RUNX1 with 
either ER or HER2 is dependent on AR status. These results suggest that the 
expression of RUNX proteins in breast cancer is highly sensitive to hormone 
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receptor status. 
 
Results 
 
Runx proteins do not regulate ribosomal RNA transcription, protein synthesis, or 
cell growth in MDA-MB-231 cells 
 
In the hematopoietic and osteoblastic lineages, RUNX1 and RUNX2, 
respectively, control cell growth by regulating the rate limiting step of protein 
synthesis by suppressing transcription of ribosomal RNA. RUNX proteins 
regulate rRNA transcription through binding to the rDNA repeats and are 
observed to colocalize with upstream binding factor (UBF) at the periphery of 
nucleoli (Young et al. 2007a, Bakshi et al. 2008, Ali et al. 2010, 2012). Both 
RUNX1 and RUNX2 have been observed to be expressed in the malignant 
metastatic MDA-MB-231 cells, which are highly proliferative (Barnes et al. 2004, 
Javed et al. 2005, Pratap et al. 2008, Stender et al. 2010). It is therefore of 
interest to investigate whether the growth-suppressive function of RUNX proteins 
are operative in breast cancer cells.  
 
We began by detecting the levels the levels of RUNX proteins in adjacent normal 
breast tissue from human patients by immunohistochemistry (Figure 3.1 A). The 
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Human Protein Atlas has previously observed that RUNX1 can be detected in 
normal breast tissue, while RUNX2 cannot (Uhlén et al. 2005, Pontèn et al. 2008, 
Uhlen et al. 2010). While examination of RUNX protein levels in patient tissues 
does not provide a good indication of the potential for RUNX proteins to regulate 
rRNA transcription, it does allow for a comparison of the levels of RUNX1 and 
RUNX2 in normal breast tissue. This approach further indicates the extent to 
which we can reproduce the observations of others. Immunohistochemical 
staining of RUNX1 and RUNX2 in adjacent normal mammary epithelial cells 
showed that RUNX1 was strongly expressed while RUNX2 was not detected at 
all (Figure 3.1 A).  
 
Immunofluorescence (IF) is a method of immunodetection of an antigen via a 
fluorescent-conjugated secondary antibody and is generally considered more 
sensitive than detection with a horseradish peroxidase (HRP)-conjugated 
secondary antibody. This method allows for examination of the subnuclear 
localization of RUNX proteins and the extent to which RUNX proteins colocalize 
with upstream binding factor (UBF), which is a required member of the RNA 
polymerase I (Pol I) complex and for rRNA transcription (Voit et al. 1995). 
Therefore, we used IF to detect the level and subnuclear localization of RUNX1, 
RUNX2, and UBF in: 1) non-tumorigenic breast cells (MCF10a), 2) malignant, 
poorly-invasive breast cancer cells (MCF-7), and 3) malignant, highly-invasive 
breast cancer cells (MDA-MB-231) (Figure 3.1 B). By qualitatively comparing of 
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the observed levels of RUNX1 and RUNX2 in normal breast tissue (Figure 3.1 
A) to the levels detected by immunostaining in MCF10a cells (Figure 3.1 B – top 
row), we similarly observed that RUNX1 is expressed, while RUNX2 barely 
detected. Weak detection of RUNX2 in the non-tumorigenic MCF10a cells and no 
detection of RUNX2 in adjacent normal breast tissue is likely a technical issue as 
RUNX2 has been observed in normal MCF10a cells by electro-mobility shift 
assay (EMSA) (Inman and Shore 2003, Shore 2005). These results also give us 
an indication of the threshold of sensitivity for detection of RUNX proteins breast 
cancer patient tissue, which will be presented later. Using IF in non-tumorigenic 
breast and breast cancer cell lines, we observed that RUNX proteins were not 
co-localized with UBF (Figure 3.1 B). This suggests that RUNX1 and RUNX2 are 
unlikely to be functioning to regulate rRNA transcription. However, these IF 
results only describe the potential for RUNX proteins to regulate rRNA 
transcription based on spatial proximity to UBF, and do not provide direct 
evidence. 
 
To further investigate the roles of endogenous RUNX1 and RUNX2, we chose to 
use the MDA-MB-231 cell line, as this cell line has the highest endogenous levels 
of both RUNX1 and RUNX2 of those examined (Figure 3.1B – bottom row). 
Utilization of this cell line, in which both RUNX1 and RUNX2 are endogenously 
expressed at high levels, also allows us to test the degree to which the functions 
of RUNX1 and RUNX2 are overlapping. RUNX2 regulates the transcription of 
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rRNA by binding to the rDNA repeats in SaOS-2 cells, therefore SaOS-2 cells 
were used as a control (Young et al. 2007a, Ali et al. 2010, 2012). Although we 
do not observe overlap in the IF signals of RUNX proteins and UBF in MDA-MB-
231 cells, we wanted to directly test the extent to which RUNX proteins are 
bound to ribosomal genes. Therefore, using chromatin immunoprecipitation 
followed by sequence-specific Real Time qPCR we measured the binding of 
RUNX1 and RUNX2 to genomic regions upstream (rDNA A) and within (rDNA 
B/C) ribosomal genes in MDA-MB-231 cells and SaOS-2 cells (Figure 3.1 C). In 
this experiment, UBF was used as a positive control for immunoprecipitation of 
ribosomal DNA, while normal rabbit immunoglobulin G (IgG) was used as a 
control for immunospecificity. UBF is more strongly bound to rDNA repeats as 
compared to RUNX proteins (Young et al. 2007a, Bakshi et al. 2008, Ali et al. 
2010, 2012), therefore the percent of input recovered by UBF 
immunoprecipitation (green bars) is plotted on the right y-axis, while normal 
rabbit IgG, RUNX1, and RUNX2 are plotted on the left y-axis. In SaOS-2 cells, 
immunoprecipitation with RUNX1 (yellow bars) or RUNX2 (green bars) recovered 
more input DNA at rDNA B and rDNA C as compared to immunoprecipitation 
with normal rabbit IgG (pink bars), which indicates that both RUNX1 and RUNX2 
are bound to the rDNA repeats in SaOS-2 cells. In MDA-MB-231 cells, we 
observed that RUNX1 immunoprecipitation recovered more DNA at rDNA B and 
rDNA C than normal rabbit IgG, indicating that RUNX1 is likely bound to rDNA. 
We also observed that while the mean amount of rDNA B and rDNA C recovered 
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by RUNX2 immunoprecipitation was more than with rabbit IgG in MDA-MB-231 
cells, there was a high degree of variability (error bars for replicates) in the 
amount of rDNA B/C recovered by RUNX2 immunoprecipitation. This suggests 
that if RUNX2 is bound to rDNA repeats in the MDA-MB-231 cells the interaction 
between RUNX2 and rDNA may be weak or only occurring in a subset of MDA-
MB-231 cells.   
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Figure 3.1: RUNX1 and RUNX2 do not colocalize with UBF and are weakly 
bound to ribosomal DNA in breast cells. 
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Figure 3.1: RUNX1 and RUNX2 do not colocalize with UBF and are weakly 
bound to ribosomal DNA in breast cells. 
 
(A) Immunohistochemical staining of RUNX1 and RUNX2 in patient samples of 
normal adjacent breast tissue. (B) Immunofluorescence staining of RUNX1, 
RUNX2 and UBF in non-tumorigenic (MCF10a), malignant, poorly-invasive 
(MCF-7) and malignant, highly-invasive (MDA-MB-231) breast cell lines. (C) 
Chromatin immunoprecipitation using normal rabbit IgG, RUNX1, RUNX2, and 
UBF from SaOS-2 osteosarcoma and MDA-MB-231 bone metastatic breast 
cancer cells followed by qPCR for regions proximal to the TSS of the human 
rDNA repeat (Ali et al. 2010, 2012). CYBB – cytochrome b-245, beta polypeptite / 
GP91-PHOX; rDNA A/B/C ribosomal DNA regions, refer to Ali et al. 2010 Figure 
1D; Runx1p1 – RUNX1 promoter 1 (p1) region. Bars represent mean percent of 
input and error bars equal SEM for two technical replicates and two biological 
replicates.  
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Combining our ChIP observations with our IF observations indicates a possible 
disconnect between the anti-nucleolar localization of RUNX proteins in whole 
cells observed by IF and the binding of RUNX proteins to rDNA repeats in 
biochemically extracted chromatin. IF and ChIP provide evidence for the location 
of a protein not the function of a protein, so the extent to which RUNX proteins 
regulate protein synthesis in breast cells has not been thoroughly addressed. 
Therefore, using the MDA-MB-231 cells as a model of breast cancer cells and 
SaOS-2 cells as a model for normal RUNX function, we investigated the 
functional contributions of RUNX proteins in the regulation of cell growth, rRNA 
transcription, and protein synthesis (Figure 3.2). To simultaneously measure the 
extent to which RUNX proteins regulate cell growth and rRNA transcription, we 
performed a time course of RNA interference (RNAi) knockdown of the 
endogenous RUNX proteins in both MDA-MB-231 and SaOS-2 cells. We 
observed that the short interfering RNAs (siRNAs) targeting RUNX1 and RUNX2 
were sufficient to significantly reduce the protein detected in whole cell lysates at 
24, 48, and 72 hours in SaOS-2 and MDA-MB-231 cells (Figure 3.2 A). We also 
saw two interesting phenomena in the levels of RUNX proteins, which were 
uniquely observed in the MDA-MB-231 cells: 1) as MDA-MB-231 cell density 
increased over time, the levels of RUNX1 and RUNX2 decreased, and 2) the 
levels of RUNX2 were significantly lower in MDA-MB-231 cells as compared to 
SaOS-2 cells. By counting the number of cells in culture after 24, 48, and 72 
hours post-transfection of siRNA, we measured the effects of RUNX proteins on 
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growth (Figure 3.2 B). Here, we observed that RUNX proteins do not 
significantly affect growth in either MDA-MB-231 cells or SaOS-2 cells. RUNX2 
has previously been observed to affect the growth of SaOS-2 cells, but only in 
the absence of histone deacetylase 1 (HDAC1) (Ali et al. 2012), so not seeing a 
growth affect in a RUNX knockdown still does not rule out RUNX-regulation of 
rRNA transcription and protein synthesis. We therefore examined the levels of 
pre-ribsomal RNA (pre-rRNA) after 24, 48, and 72 hours (Figure 3.2 C). pre-
rRNA is rapidly processed into mature rRNA, and is used as a proxy for 
measuring rRNA transcription rates (Grummt and Voit 2010). Knockdown of 
RUNX1 and RUNX2 in Kasumi-1 and SaOS-2 cells, respectively, has resulted in 
reduction of pre-rRNA levels (Young et al. 2007a, Bakshi et al. 2008, Ali et al. 
2010, 2012). We observed that knockdown of RUNX2 in SaOS-2 caused a 
significant increase in pre-rRNA levels cells at 24, 48, and 72 hours post-
transfection, and knockdown of RUNX1 in SaOS-2 caused an increase only at 
the 24 hour time point (Figure 3.2 C – left). In contrast, knockdown of RUNX 
proteins in MDA-MB-231 cells had no significant effects on pre-rRNA levels at 
any time post-transfection (Figure 3.2 C – right). Pulse-labeling proliferating 
cells with 35S-tagged amino acids allows for a measurement of the rate of protein 
synthesis in the cell population. 48 hours post-transfection of RUNX siRNAs, 
SaOS-2 and MDA-MB-231 cells were pulse labeled with radiolabeled methionine 
and cysteine to measure the effects of RUNX proteins on the rate of protein 
synthesis (Figure 3.2 D). Each replicate experiment was quantified by 
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densitometry and combined (Figure 3.2 D – right). We observed that RUNX1 
and RUNX2 significantly affected the rate of protein synthesis in SaOS-2 cells, 
but not at all in MDA-MB-231 cells. These observations are consistent with the 
results for pre-rRNA levels following knockdown of RUNX proteins (Figure 3.2 
C).  
 
Our combined observations in MDA-MB-231 cells show that RUNX proteins do 
not co-localize with components of RNA Pol I-mediated transcription (UBF) by 
immunofluorescence (Figure 3.1 B), are not strongly bound to the rDNA by ChIP 
(Figure 3.1 C), and do not appear to affect pre-rRNA levels (Figure 3.2 C) or 
protein synthesis rates (Figure 3.2 D) by RNAi knockdown of Runx proteins. 
These results clearly demonstrate that Runx proteins do not regulate the 
transcription of rRNA in MDA-MB-231 cells. Transcription and processing of 
rRNA are rate limiting steps for cellular growth. The observation that Runx 
proteins are not affecting these processes is consistent with the result that Runx 
proteins do not affect the growth of MDA-MB-231 cells (Figure 3.2 B). 
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Figure 3.2: RUNX1 and RUNX2 in MDA-MB-231 cells does not appear to affect 
cell growth, ribosomal RNA transcription or protein synthesis. 
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Figure 3.2: RUNX1 and RUNX2 in MDA-MB-231 cells does not appear to affect 
cell growth, ribosomal RNA transcription or protein synthesis. 
 
(A) Representative western blot in SaOS-2 (top panel) and MDA-MB-231 (bottom 
panel) cells detecting levels of RUNX1 (top blots), RUNX2 (middle blots), and 
Lamin C (bottom blots) in response to siRNA 24, 48, and 72 hours (x-axis) post-
transfection. RUNX2 blots in SaOS-2 panel are for linear detection range (upper) 
and equal exposure to MDA-MB-231 cells (lower). (B) Cell counts for MDA-MB-
231 (left panel) and SaOS-2 (right panel) at 24, 48, and 72 hours following 
transfection with siRNA. Symbol represents mean and error bars represent SEM 
for 3 transfection replicates with two counting replicates each for 2 biological 
replicates. (C) Time course of knockdown of RUNX proteins in MDA-MB-231 and 
SaOS-2 cells. NS = Non-silencing siRNA, R1 = RUNX1 siRNA, R2 = RUNX2 
siRNA, and D = RUNX1 and RUNX2 combined siRNAs. X-axis is time post 
transfection, at which point RNA was isolated, cDNA amplified and qPCR for pre-
rRNA was executed. Relative expression values are plotted against ACTB 
internal control using delta-Ct method (Bustin et al. 2009). Bars represent mean 
relative expression and error bars equal SEM for two technical replicates each of 
two biological replicates. (D) Representative radiograph of 35S-Met/Cys pulse-
labeled SaOS-2 (left half of blot) or MDA-MB-231 (right half of blot) protein 
lysates run on an SDS-PAGE gel and exposed to film following 48 hours of 
transfection (left panel). Densitometric mean and SEM (error bars) of 35S-
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Met/Cys incorporation for SaOS-2 and MDA-MB-231 cells for 2 biological 
replicates (right panel). (All) NS = Non-silencing siRNA, R1 = RUNX1 siRNA, R2 
= RUNX2 siRNA, and D = RUNX1 and RUNX2 combined siRNAs.   
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Expression of RUNX proteins in MDA-MB-231 cells promotes an invasive 
phenotype 
 
Given that we observed such disparate effects of RUNX knockdown on rRNA 
expression, protein synthesis and cell growth between breast cancer and 
osteosarcoma cells, we sought to understand the potentially novel transcriptional 
functions of RUNX proteins in MDA-MB-231 breast cancer cells. To this end, we 
performed Affymetrix transcriptome analysis under conditions where cells were 
transfected with either a non-silencing control or a combined pool of RUNX1 and 
RUNX2 siRNAs. We identified 66 protein coding genes whose transcript levels 
were changed more than 1.5 fold and whose fold changes were reproducible 
across biological replicates (p < 0.05). Using DAVID (Huang et al. 2009a, 2009b) 
to understand the biological consequences of changes in the levels of these 
transcripts, we found these genes to be ontologically associated with terms 
related to adhesion, migration, and invasion (Table 3.1). One striking observation 
found in the genes responsive to RUNX RNAi in MDA-MB-231 cells was the lack 
of genes that are regulated during hematopoiesis and osteoblastogenesis by 
RUNX1 and RUNX2 respectively (Vradii et al. 2005, Young et al. 2007b, van der 
Deen et al. 2012). This observation combined with the non-regulation of rRNA 
transcription suggests that endogenously-expressed RUNX1 and RUNX2 in 
MDA-MB-231 cells have distinct regulatory roles as compared to RUNX1 and 
RUNX2 in the hematopoietic and osseous lineages, respectively.  
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Table 3.1: Ontological terms enriched in genes responsive to RUNX-siRNA. 
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Table 3.1: Ontological terms enriched in genes responsive to RUNX-siRNA. 
 
Using DAVID, genes responsive (fold-change >= 1.5, p-value < 0.05) to RUNX-
siRNA were subjected to ontological term clustering to search for over-
represented GO terms associated with Runx-siRNA-responsive genes. 
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Given the ontological associations of the RUNX-siRNA-responsive genes (Table 
3.1), we investigated the extent to which RUNX expression might affect the 
invasiveness of MDA-MB-231 cells. One way to measure the invasiveness of a 
cell line is to perform a Matrigel invasion assay. In these experiments, cells are 
cultured in the top of a transwell insert and a chemoattractant is cultured under 
and surrounding the insert. The bottom of the insert has small holes through 
which the cells can migrate towards the chemoattractant. The control experiment 
is just naked plastic, while the invasion experiment has a layer of Matrigel 
between the cells and bottom of the insert through which the cells have to invade 
to migrate towards the chemoattractant. After the cells have been allowed to 
migrate towards to chemoattractant for a fixed period of time, cells are fixed in 
ethanol and cells that did not migrate through the pores in the insert are 
removed. Cells that have moved through the pores of the insert are now adhered 
to the bottom of the insert, these are stained and the numbers of cells which 
have migrated or invaded are quantified. While it is known that overexpression of 
Mus musculus Runx2 in MDA-MB-231 cells causes increased invasiveness 
(Barnes et al. 2004, Javed et al. 2005), it is not known how RUNX1 contributes to 
the invasiveness of MDA-MB-231 cells. Using Matrigel invasion assays, we 
observe that knockdown of RUNX1 or RUNX2 (Figure 3.3 A) reduces the 
invasiveness of MDA-MB-231 cells (Figure 3.3 B). These results are in 
accordance with what was expected based on the DAVID analysis.  
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Figure 3.3 RUNX proteins promote the invasiveness of MDA-MB-231 cells 
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Figure 3.3 RUNX proteins promote the invasiveness of MDA-MB-231 cells 
(A) Representative Western blot showing protein levels for RUNX1 (top blot), 
RUNX2 (middle blot), and Beta-Actin (lower blot) following 48 hours of siRNA 
transfection. (B) Column plot depicting mean and SEM (error bars) percent of 
invasion for each siRNA transfection (N=2). (All) NS = Non-silencing siRNA, R1 
= RUNX1 siRNA, R2 = RUNX2 siRNA, and D = RUNX1 + RUNX2 siRNAs.  
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RUNX proteins share a highly conserved Runt homology domain, which binds 
the same consensus sequence (Van Wijnen et al. 2004); however, it is not 
known the extent to which these two proteins overlap in function when 
endogenously expressed in the same cell line. To address this, we performed 
gene-specific Real-Time qPCR on genes identified by Affymetrix using primer 
pairs designed by FoxPrimer (see Chapter 4 for methods). Of the 66 total genes, 
we were able to validate 44 primer pairs that were greater than 80% efficient as 
measured by standard curve (Bustin et al. 2009). Using these 44 genes, we 
performed qPCR on cDNA amplified from RNA isolated from MDA-MB-231 cells 
transfected with non-targeting, RUNX1, RUNX2, or RUNX1+RUNX2 siRNA and 
found that the expression of 41 genes were significantly changed compared to 
control in response to at least one siRNA transfection. Categorizing these 
transcripts by responsiveness to RUNX siRNA resulted in three major classes 
(Figure 3.4): 1) responsive to either RUNX1 or RUNX2 siRNA (Figure 3.5 A), 2) 
primarily responsive to RUNX1 siRNA (Figure 3.5 B), and 3) primarily 
responsive to RUNX2 siRNA (Figure 3.5 C). Five genes for which we were able 
to design efficient primers for Real Time qPCR did not show a significant change 
in expression in the confirmation experiments (data not shown). One gene, 
myelin protein zero-line 2 (MPZL2), showed an increase in detection in response 
to RUNX siRNAs, and therefore did not fall into the three major categories (data 
not shown). The observation that so many of the genes (approximately 2/3) are 
primarily responsive to only one RUNX protein is quite unexpected. This 
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suggests that while the phenotypic response of RUNX protein knockdown is 
similar in MDA-MB-231 cells, the mechanisms in use by RUNX1 and RUNX2 
may be different. 
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Figure 3.4 Genes responsive to RUNX-siRNAs fall into three major categories 
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Figure 3.4 Genes responsive to RUNX-siRNAs fall into three major categories 
 
Mean and SEM (error bars) plots of three major classes of genes identified and 
validated by Affymetrix Human Gene 1.0ST array based on response to 48 hours 
of siRNA transfection. NS = Non-silencing siRNA, R1 = RUNX1 siRNA, R2 = 
RUNX2 siRNA, and D = RUNX1 + RUNX2 siRNAs.  
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Figure 3.5 Real Time qPCR validation of Affymetrix-identified genes 
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Figure 3.5 Real Time qPCR validation of Affymetrix-identifed targets 
 
Real Time qPCR validation of genes responsive to RUNX-siRNA ordered by 
response group: (A) responsive to either, (B) reponsive to RUNX1, and (C) 
reponsive to RUNX2 . Primers were designed using FoxPrimer (Chapter 4). Bars 
represent mean and error bars are SEM for two biological replicates for each 
gene normalized by delta-delta-Ct to ACTB.  
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Alongside the Affymetrix experiments, we performed ChIP-seq for endogenous 
RUNX1 and RUNX2 in MDA-MB-231 cells. As mentioned before, the Affymetrix 
experiment was done using a double-knockdown system. Previous models of 
RUNX-mediated transcriptional functions based on single gene regulation 
suggest that we should be able to use RUNX1 and RUNX2 binding sites to 
determine which genes identified by Affymetrix can be uniquely regulated by 
RUNX1 or RUNX2 in MDA-MB-231 cells (Lian et al. 2006). Accordingly, binding 
within the promoter region of a gene should be sufficient for RUNX to 
transcriptionally regulate gene expression in trans. In our ChIP-seq of 
endogenous RUNX1 and RUNX2 in MDA-MB-231 cells, we found that RUNX1 
and RUNX2 did not share many of the same binding sites (Figure 3.6 A), which 
may explain the large number of genes that were uniquely responsive to RUNX1 
or RUNX2 siRNA (Figure 3.4 & Figure 3.5). Contrary to previous models, where 
RUNX proteins exclusively bind to promoter regions, we also found that the vast 
majority of RUNX binding sites defined by MACS (Zhang et al. 2008) were not 
located within promoter regions. When defining a promoter region as 1Kb 5’ of 
the transcriptional start site (TSS) we observed only about 10% and less than 1% 
of all RUNX1 and RUNX2 peaks, respectively, were bound within the promoters 
of RefSeq (Pruitt et al. 2009) genes in MDA-MB-231 cells (Figure 3.6 B). These 
observations are particularly interesting because all RUNX proteins share the 
same common DNA sequence binding motif (Figure 3.6 C), which was defined in 
vitro on naked DNA (Melnikova et al. 1993), however, in MDA-MB-231 cells there 
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was not a lot of overlap between the binding of RUNX1 and RUNX2. This 
suggests that the in vivo binding of RUNX proteins is more complicated than 
sequence motif recognition alone. 
 
To investigate a potential mechanism as to how RUNX1 and RUNX2 are not 
occupying many of the same binding sites, we performed discriminative de novo 
motif discovery (Heinz et al. 2010) on the enriched intervals defined by MACS 
and found that the RUNX1 ChIP-Seq was enriched for a motif very similar to a 
previously identified RUNX1 motif, while the motif enriched in the RUNX2 ChIP-
Seq was most similar to the motif discovered by a PU.1 ChIP-seq (Figure 3.6 D). 
PU.1 is a member of the E-twenty six (ETS) transcription factor family, all of 
which bind a similar sequence motif (Gutierrez-Hartmann et al. 2007). Runx2 has 
been shown to interact with Ets1 and synergistically regulate gene expression in 
murine cells (Sato et al. 1998), so it is possible that in MDA-MB-231 cells much 
of the DNA-binding activity of RUNX2 is derived through an interaction with an 
ETS factor. However, it is not known which ETS factor RUNX2 may be 
interacting with in MDA-MB-231 cells. Runx2 has also been observed to 
synergistically cooperate with CCAAT/enhancer binding proteins alpha and delta 
(C/EBPα & C/EBPδ) through a protein-protein interaction in the osteocalcin 
promoter (Gutierrez et al. 2002). In this study, Runx2 was still recruited to the 
osteocalcin promoter even in when the RUNX-binding site was mutated. This 
suggests that RUNX2 in MDA-MB-231 cells has the potential to be recruited to 
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DNA independently of the RUNX-binding sequence by protein-protein 
interactions with co-factors. The difference in motifs found within the enriched 
regions along with the significantly reduced number of RUNX2 peaks in 
promoters suggests that in the context of MDA-MB-231 cells, RUNX2 
transcriptional activities may be quite different than those of RUNX1.  
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Figure 3.6 RUNX proteins do not bind similar regions in MDA-MB-231 cells 
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Figure 3.6 RUNX proteins do not bind similar regions in MDA-MB-231 cells 
(A) Venn diagram depicting the number of overlapping RUNX1 and RUNX2 
ChIP-seq peak regions as identified by MACS (Zhang et al. 2008). (B) Pie chart 
of the genomic locations of RUNX1 (left) and RUNX2 (right) MACS peaks, which 
are found 2Kb 5’-TSS to the TSS (black) as compared to anywhere else in the 
genome (grey). (C) SeqLogo of the consensus RUNX motif (Heinemeyer et al. 
1998, Bryne et al. 2008). (D) Top results of discriminative motif discovery for the 
sequences within the genomic intervals defined as peaks for RUNX1 (top) and 
RUNX2 (bottom).  
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Functional RUNX1 peaks are associated with binding near the TSS and 
enrichment of H3K4me3 
 
To understand what role chromatin may be playing in the binding of RUNX 
proteins to DNA, we compared RUNX1 and RUNX2 ChIP-seq data with ChIP-
seq data for H3K4me3, H3K27me3, and H3K9me2 in MDA-MB-231 cells (from 
Chapter 2). We focused on the discovery of proximal (within 10Kb of genes) 
patterns in RUNX1 or RUNX2 binding as based on previous models of RUNX 
protein functions we had high confidence these regions would give insight into 
potential regulatory roles of RUNX proteins (Lian et al. 2006). Our goal was to 
understand if a pattern of RUNX1, RUNX2, H3K4me3, H3K27me3, and 
H3K9me2 binding was found near the genes that are responsive to RUNX 
siRNA. To identify these patterns, we created a matrix of enrichment data where 
each relative genomic region1 for each mark is treated as a dimension and for 
each gene measured using the Affymetrix arrays a point based on these 
dimensions is defined in high-dimensional space using the corresponding 
enrichment ratio (IP reads / input reads). Next, we applied k-means clustering to 
partition these points into clusters based on Euclidean distance between all 
points and randomly generated cluster centers. The centers are randomly 
regenerated until a best fit for cluster assignment is reached. Based on these 
                                            
1 See Chapter 5 for more detailed methods regarding the definition of relative 
genomic regions. 
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cluster definitions, we plotted a heat map of the enrichment (IP reads / input 
reads) for relative genomic regions for each gene for each factor (Figure 3.7 A). 
When attempting to cluster with only RUNX proteins, we were not able to identify 
any meaningful clusters in relation to RUNX siRNA-responsive genes (data not 
shown). The genes responsive to RUNX siRNA were plotted both within the main 
(clustered) figure and on their own (Figure 3.7 A – bottom). Visually, the binding 
profile of RUNX1, RUNX2, H3K4me3, H3K27me3, and H3K9me2 near RUNX 
siRNA-responsive genes looked most similar to the purple and light blue clusters. 
Using a chi-squared contingency table to identify the clusters in which RUNX 
siRNA-responsive genes are most enriched or depleted, we found that RUNX 
siRNA-responsive genes were overrepresented in the purple, pink, light blue and 
orange clusters (Figure 3.7 B). Based on the patterns of H3K4me3, which is 
associated with transcriptional activation and the transcriptionally repressive 
marks H3K27me3 and H3K9me2, we expected that the gene expression patterns 
would be similar (Li et al. 2007). Using gene expression measured by Affymetrix 
arrays, we plotted the distribution of robust means average (RMA) (Irizarry et al. 
2003) transcript detection levels for each gene in each cluster as a box and 
whiskers plot (Figure 3.7 C). Within the orange-red, black, grey, yellow, red, and 
blue clusters, the transcriptional initiation-associated chromatin modification, 
H3K4me3, was strongly enriched near the TSS, and these clusters contained 
some of the highest expressed genes as defined by Affymetrix arrays (Figure 3.7 
C). Four of the clusters (purple, pink, light blue and orange) which were 
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overrepresented for genes responsive to RUNX siRNA were similarly enriched 
for H3K4me3 near the TSS (Figure 3.7 A) and contained genes that are highly 
expressed (Figure 3.7 C). This suggests that the genes regulated by RUNX 
proteins in MDA-MB-231 cells are among the most highly expressed transcripts. 
We observed a clear enrichment of RUNX1 binding near the TSS of genes within 
these clusters, while RUNX2 binding did not appear to be strongly focused 
anywhere (Figure 3.7 A). However, considering only the genes responsive to 
RUNX siRNA (Figure 3.7 A – bottom) this pattern of RUNX1 binding near the 
TSS was less apparent. This suggested that the strongest RUNX1 binding 
events near the TSS may not be associated with a functional response in gene 
expression when RUNX1 is knocked down using siRNA. 
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Figure 3.7 Gene-centric clustering of RUNX1, RUNX2, H3K4me3, H3K27me3, 
and H3K9me2 show that RUNX1 is primarily upstream of genes marked by 
H3K4me3 near the TSS and are strongly expressed. 
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Figure 3.7 Gene-centric clustering of RUNX1, RUNX2, H3K4me3, H3K27me3, 
and H3K9me2 show that RUNX1 is primarily upstream of genes marked by 
H3K4me3 near the TSS and are strongly expressed. 
 
(A) Heatmap of signal ratios (IP/Input) for each RefSeq (Pruitt et al. 2009) gene 
(row) measured by Affymetrix Human Gene 1.0ST array. For each gene, 30 
relative genomic regions were defined: 10Kb 5’-TSS to TSS in 1Kb steps, TTS to 
10Kb 3’-TTS in 1Kb steps, and TSS to TTS in 10 approximately equal steps 
(normalized to 1Kb per step). The matrix of signal ratios per relative genomic 
region per transcription factor / histone modification per gene were then 
subjected to k-means clustering to identify 12 clusters (marked by colors on left). 
Scale is presented below heat map. (B) Chi-squared table showing expected 
(distribution of all genes) versus observed (distribution of genes responsive to 
RUNX siRNA) per cluster color. (C) Mean RMA-normalized expression values 
(Irizarry et al. 2003) for the genes in each cluster in box and whisker plot. 
Horizontal red dotted line represents the mean RMA-normalized detection level 
of all negative control probes, which is later used to define expressed versus 
non-expressed genes.  
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RUNX1 is associated with actively expressed genes and weakly associated with 
RUNX siRNA responsive genes. 
 
To understand further how RUNX binding is associated with gene expression in 
the MDA-MB-231 cells, we used PeaksToGenes to perform statistical tests on 
the enrichment of each factor in relative genomic regions. As we saw in Figure 
3.7, strong RUNX1 binding was most concentrated on the TSS of genes that are 
likely to be expressed based on the enrichment of H3K4me3 in the same region 
and the cluster of genes having a generally high expression distribution (Figure 
3.7 C). However, this is not direct evidence that RUNX1 preferentially binds to 
expressed genes as many genes in these k-means-identified clusters are not 
responsive to RUNX siRNA. To directly test whether RUNX protein binding in 
MDA-MB-231 cells is associated with actively expressed genes, we first bisected 
the list of genes whose transcript levels are measured by Affymetrix Human 
Gene 1.0ST arrays into two groups. Then, using internal spike-in negative control 
probe sets, expressed genes and non-expressed genes were respectively 
defined as transcripts whose mean detection level across all biological replicates 
were greater than or less than or equal to the mean of the negative control probe 
sets.  
 
To determine the validity of our division of transcripts into expressed genes or 
non-expressed genes, we first tested whether binding of H3K4me3 (activating), 
153 
 
H3K27me3 (silencing) and H3K9me2 (silencing) were appropriately enriched in 
binding near expressed or non-expressed genes (Li et al. 2007). Using 
PeaksToGenes, we observed that H3K4me3 (Figure 3.8 – top) binding was 
significantly enriched near the TSS of expressed genes (green line), while 
binding of H3K27me3 (Figure 3.8 – middle) and H3K9me2 (Figure 3.8 – 
bottom) was significantly enriched across the entire region. Based on the 
associations of these chromatin modifications with gene expression (Li et al. 
2007), these results suggest that our use of the Affymetrix spike-in controls 
allowed for reasonably appropriate definitions of expressed and non-expressed 
genes. There is a caveat with our bisection, which is that there are likely to be 
some incorrectly-classified genes, however, the robust associations we observed 
between the positional enrichment histone modifications and expression category 
suggests that these misclassifications were infrequent. 
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Figure 3.8 Chromatin marks are appropriately associated with expressed versus 
non-expressed genes in MDA-MB-231 cells. 
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Figure 3.8 Chromatin marks are appropriately associated with expressed versus 
non-expressed genes in MDA-MB-231 cells. 
 
PeaksToGenes analysis of H3K4me3 enrichment (upper panel), H3K27me3 
enrichment (middle panel) and H3K9me2 enrichment (lower panel) for expressed 
genes (green line) and non-expressed genes (red line). Triangles are Wilcoxon 
Rank-Sum Test p-values (right y-axis) and error bars are SEM. For more detailed 
methods, please see Chapter 5.  
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Extending this PeaksToGenes analysis to the binding of RUNX1 and RUNX2 
near expressed (green line) and non-expressed genes (red line), we found that 
RUNX1 binding is significantly enriched within the promoters (-2Kb of the TSS) of 
expressed genes and weakly so in regions flanking expressed genes (Figure 3.9 
A – left). RUNX2 binding was only weakly associated in regions flanking the 
gene bodies of expressed genes and not enriched near the promoters (Figure 
3.9 A – right). Interestingly, both RUNX1 and RUNX2 binding within the gene 
body (TSS to TTS) was strongly associated with genes defined as non-
expressed (Figure 3.9 A). Due to the length-based normalization done within 
gene bodies, there is consistently more signal found within gene bodies. 
Because of this technicality, statistical tests were only done within a single 
relative genomic region not across relative genomic regions2. It is difficult to know 
how statistically significant each individual binding event is when considering 
binding ratios. Specifically, a binding ratio of two-fold could be derived from two 
reads in the IP and one read in the Input, or the same two-fold ration could have 
been derived from 50 reads in the IP and 25 reads in the Input. It is more likely 
that the two-fold enrichment measured in the second case is more reproducible. 
However, instead of setting some kind of threshold for the minimum number of 
reads within a region to calculate a binding ratio, we relied upon the peak calling 
algorithm employed by MACS (Zhang et al. 2008). Peak-calling algorithms, such 
as MACS, measure signal ratios and then using both global and local parameters 
                                            
2 Discussed further in Chapter 5. 
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of variations in read numbers to determine whether a certain region is statistically 
significantly enriched for reads in the IP sample. To determine whether there 
were differences in the associations of the most significant regions (MACS 
peaks) of RUNX1 and RUNX2 with expressed or non-expressed genes, we 
applied PeaksToGenes analysis. We employed a non-parametric Wilcoxon Rank 
Sum test, which allows for non-normally distributed data and for unequal sample 
sizes (Wilcoxon 1945); the binding data for RUNX1 and RUNX2 in MDA-MB-231 
cells fit these parameters. Using RUNX1 and RUNX2 peak regions, we observed 
a non-significant association of RUNX1 peaks with regions near the TSS of 
expressed genes (blue line) (Figure 3.9 B – left) while RUNX2 peaks were not 
differentially associated with either expressed (blue line) or non-expressed genes 
(orange line) (Figure 3.9 B - right). While RUNX1 binding appeared to be 
increased near the TSS of expressed genes (blue line) as compared to non-
expressed genes (orange line), the result of the Wilcoxon Rank Sum test was not 
statistically significant. As we observed in (Figure 3.6 B), RUNX2 peaks were 
generally not found near the promoters of either expressed or non-expressed 
genes (Figure 3.9 B – right). Using MACS peaks instead of raw signal ratios as 
a measure of RUNX protein binding, we observed that the binding of RUNX 
proteins within the gene bodies (TSS to TTS) was no longer preferentially 
associated with non-expressed genes (red line in Figure 3.9 A, orange line in 
Figure 3.9 B). This suggests that the binding of RUNX proteins within gene 
bodies of non-expressed genes is weak compared to other regions (therefore not 
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defined as peaks), yet this binding is highly significant when the same relative 
genomic regions are compared to expressed genes (Figure 3.9 A). What this 
PeaksToGenes analysis of RUNX2 peaks also reveals is that RUNX2 peaks 
were very poorly associated with genes in general as compared to RUNX1; while 
RUNX1 had approximately 20 times more peaks in MDA-MB-231 cells as 
compared to RUNX2 (Figure 3.6 A), the mean enrichment of RUNX1 and 
RUNX2 in genic regions (within genes and 10Kb regions flanking gene bodies) 
was approximately 100-fold different (3.4x10-2 peaks per Kb and 3.1x10-4 peaks 
per Kb respectively) (Figure 3.9 B). Therefore, although there are differences in 
the number of highly-enriched peak regions for RUNX1 and RUNX2, the 
distribution of these peaks was not similar with respect to genic versus intergenic 
regions. These positional relationships observed for RUNX2 binding are quite 
different than the results obtained for the binding of endogenous RUNX proteins 
in osteosarcoma (Van der Deen et al. 2012), leukemia, and osteoblasts 
(unpublished findings – see Appendix). RUNX1, binding in genic regions 
appeared to be concentrated near actively expressed genes, which is consistent 
with previous studies of Runx1 in leukemic and hematopoietic cells (Pencovich et 
al. 2011, Tijssen et al. 2011, Wang et al. 2011b). Genes responsive to RUNX 
siRNA were overrepresented in clusters whose transcript levels were generally 
high, indicating that they are actively expressed genes (Figure 3.7). Therefore, 
we conclude that RUNX siRNA-responsive genes are likely to be expressed. 
Through PeaksToGenes analysis, we discovered that RUNX1 is preferentially 
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bound near the TSS and promoter regions of actively-expressed genes, while 
RUNX2 was not significantly associated with genic regions. Based on these 
results, we can hypothesize that RUNX1 binding within these regions is likely to 
be most associated with genes responsive to RUNX siRNA.  
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Figure 3.9 PeaksToGenes analysis of RUNX1 and RUNX2 binding showed that 
RUNX1 promoter binding was strongly associated with expressed genes 
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Figure 3.9 PeaksToGenes analysis of RUNX1 and RUNX2 binding showed that 
RUNX1 promoter binding was strongly associated with expressed genes 
 
(A) RUNX1 signal ratios (IP/Input) (left) and RUNX2 signal ratios (IP/Input) (right) 
associations with expressed (green) versus non-expressed (red) genes. (B) 
Associations of RUNX1 peaks (left) and RUNX2 peaks (right) with expressed 
(blue) versus non-expressed (orange) genes. (A & B) For each relative genomic 
region (as shown in Figure 3.7 A), the series of values corresponding to the 
number of peaks or the signal ratios (IP/Input) or number of peaks was taken for 
expressed or non-expressed genes and a Wilcoxon Rank-Sum Test was 
performed. Plotted is the mean value of each set (as a line – left y-axis) and the 
resultant p-value at each relative genomic region (as the triangles – right y-axis). 
Error bars are SEM. For more detailed methods please see Chapter 5. 
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Genes responsive to RUNX siRNA are associated with H3K4me3 and RUNX1 
binding near the TSS 
 
While we observed that RUNX1 binding is preferentially located within the 
promoters of expressed genes, we wanted to address whether the binding 
patterns of RUNX1 or RUNX2 in MDA-MB-231 cells were preferentially 
associated with genes responsive to RUNX siRNA. If we observe that RUNX1 or 
RUNX2 is generally bound with certain region relative to genes responsive to 
RUNX siRNA, we can conclude that this binding of RUNX1 or RUNX2 is likely to 
be responsible for the functional responses observed after RUNX siRNA 
transfection.  As we had observed that RUNX1 binding is preferentially 
associated with the promoters and TSS regions of actively-expressed genes 
(Figure 3.9), and that genes responsive to RUNX siRNA are likely to be highly 
expressed (Figure 3.7), we therefore used PeaksToGenes to directly test 
whether RUNX1 binding is more enriched near genes responsive to RUNX 
siRNA. 
 
Before looking at RUNX1 and RUNX2 binding, we first examined whether binding 
of H3K4me3, H3K27me3, or H3K9me2 is enriched near genes responsive to 
RUNX siRNA. We observed that genes responsive to RUNX siRNA were 
overrepresented in clusters that have strong H3K4me3 signal near the TSS 
163 
 
compared to other clusters and weak H3K27me3 and H3K9me2 signal 
throughout the measured genic region compared to other clusters (Figure 3.7 A 
& B). Therefore, we used PeaksToGenes to contrast the binding of these 
chromatin marks near genes that are either responsive (purple line) or non-
responsive (brown line) to RUNX siRNA (Figure 3.10). We observed that the 
activating histone modification H3K4me3 was weakly associated with the TSS 
regions of RUNX siRNA-responsive genes (Figure 3.10 – top), which indicates 
that in general, these RUNX siRNA-responsive genes (purple line) have 
H3K4me3 near the TSS, but not significantly more than other genes (brown line). 
When analyzing the binding of the repressive histone modifications H3K27me3 
(Figure 3.10 – middle) and H3K9me2 (Figure 3.10 – bottom) we observed that 
the binding of these marks were generally more associated with RUNX siRNA 
non-responsive genes (brown line) than with RUNX siRNA responsive genes 
(purple line). Thus, the RUNX siRNA-responsive genes are characterized by 
enrichment of H3K4me3 binding near the TSS and a paucity of H3K27me3 or 
H3K9me2 binding, which suggests that RUNX proteins are regulating the 
transcript levels of euchromatic genes that are likely to be actively expressed. 
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Figure 3.10 Genes responsive to RUNX siRNA are not associated with 
H3K27me3 or H3K9me2, and are associated with H3K4me3 near the TSS 
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Figure 3.10 Genes responsive to RUNX siRNA are not particularly associated 
with any of the histone marks examined. 
 
PeaksToGenes analysis of H3K4me3 signal ratios (IP/Input) (upper panel), 
H3K27me3 signal ratios (IP/Input) (middle panel) and H3K9me2 signal ratios 
(IP/Input) (lower panel) for genes responsive to RUNX siRNA (purple line) and 
genes non-responsive to RUNX siRNA (brown line). Triangles are Wilcoxon 
Rank-Sum Test p-values and error bars are SEM. See Chapter 5 for more 
detailed methods. 
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We next examined the relationships between the binding patterns of RUNX1 and 
RUNX2 in MDA-MB-231 cells and genes responsive to RUNX siRNA. Comparing 
the enrichment of binding (signal ratio) near RUNX siRNA-responsive genes to 
RUNX siRNA non-responsive genes, we observed that RUNX1 binding was non-
significantly more associated with the upstream and promoter regions of genes 
responsive to RUNX siRNA (purple line) (Figure 3.11 A - left). RUNX2 binding 
does not appear to have a preferential enrichment near the RUNX siRNA-
responsive genes or the RUNX siRNA non-responsive genes (Figure 3.11 A - 
right). The same rationale used for the inclusion of MACS peaks for this analysis 
applies here when comparing the binding of RUNX proteins near RUNX siRNA-
responsive genes or RUNX siRNA non-responsive genes. Here, we observed 
that RUNX1 peaks were non-significantly enriched near the TSS of RUNX siRNA 
responsive genes (green line) (Figure 3.11 B – left). Unexpectedly, there was 
not a single RUNX2 peak within the gene body or within 10Kb of any genes 
responsive to RUNX siRNA (green line) (Figure 3.11 B – right). Neither RUNX2 
signal ratio analysis (Figure 3.11 A – right) nor RUNX2 MACS peaks analysis 
(Figure 3.11 B – right) provided any indication of how RUNX2 may be 
functioning to regulate gene expression in MDA-MB-231 cells. We observed that 
in MDA-MB-231 cells RUNX2 is not binding to the RUNX motif (Figure 3.6 C), 
has very few peaks (Figure 3.6 A) and has both nuclear and cytoplasmic 
localization (Figure 3.1 B). Transfection of RUNX2 siRNA in MDA-MB-231 cells 
affected the transcript levels of many genes that are unrelated to bone (Table 3.1 
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& Figure 3.5 C) and were not observed to be changed when RUNX2 is knocked 
down in an osteoblastic cell such as SaOS-2 (Young et al. 2007b, van der Deen 
et al. 2012). Given the deregulated sub-cellular localization and genomic binding 
properties of RUNX2 we cannot determine the mechanisms by which RUNX2 is 
regulating the transcript levels of RUNX2 siRNA-responsive genes. Considering 
the preferential association of RUNX1 binding (Figure 3.7 A & Figure 3.11 A – 
left & Figure 3.11 B – left) and of H3K4me3 binding (Figure 3.10 – top) near 
the TSS of RUNX siRNA-responsive genes, leads us to conclude that this 
binding is functionally important for transcriptional regulation of genes responsive 
to RUNX siRNA. In our analysis of RUNX1 and RUNX2 binding patterns near 
genes responsive to RUNX siRNA, we chose to consolidate the genes 
responsive to RUNX1 siRNA, responsive RUNX2 siRNA and responsive to either 
into one group. There are several reasons for doing this: 1) Only 66 genes were 
identified to be responsive to combined RUNX1 and RUNX2 siRNA transfection, 
which is much less than we had expected given similar RUNX2 studies in SaOS-
2 cells (Young et al. 2007b, van der Deen et al. 2012), 2) 66 genes is a small 
enough list to make statistical tests less robust, separating the genes into smaller 
groups would make these tests even less informative, and 3) of the 66 genes 
identified to be responsive to RUNX siRNA, we were only able to experimentally 
validate 44 of them using separate RUNX1 and RUNX2 siRNAs (Figure 3.4 & 
Figure 3.5), which would make point number 2 an even larger concern once the 
genes are separated by response pattern. We observed that RUNX1 binding is 
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preferentially associated with the TSS of RUNX siRNA-responsive genes, and if 
we extend the trend observed in Figure 3.4, approximately 1/2 of these genes 
would not responsive to RUNX1 siRNA. Therefore, we expect this association to 
be stronger when only considering RUNX1 siRNA-responsive genes. A technical 
issue, which can be observed in Figure 3.5, is that the response to transfection 
of both RUNX1 and RUNX2 siRNA is typically less robust than for a single 
siRNA. This leads us to conclude that the samples used for Affymetrix analysis 
may be missing a great deal of information regarding genes that are uniquely 
responsive to RUNX1 or RUNX2. Extrapolating this idea to the binding pattern of 
RUNX1 in MDA-MB-231 cells, it is possible that many of the binding events 
proximal to the TSS were actually responsible for the regulation of these genes 
but were masked in the Affymetrix experiment due to our use of combined 
siRNAs. 
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Figure 3.11 Genes responsive to RUNX siRNA are are slightly more associated 
with RUNX1 binding near the TSS 
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Figure 3.11 Genes responsive to RUNX siRNA are slightly more associated with 
RUNX1 binding near the TSS. 
 
PeaksToGenes analysis of RUNX1 (left) and RUNX2 (right) (A) enrichment 
(IP/Input) and (B) MACS peaks. Purple line: mean signal ratio (IP/Input) for 
binding near RUNX siRNA responsive genes. Brown line: mean signal ratio 
(IP/Input) for binding near RUNX siRNA non-responsive genes. Green line: mean 
peaks per relative genomic region for RUNX siRNA responsive genes. Pink line: 
mean peaks per relative genomic region for RUNX siRNA non-responsive genes. 
No p-values were significant (<= 0.05) for Wilcoxon Rank-Sum Test and were not 
plotted. Error bars are SEM. See Chapter 5 for more detailed methods. 
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RUNX proteins are expressed in samples isolated from human patients of breast 
cancer 
 
We have examined the phenotypic contributions and functions of RUNX1 and 
RUNX2 in MDA-MB-231 cells. These in vitro results suggest possible 
mechanisms or roles for RUNX1 and RUNX2 in human breast cancer patients, 
but do not allow for insight into the clinical relevance of RUNX1 and RUNX2 
expression in breast cancer cells. The MDA-MB-231 cell line is a model of 
advanced bone, brain and lung metastatic breast cancer (Yoneda et al. 2001), 
however, it does not allow for insight into whether RUNX proteins are expressed 
during tumor initiation or progression to the metastatic state. Recent in vivo 
immunohistochemical evidence suggests that RUNX1 protein is detected in the 
epithelial cells of both normal breast tissue and breast cancer tissue (Uhlén et al. 
2005, Pontèn et al. 2008, Uhlen et al. 2010), and that increased RUNX2 
expression is associated with the disease state (Das et al. 2009, Onodera et al. 
2010). It is therefore important to correlate in vivo expression of RUNX1 and 
RUNX2 with prognostic and diagnostic markers of breast cancer in various 
stages leading up to and including metastatic disease. 
 
Using formalin-fixed paraffin-embedded (FFPE) human breast cancer samples 
from the UMMS tissue bank and FFPE human breast cancer tissue microarrays 
(TMAs) from US BioMax, we stained tissue samples from more than 125 patients 
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with antibodies for RUNX1 or RUNX2. The TMAs from US BioMax were 
BR1503a and BR10010, which are breast cancer progression and breast cancer 
metastasis to lymph node arrays, respectively. BR10010 is a matched metastatic 
breast cancer array of samples taken from 25 patients; for each patient BR10010 
contains two samples each of tissue from primary breast tissue and lymph tissue 
to which the primary breast tumor has metastasized. Primary tumor samples and 
metastatic tumor samples analyzed had not metastasized to or been taken from 
distal tissues such as brain, lung, liver or bone. Typically, once patients present 
with distal metastases, biopsies or fine needle aspirates (FNAs) are no longer 
taken for analysis, so it is difficult to obtain samples from advanced metastatic 
disease.  
 
Using a semi-quantitative scoring system, two researchers blindly scored TMAs 
stained with RUNX1 and RUNX2 to determine whether RUNX protein expression 
was associated with any prognostic or diagnostic markers of breast cancer 
progression (Figure 3.12 A). Strong expression of RUNX1 was observed in 
almost all mammary epithelial cells of any pathology, while RUNX2 positive 
tissues were less frequent (Figure 3.12 B-D). Using this scoring system, we 
examined the extent to which the expression levels of RUNX proteins are 
significantly more or less associated with the expression of: HER2, PR, ER, and 
AR; as well as the cytopathologically-defined: TNM (tumor size, node status, and 
distal metastases status), breast cancer grade, breast cancer stage, pathology, 
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and tissue type. We did not observe RUNX1 expression to be preferentially 
associated with any particular subtype of breast cancer (Figure 3.12 C – left), 
while RUNX2 expression was primarily observed in invasive ductal carcinoma 
compared to normal adjacent tissue, fibroadenoma, cystosarcoma phyllodes, 
ductal carcinoma in situ, and metastatic breast tissue to the lymph nodes (Figure 
3.12 C - right). The column graphs presented are the mean RUNX protein 
detection score associated with the subtype. While these graphs may give the 
impression that few or no samples were judged to be greater than ‘++’ for 
RUNX2, the low mean score is actually due to the high number of samples for 
which RUNX2 was not detected. Interestingly, while RUNX proteins appear to 
play a role in the invasiveness of MDA-MB-231 cells, we observe that breast 
cancer cells that have metastasized to the lymph node have significantly less 
RUNX1 (Figure 3.10 D – left) and RUNX2 (Figure 3.10 – right) expression than 
in the primary tumor site. This comparison is derived from the BR10010 array in 
which primary and metastatic patient tissues were matched and from the 
BR1502a in which metastatic and non-metastatic tissues primary tissues were 
compared. This observation is similar to a previous study in which a significant 
reduction in RUNX1 transcript levels in metastatic breast tissue was observed 
compared to non-metastatic breast cancer tissue (Dairkee et al. 2004), and 
suggests that the invasive phenotype in vitro associated with RUNX1 and 
RUNX2 is unlikely to have participated metastasis to primary lymph nodes.  
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Figure 3.12 RUNX1 is expressed in normal breast and multiple breast cancer 
subtypes, while RUNX2 is primarily expressed in invasive ductal carcinoma. Both 
RUNX1 and RUNX2 expression is significantly lower in breast cancer cells that 
have metastasized to lymph tissue. 
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Figure 3.12 RUNX1 is expressed in normal breast and multiple breast cancer 
subtypes, while RUNX2 is primarily expressed in invasive ductal carcinoma. Both 
RUNX1 and RUNX2 expression is significantly lower in breast cancer cells that 
have metastasized to lymph tissue. 
 
(A) Representative images of scoring rubric taken from invasive ductal 
carcinoma samples for RUNX1 (top row) and RUNX2 (bottom row). (B) 
Representative images of RUNX1 (upper panel) and RUNX2 (lower panel) in 
NAT (normal adjacent tissue), FibroAd (fibroadenoma), CysPh (cystosarcoma 
phyllodes), DCIS (ductal carcinoma in situ), IDC (invasive ductal carcinoma), and  
Met (breast tissue metastasized to lymph). (C) Mean and SEM (error bars) score 
given to RUNX1 (left) and RUNX2 (right) staining for each pathology type. * = 
Kruskal-Wallis p-value < 0.05 comparing RUNX2 scores in IDC to Met (right). (D) 
Mean and SEM (error bars) score given to RUNX1 (left) and RUNX2 (right) 
staining for tissue type. **  = Kruskal-Wallis p-value < 0.01 comparing RUNX1 
staining in Malignant to Metastatic (left). **  = Kruskal-Wallis p-value < 0.01 
comparing RUNX2 staining in Malignant to Metastatic (right). 
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RUNX1 is primarily expressed in normal tissue and in early smaller tumors, while 
RUNX2 is primarily expressed in middle to late-stage larger tumors 
 
Next we examined whether the expression intensity of RUNX1 or RUNX2 in the 
malignant cells was associated with diagnostic markers of breast cancer (tumor 
node metastasis (TNM), grade, and stage). This analysis will allow us to 
understand whether RUNX proteins have a temporal relationship with disease 
progression.  
 
TNM is a scoring metric used to define the size of the primary tumor as well as 
the extent to which the tumor has metastasized to proximal (node status) and 
distal sites3. T is for the size of the tumor, and has the following designations: 1) 
Tx – tumor was not able to be classified, 2) Tis – ductal carcinoma in situ, 3) T0 – 
no tumor, 4) T1 – can be broken down into the following four categories: i) T1mi 
– tumor diameter is less than 0.1cm, ii) T1a – tumor diameter is greater than 
0.1cm but less than 0.5cm, iii) T1b – tumor diameter is greater than 0.5cm but 
less than 1.0cm, and iv) T1c – tumor diameter is greater than 1cm but less than 
2cm, 5) T2 – tumor diameter is greater than 2cm but less than 5cm, 6) T3 – the 
tumor diameter is greater than 5cm, and 7) T4 – can be broken down into four 
categories: i) T4a – tumor has invaded into chest wall, ii) T4b – tumor has 
                                            
3 http://www.cancerresearchuk.org/cancer-help/type/breast-cancer/treatment/tnm-breast-cancer-
staging - last accessed March 31st, 2013 
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invaded into skin and patient presents with local swelling, iii) T4c – both T4a and 
T4b, and iv) T4d – tumor is classified as inflammatory carcinoma, local area is 
red, swollen and painful to the touch. N is for the characterization of the node 
stages, and the relevant categorization is as follows: 1) NX – samples cannot be 
assessed, 2) N0 – nodes are negative for metastases, 3) N1 – positive 
metastases in nodes of upper armpit and nodes are not stuck to surrounding 
tissues, 4) N2 – positive metastases in nodes of upper armpit, which are stuck to 
each other and surrounding tissues or positive metastases in internal mammary 
nodes. There are further designations for node status, but none of these were 
present in the US BioMax arrays or samples from UMMS analyzed. Similarly, the 
M designation is for distal metastases and, as discussed above, because we did 
not analyze any samples with distal metastases the classifications of this 
parameter will not be discussed.  
 
Breast cancer staging is a method of grouping the TNM classifications. These 
groupings have been observed to have similar clinical outcomes, and are treated 
likewise4. There are more stages defined than were present in the arrays 
analyzed from US BioMax. Only the stages represented on these arrays and 
subsequently immunostained for RUNX proteins will be discussed here. Stage 0 
is cancer in situ or TisN0M0. Stage I is small tumors (less than 2cm in diameter). 
                                            
4 http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-staging - Last accessed 
March 31st, 2013. 
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Stage I is bisected into Ia and Ib, however, the staging data from US BioMax did 
not have this distinction. Stage Ia tumors are non-metastatic (T1N0M0), while 
stage Ib tumors have micrometastases to the axillary lymph nodes (T1N1miM0). 
The US BioMax data for stage two is defined as Stage II, Stage IIa, and Stage 
IIb. While there is not a clear definition for what Stage II is, stage IIb and Stage 
IIb are well-defined. It is likely that tumors classified as Stage II only had 
characteristics of both IIa and IIb such that a distinction could not be made. 
Stage IIa is small tumors that have metastasized to the lymph nodes (T1N1M0), 
but not to distal organs. Stage IIb is larger tumors that may or may not have 
metastasized to the lymph nodes (T2N1M0 or T3N0M0), and the tumor has not 
metastasized to distal organs. Stage IIIa is tumors no larger than 5cm in diameter 
that have metastasized to many axillary lymph nodes or internal mammary lymph 
nodes (T0-2N2M0), or tumors that are large (greater than 5cm in diameter) that 
have not invaded the skin or chest wall and have spread to multiple lymph nodes 
(T3N1-2M0). Stage IIIa tumors have not metastasized to distal organs. Stage IIIb 
tumors have invaded the chest wall or skin and may or may not have 
metastasized to the lymph (T4N0-2M0), but have not metastasized to distal 
organs. No samples of Stage IIIc or Stage IV were present in this study. 
 
Tumor grade is a measure of how abnormal the cells and tissue structure are in a 
179 
 
patient sample5. These grades correlate with how likely a tumor is to proliferate 
and affect diagnosis and prognosis. The scoring system employed by the US 
BioMax was not breast cancer-specific; rather US BioMax used the general 
scoring system that can be applied to all tumors. Grade 1 is low grade and well 
differentiated. Grade 2 is intermediate grade and moderately differentiated. 
Grade 3 is high grade and poorly differentiated. 
 
We observed RUNX1 expression to be significantly associated with small, non-
metastatic tumors (T1N0M0) (Figure 3.13 A – left) and RUNX2 expression was 
significantly associated with large, non-metastatic tumors that have grown into 
the chest wall or skin, but have not metastasized (T4N0M0) (Figure 3.13 A - 
right). Again, we observed that RUNX1 was significantly associated with grade 1 
(low grade), well differentiated breast cancer (Figure 3.13 B – left), while 
RUNX2 was associated with grade 2 (intermediate grade), moderately 
differentiated breast cancer (Figure 3.13 B - right). Contrasting RUNX 
expression against breast cancer stage, we observed that RUNX1 expression 
was most associated with stage I breast cancer (Figure 3.13 C – left), while 
RUNX2 expression was observed to be most associated with stage IIIb breast 
cancer (Figure 3.13 C - right).  
 
                                            
5 http://www.cancer.gov/cancertopics/factsheet/detection/tumor-grade - Last accessed March 
31st, 2013 
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Taken together, these associations of RUNX1 and RUNX2 staining intensity with 
early and late disease states, respectively, we hypothesize that RUNX proteins 
are likely participating in a defined event of breast cancer progression within the 
primary tumor. Unfortunately, our in vitro cell model is a very late-stage model, so 
we do not know what processes may be regulated as a consequence of RUNX 
expression at a these earlier time points. It is quite interesting that the expression 
of RUNX2, which has been shown to promote the invasive and osteolytic 
properties of MDA-MB-231 cells (Barnes et al. 2004, Javed et al. 2005, Pratap et 
al. 2008), is so specifically associated with non-metastatic disease (T4N0M0) 
(Figure 3.13 A – right). We can, however, make some correlation between the 
invasive phenotypes observed in association with RUNX2 in vitro with the 
observation that RUNX2 expression was significantly associated with breast 
tumors that have invaded into the chest wall or skin. It is, however, important to 
note that most metastatic tumors examined had not invaded into the chest wall or 
skin, so it appears that RUNX2 is not playing a role in breast cancer metastasis. 
Previously, RUNX1 was shown to have a statistically significant rate of mutations 
in breast cancer patients (The Cancer Genome Atlas Network 2012), which 
suggests that RUNX1 may function as a tumor suppressor. Here, we observed 
that the expression of RUNX1 was primarily associated with early, malignant 
tumors (T1N0M0) (Figure 3.13 A – left) that are low grade and well differentiated 
(Grade 1) (Figure 3.13 B – left) as compared to normal or advanced disease 
tissue. It is unknown whether RUNX1 is mutant in these early tumors we have 
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examined, so we cannot determine the extent to which the RUNX1 protein 
detected is functioning normally. Therefore, it is difficult to speculate what role 
RUNX1 may be playing in breast disease progression, and further highlights the 
need to investigate the properties of RUNX1 in breast cancer (Janes 2011). 
  
182 
 
Figure 3.13 RUNX1 is primarily associated with early, smaller tumors while 
RUNX2 is most associated with late, larger tumors. 
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Figure 3.13 RUNX1 is primarily associated with early, smaller tumors while 
RUNX2 is most associated with late, larger tumors. 
 
(A) Mean and SEM (error bars) RUNX1 (left) and RUNX2 (right) scores 
associated with TNM (tumor node metastases) stages. **** = Kruskal-Wallis p-
value < 0.0001 comparing RUNX1 staining in T1N0M0 to – (normal) (left). *** = 
Kruskal-Wallis p-value < 0.0001 comparing RUNX2 staining in T4N0M0 to – 
(normal) (right). (B) Mean and SEM (error bars) RUNX1 (left) and RUNX2 (right) 
scores associated with breast cancer grades. * = Kruskal-Wallis p-value < 0.05 
comparing RUNX1 staining in Grade 1 versus Grade 2 (left). ** = Kruskal-Wallis 
p-value < 0.01 comparing RUNX2 staining in Grade 2 versus – (normal) (right). 
(C) Mean and SEM (error bars) RUNX1 (left) and RUNX2 (right) scores 
associated with breast stage. **** = Kruskal-Wallis p-value < 0.05 comparing 
RUNX1 staining in Stage I versus – (normal) / Stage IIb / IIa (left). * = Kruskal-
Wallis p-value < 0.05 comparing RUNX2 staining in Stage IIIb versus – (normal) 
(right).  
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RUNX1 expression is correlated with AR expression and has a strong 
association with ER+ breast cancer, which is dependent on AR status 
 
As RUNX2 has been previously reported to be primarily expressed in ER- Asian 
breast cancer patients (Das et al. 2009), and RUNX1 has been reported to 
function as a tethering factor for ER-alpha in vitro (Stender et al. 2010), it is of 
particular interest to define the associations between RUNX protein expression 
and ER in North American breast cancer patients. We observed that RUNX1 
expression was significantly associated with ER+ breast cancer (Figure 3.14 A – 
left), while RUNX2 expression was not dependent on ER status (Figure 3.14 A - 
right). This observation is particularly interesting because RUNX2 expression 
has previously been shown to be inversely correlated with ER in vitro and in 
Asian breast cancer patients (Das et al. 2009, Chimge et al. 2011), which is 
contradictory to what we have observed in North American patients. A further 
contradictory result is the observation that RUNX2 was an independent predictor 
of breast disease, progression and metastasis in Asian patients (Onodera et al. 
2010), while in North American patients we observed RUNX2 is not an 
independent prognostic factor and is primarily expressed in large, invasive, non-
metastatic (T4N0M0) ductal carcinoma (Figure 3.12 B & Figure 3.13 A – right).  
Breast cancer incidence and death is much higher in North America as compared 
to Asia, and it is hypothesized that environmental factors (such as diet and 
lifestyle) rather than genetics contribute to these observed differences in breast 
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cancer epidemiology (Jemal et al. 2010). It is unknown which factor or 
combination of factors may be driving the differences observed in the expression 
patterns of RUNX2 between North American and Asian patients. Further, there 
are no studies that provide a strong link between RUNX2 expression levels and 
environmental factors. 
 
Extending our analysis to HER2, we found that the expression of both RUNX1 
and RUNX2 were associated with HER2+ breast cancer (Figure 3.14 B), an 
observation which, in the case of RUNX1, was dependent on ER status (Figure 
3.14 C). Neither RUNX1 nor RUNX2 expression were observed to be 
significantly associated with PR status (Figure 3.14 D), however, RUNX1 
expression was significantly associated with ER+/PR- breast cancer (Figure 3.14 
E). We further observed that RUNX2 expression was not altered by combined 
ER/PR status (data not shown). 
 
In breast cancer, androgen receptor (AR) is a prognostic indicator, known to 
inhibit the activity of ER-alpha (Hickey et al. 2012). We observed that RUNX1 
expression levels were correlated with AR levels (Figure 3.14 F), and the 
association of RUNX1 expression with ER+ breast cancer was highly dependent 
on AR status (Figure 3.14 G). RUNX2 expression was not observed to be 
affected by AR status or AR/ER combined status (data not shown). This 
observation represents a potentially novel subtype of breast cancer, which is 
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RUNX1, ER, and AR positive. Based on our observations (Figure 3.13 A – left), 
this subtype of cancer is likely to be a low grade, small tumor. 
 
A common means of describing breast cancers in both prognostic and diagnostic 
terms is to look at the combined statuses of HER2, ER and PR (Allred et al. 
1998). We therefore investigated the extent to which combining these growth and 
hormone receptor statuses affected the observed expression levels of RUNX 
proteins. We observed no statistically significant associations between these 
triple statuses with RUNX1 (Figure 3.14 H – left) or RUNX2 (Figure 3.14 H - 
right). However, the previously observed trend for RUNX2 association with 
HER+ breast cancer (Figure 3.14 B – right) was observed when looking at all 
three receptors combined (Figure 3.14 H – right). 
 
These results demonstrate that the expression of RUNX proteins, while not 
correlated with disease progression, are sensitive to growth and hormone 
receptor expression patterns. Given the observed functional differences for 
RUNX proteins between osteosarcoma and breast cancer cells, we hypothesize 
that RUNX proteins in the presence or absence of these hormone receptors may 
have quite distinct functional roles. A key finding in our comparison of RUNX1 
and RUNX2 expression levels with growth/hormone receptor status was that 
triple-negative (HER2-/PR-/ER-) breast cancer was associated with the lowest 
RUNX1 levels (Figure 3.14 H – left) and nearly the lowest RUNX2 levels (Figure 
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3.14 – right). Triple-negative breast cancer is clinically associated with poor 
patient outcome (Dent et al. 2007), and the observation that the expression of 
RUNX proteins in human breast cancer was more associated with at least one 
growth/hormone receptor (Figure 3.14) leads us to hypothesize that RUNX-
positive breast cancer is associated with positive patient outcome. The presence 
of HER2, ER, or PR is used to determine treatment regimens targeted towards 
these receptors and generally patients have higher survival rates (Dent et al. 
2007). Unfortunately, our hypothesis was not testable with these samples as we 
did not have access to patient outcome data such as survival, disease-free 
survival or metastatic events.  
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Figure 3.14 RUNX1 expression correlates with AR expression in breast cancer. 
RUNX1 is primarily associated with HER2+/PR-/ER+ breast cancers, and 
RUNX1 association with ER+ breast cancer is dependent on HER2+ and AR+ 
status. RUNX2 expression is primarily associated with HER+ breast cancers. 
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Figure 3.14 RUNX1 expression correlates with AR expression in breast cancer. 
RUNX1 is primarily associated with HER2+/PR-/ER+ breast cancers, and 
RUNX1 association with ER+ breast cancer is dependent on HER2+ and AR+ 
status. RUNX2 expression is primarily associated with HER+ breast cancers. 
 
(A) Mean and SEM (error bars) scores for RUNX1 (left two columns) and RUNX2 
(right two columns) in ER+ and ER- breast cancers. * = Kruskal-Wallis p-value < 
0.05 comparing RUNX1 scores in ER+ versus ER-. (B) Mean and SEM (error 
bars) scores for RUNX1 (left two columns) and RUNX2 (right two columns) in 
HER2+ and HER2- breast cancers. * = Kruskal-Wallis p-value < 0.05 comparing 
RUNX1 scores in HER2+ versus HER2-. ** = Kruskal-Wallis p-value < 0.01 
comparing RUNX2 scores in HER2+ versus HER2-. (C) Mean and SEM (error 
bars) scores for RUNX1 (left panel) and RUNX2 (right panel) combining HER2 
and ER statuses in breast cancer samples. ** = Kruskal-Wallis p-value < 0.01 
comparing RUNX1 scores in HER2+/ER+ versus HER2-/ER-. ** = Kruskal-Wallis 
p-value < 0.01 comparing RUNX2 scores in HER2+/ER- or HER2+/ER+ versus 
HER2-/ER-. (D) Mean and SEM (error bars) scores for RUNX1 (left two columns) 
and RUNX2 (right two columns) in PR+ and PR2- breast cancers. (E) Mean and 
SEM (error bars) scores for RUNX1 combining PR and ER statuses in breast 
cancer samples. **** = Kruskal-Wallis p-value < 0.0001 comparing RUNX1 
scores in PR-/ER+ versus PR-/ER-. (F) Mean and SEM (error bars) of RUNX1 
score associated with AR score (x-axis). **** = Kruskal-Wallis p-value < 0.0001 
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comparing RUNX1 scores in AR- to AR++ or AR+++ (F). Mean and SEM (error 
bars) scores for RUNX1 combining AR and ER statuses in breast cancer 
samples. **** = Kruskal-Wallis p-value < 0.0001 comparing RUNX1 scores in 
AR+/ER- or AR+/ER+ versus AR-/ER- (G). Mean and SEM (error bars) scores for 
RUNX1 (left panel) and RUNX2 (right panel) in all permutations of HER2, PR and 
ER. RUNX1 (left panel) non-parametric (Kruskal-Wallis) ANOVA p-value < 0.05. 
RUNX2 (right panel) non-parametric (Kruskal-Wallis) ANOVA p-value < 0.01 (H). 
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Discussion 
 
Here we present an unbiased analysis of the functions of RUNX1 and RUNX2 in 
MDA-MB-231 cells. We demonstrate that RUNX proteins did not affect the rate of 
protein synthesis MDA-MB-231 cells through the transcriptional regulation of 
ribosomal RNA as they did in SaOS-2 cells. Using transcriptome-wide profiling of 
gene expression following knockdown of RUNX proteins, we found that the 
majority of genes responsive to RUNX siRNA were uniquely responsive to either 
RUNX1 or RUNX2. This observation is particularly interesting as this is the first 
analysis of the extent to which endogenous RUNX1 and RUNX2 functionally 
overlap on a genome-wide scale. This study is also the first time the genome-
wide binding profile of RUNX proteins has been characterized using endogenous 
protein in a breast cancer cell line. Similar to the observations made for 
transcriptome functions, RUNX binding positions had very little overlap. Given 
that RUNX proteins share a highly-conserved Runt-homology domain 
responsible for DNA-binding, this is a very interesting result. Because this is an in 
vivo result and not an EMSA or other in vitro approach, this suggests that RUNX 
proteins are sensitive to more than just local genomic sequence when interacting 
with chromatinized DNA. As discussed earlier, previous studies have 
demonstrated that RUNX proteins can be recruited to genomic regions through 
protein-protein interactions with co-factors that are independent of a RUNX-
binding site (Gutierrez et al. 2002). Our results suggest that the genomic 
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locations of RUNX proteins are sensitive to more than just the local sequence 
motifs. The binding of other transcription factors has similarly been shown to be 
sensitive to co-factors and chromatin states (Wang et al. 2012), so our 
observations we not unexpected. Given that RUNX proteins appear to be 
sensitive to context, we propose that understanding the contextual factors that 
affect the binding and regulatory roles of RUNX proteins are equally as important 
as studying the temporal expression patterns of RUNX proteins in breast cancer 
progression and metastasis. 
 
We also observed that while the majority of RUNX1 binding loci are not in the 
“promoter” of genes, those near the TSS were highly likely to be functional 
binding sites as these locations were enriched for H3K4me3 and near genes that 
were responsive to RUNX siRNA. We observed strong RUNX “foci” when 
staining nuclei for RUNX proteins, which leads us to believe that RUNX proteins 
are in close three-dimensional proximity with one another in intact nuclei. A 
limitation of this current study is the ability to understand how these non-promoter 
intergenic RUNX binding loci are related to one another in three-dimensional 
context, especially given evidence suggesting that RUNX1 mediates chromatin 
looping to activate gene expression (Jiang and Peterlin 2008, Levantini et al. 
2011). 
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This study is also the first study to analyze the expression of RUNX1 in human 
breast cancer patients via immunohistochemistry and the first study to examine 
RUNX2 expression in North American patients. Our results demonstrate that in 
North American patients RUNX proteins were not independent prognostic factors 
of disease. The observation that RUNX1 and RUNX2 were associated with early 
and late disease states, respectively, and regulated a novel cohort of genes in 
vitro suggests that RUNX proteins may play important temporal roles during 
tumor progression. This is an important point given the many observations of the 
context-specific roles for RUNX proteins (Cameron and Neil 2004). While RUNX1 
may function as a tumor-suppressor protein in normal mammary epithelial cells 
(Kadota et al. 2010, Wang et al. 2011a), we observed RUNX1 functions to 
promote the invasive/metastatic potential of malignant metastatic MDA-MB-231 
cells. Extending these in vitro observations to our observations in human patients 
suggest that it will be quite interesting to investigate the functions of RUNX 
proteins when expressed in breast cancer cells of varying hormone receptor 
statuses. However, as discussed before, RUNX1 is frequently mutated in human 
breast cancer (The Cancer Genome Atlas Network 2012), and we have observed 
that RUNX1 expression is low in late disease and significantly lower in metastatic 
diease. These previously observations, combined with our study suggest that 
RUNX1 may play an important tumor suppressor role in breast cancer. As 
cancers progress, traits that give the cells a growth advantage for the cancer 
cells are selected. Therefore, the observations that RUNX1 expression is 
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reduced in late-stage and metastatic disease, combined with the high rate of 
mutations observed in the RUNX1 gene suggests that it is advantageous for the 
cell to have either less RUNX1 or a mutant form of RUNX1. 
 
These results show a strong correlation between RUNX1 expression and 
androgen receptor (AR) expression. This is especially interesting as AR 
expression is an emergent marker associated with disease progression and 
treatment (Hickey et al. 2012). This study further shows that RUNX2 expression 
is not associated with estrogen receptor (ER) status, while one study in Asian 
patients found that RUNX2 expression is inversely correlated with ER expression 
(Das et al. 2009) and another study in Asian patients defined RUNX2 as an 
independent prognostic marker of breast cancer (Onodera et al. 2010). The 
differences observed between RUNX2 clinical associations in North American 
patients and Asian patients reinforce the idea that the expression and functions 
of RUNX proteins are highly sensitive to context. A recent study in North 
American breast cancer patients by The Cancer Genome Atlas Network showed 
that neither RUNX1 nor RUNX2 expression is significantly associated with 
disease progression (The Cancer Genome Atlas Network 2012). This study also 
found that in ER+ breast tumors, RUNX1 has a significant frequency of mutations 
that would cause early translational termination. The endogenous RUNX1 in the 
MDA-MB-231 is the correct length, so our in vitro studies did not address the 
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functions of these truncated RUNX1 proteins; however, previous work has shown 
that shortened RUNX transcripts lack the ability to interact with the nuclear matrix 
and therefore cannot function correctly (Zeng et al. 1997). This may be a 
potential mechanism by which the tumor suppressor functions observed for 
RUNX in normal mammary epithelial cells can be bypassed (Kadota et al. 2010, 
Wang et al. 2011a). 
 
There are several technical limitations of this study that are important to discuss. 
First, our RNAi study was not as well-controlled as it could be. We did not use 
multiple siRNAs targeting RUNX mRNAs to demonstrate that the majority of the 
genes responsive to the RUNX siRNA transfections were specific and not off-
target effects. We also did not perform a compensation experiment in which we 
express transgenic RUNX protein following an siRNA-mediated knockdown of 
the endogenous protein to rescue the transcriptional effect of the knockdown. 
With these caveats, we recognize that an unknown number of genes identified by 
Affymetrix could be the result of off-target effects. This is hopefully not the case 
as the number of genes (66) was quite small as compared to the several hundred 
genes identified in knockdowns done in SaOS-2 cells (Young et al. 2007b, van 
der Deen et al. 2012) or by overexpression of Runx2 in MCF-7 cells (Chimge et 
al. 2011). Another important consideration to make is our use of the MDA-MB-
231 cells as a model cell line for RUNX protein functions in breast cancer. MDA-
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MB-231 cells are isolated via pleural effusion from a patient who had a recurrent 
disease following mastectomy and treatment with 5-fluorouracil followed by 
combined treatment with Adriamycin, Cytoxan, and methotrexate (Brinkley et al. 
1980). The patient was again treated with methotrexate 5 days prior to isolation 
of MDA-MB-231 cells, and the patient died a few months after isolation of the 
cells. Therefore, these MDA-MB-231 cells represent an extremely aggressive 
form of breast cancer. We observed much weaker expression of RUNX proteins 
in more advanced breast cancers and significantly less in metastatic breast 
disease. Further, we observed that RUNX proteins were more strongly 
expressed when the breast cancer was positive for at least one growth or 
hormone receptor. MDA-MB-231 cells are triple-negative breast cancer cells, 
which further make them a less appropriate cell-based model for studying the 
functions of RUNX proteins in breast cancer. This is especially critical given that 
we are proposing that the functions of RUNX proteins are sensitive to cellular 
context. A further complication, for which we have not addressed, is the mutation 
status of RUNX1 and RUNX2 in MDA-MB-231 cells. As mentioned before, we 
observed that the RUNX1 and RUNX2 Western blot bands migrated at the 
appropriate molecular weight in an SDS-PAGE gel, so we do not suspect that 
RUNX proteins were truncated in MDA-MB-231 cells. However, this does not rule 
out the possibility that these RUNX genes may have point mutations that cause 
aberrant functions. We have operated under the assumption that RUNX1 and 
RUNX2 were wild-type in MDA-MB-231 cells, but we should not rule out the 
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possibility that many of the breast cancer-specific functional roles for RUNX1 and 
RUNX2 we have observed may be a consequence of mutations. 
 
Materials and Methods 
 
Tissue Microarrays 
 
TMAs (BR1503a & BR10010) were obtained from US BioMax. Information 
pertaining to Grade, Stage, TNM, Type, ER, PR, HER2, AR, p53, and ki67 were 
provided by US BioMax. 
 
BR1503a is a primary breast tissue array of 150 samples of 75 patient cases: 3 
cases of adjacent normal breast tissue, 3 cases of breast fibroadenoma, 2 cases 
of breast cystosarcoma phyllodes, 7 cases of breast intraductal carcinoma, and 
60 cases of breast invasive ductal carcinoma. Duplicate cores per case. 
 
BR10010 is a breast carcinoma and matched metastatic carcinoma array of 100 
samples of 50 patient cases: 46 cases of invasive ductal carcinoma, 1 case of 
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micropapillary carcinoma, 2 cases of invasive lobular carcinoma, and 1 case of 
neuroendocrine carcinoma. Duplicate cores per case. 
 
Immunohistochemistry 
 
RUNX2 staining was done using a lab stock of Mouse Monoclonal hybridoma 
(IgG purified) clone 8G5 as previously (Das et al. 2009) with the following 
modification: antibody concentration was reduced to 1:500 dilution. 
 
RUNX1 staining was done as previously described (Liu et al. 2011) using RUNX1 
Rabbit Polyclonal 4334 from Cell Signaling. 
 
Histology Quantification 
 
Each tissue section was imaged and independent researchers blindly scored the 
sections based on the metric in Figure 3.12 A, which is based on the nuclear 
intensity of DAB. 
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Histological Statistics 
 
Statistical analyses were performed by converting histological scores (-, +, ++, 
+++, and ++++) into scalar variables (0, 100, 200, 300, and 400). Scores such as 
+/++ were converted to the halfway point i.e. 150. Statistical testing was 
performed in GraphPad Prism using the Kruskal-Wallis non-parametrc ANOVA or 
(for 3 or more groups) or the non-parametric t-tests (Wilcoxon Rank-Sum). Non-
parametric tests were used as the data values are not normally distributed. 
Kruskal-Wallis ANOVA tests were followed by multiple comparisons for each 
group. 
 
siRNA Oligos 
 
Smart Pool: ON-TARGETplus Non-silencing siRNA (D-001810-0X) Dharmacon. 
SMARTpool: ON-TARGETplus RUNX1 siRNA (L-003926-00-0005) Dharmacon 
SMARTpool: ON-TARGETplus RUNX2 siRNA (L-012665-00-0005) Dharmacon 
 
siRNA Transfection 
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siRNA transfection was done using Oligofectamine (Invitrogen) and Opti-MEM 
(Invitrogen) using 50nM siRNA according to manufacturer’s instructions. 
 
Affymetrix Arrays and Analysis 
 
Human Gene 1.0ST arrays from Affymetrix were used to measure gene 
expression levels in MDA-MB-231 cells following Runx siRNA transfection. cRNA 
amplification and hybridization to the array was performed by the UMASS 
Medical School Genomic Core as previously described (Dowdy et al. 2010). 
 
Analysis was performed in R to execute normalization, quality control, transcript-
level reporting, annotation, and contrast tests. The “affy” (Gautier et al. 2004) 
package was used to read in raw fluorescent values from arrays; values were 
normalized across all arrays using quantile normalization (Bolstad et al. 2003), 
robust means average (RMA) background correction and median polish (Irizarry 
et al. 2003). Quality control plots were generated to ensure the arrays did not 
have any artifacts and post-processing values were in similar ranges. Transcripts 
were annotated using the “annotate” package, the 
“hugene10sttranscriptcluster.db” package. Contrast tests were generated and 
performed using the “limma” package. 
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Matrigel Invasion and Migration Assays 
 
Proliferating MDA-MB-231 cells were trypsinized and counted using Cellometer 
Auto T4 Cell Counter. A cell suspension of 100,000 cells/mL in growth medium 
was prepared and 100μL of the suspension was loaded into each BD Matrigel 
24-well 8.0 µm PET Membrane Invasion Chamber (#354483). Matrigel coated 
plates, and control insert plates had 500μL NIH3T3-conditioned medium loaded 
in the bottom as the chemoattractant. Plates and chemoattractant medium were 
incubated at 37°C for 3-4 hours prior to loading MDA-MB-231 cells. Cells were 
incubated for 16 hours at 37°C in 5% CO2 and then fixed and stained using the 
Fisher HealthCare PROTOCOL Hema 3 Manual Staining System (#22-122-911) 
according to the manufacturer's instructions. Matrigel and cells that did not 
invade were eliminated by cotton swabs. Cells that had migrated or invaded to 
the other side of the inserts were counted using an inverted light microscope. 
 
Immunofluorescence 
 
Cells were grown on gelatin-coated coverslips, fixed, stained, and imaged for 
RUNX1 (Cell Signaling Rabbit Polyclonal RUNX1 4334), RUNX2 (Santa Cruz 
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Biotechnologies Rabbit Polyclonal RUNX2 M-70), and UBF (Santa Cruz 
Biotechnologies Mouse Monoclonal UBF F-9) as previously described (Ali et al. 
2010, 2012). 
 
Growth Curve 
 
For each biological replicate, cells were plated at equal density (150,000 cells per 
well on day 1). On day 2, three wells of a 6-well plate per time point (24, 48, and 
72 hours post-transfection) were transfected with siRNA. At each time point, 
three wells per siRNA were trypsinized, spun down, and resuspended in equal 
volume growth media. The cell suspension from each well was used on each 
side of a Cellometer counting slide and counted using a Cellometer T4 Auto Cell 
Counter (making 6 technical replicates per time point, per biological replicate). 
 
35S-Protein Synthesis Labeling 
 
Protein synthesis was measured as described in (Ali et al. 2010, 2012). Briefly, 
cells were grown in Met/Cys free medium prior to pulse labeling with EasyTag 
EXPRESS35S Protein Labeling Mix (Perkin Elmer). Protein was lysed and run on 
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an SDS-PAGE gel, then dried on Whatman paper. Blot was exposed to film and 
densitometry was used to quantify differential amino acid incorporation. 
 
Chromatin Immunoprecipitation 
 
ChIP conditions for RUNX1, RUNX2 and UBF in MDA-MB-231 cells as described 
(Lee et al. 2006) with the following modifications:  
Crosslinking 
1. Cells were grown to near-confluence in 100mm dishes. 10 plates per ChIP 
antibody are used. 
2. Cells were washed in 37°C serum-free medium twice, and then placed in 
10mL 37°C serum-free medium before addition of 1mL crosslinking buffer 
(50mM HEPES-KOH, 100mM sodium chloride, 1mM EDTA, 0.5mM 
EGTA, 2.75% w/v formaldehyde) and incubated for 5 minutes at room 
temperature. 
3. 500µL freshly-prepared 2.5M glycine was added to quench crosslinking 
reaction, and incubated for 5-10 minutes at room temperature. 
4. Plates were then placed on ice such that the plates were surrounded by 
ice on all sides and washed twice with ice-cold PBS. Then, 500µL of ice-
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cold PBS supplemented with Roche cOmplete EDTA-Free Protease 
Inhibitor and 25nM MG132 is added. 
5. Cells were scraped and placed in nuclease-free 1.75mL tubes (Axygen 
MCT-175-C 1.7) and spun at 500g for 5 minutes at 4°C. 
6. Supernatant was removed and tube was dropped in liquid nitrogen and 
stored at -80°C until sonication. 
Nuclear Isolation & Sonication 
1. Cells were removed from -80°C and placed on ice in 1mL freshly-prepared 
ice-cold Buffer A (50mM HEPES-KOH pH 7.5, 140mM sodium chloride, 
1mM EDTA, 10% v/v glycerol, 0.5% v/v NP-40, 0.25% v/v Triton X-100, 1x 
cOmplete EDTA-Free Protease Inhibitor, 25µM MG-132 in nuclease-free 
water). 
2. Once cells had thawed, tubes were placed on upright rotator at 4°C for 10 
minutes. 
3. Nuclei were spun down at 700g for 5 minutes at 4°C and Buffer A 
supernatant was removed. 
4. Nuclei were resuspended in 1mL freshly-prepared ice-cold Buffer B 
(10mM Tris-HCl pH 8.0, 200mM sodium chloride, 1mM EDTA, 1mM 
EGTA, 1x cOmplete EDTA-Free Protease Inhibitor, 25µM MG-231 in 
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nuclease-free water) and placed on upright rotator at room temperature for 
10 minutes. 
5. Nuclei were spun down at 700g for 5 minutes at 4°C and Buffer B 
supernatant was removed. 
6. Nuclei were resuspended in freshly-prepared ice-cold Buffer C (10mM tris-
HCL pH 8.0, 100mM sodium chloride, 1mM EDTA, 1mM EGTA, 0.1% w/v 
sodium deoxycholate, 0.5%w/v N-lauroylsarcosine, 1x cOmplete EDTA-
Free Protease Inhibitor, 25µM MG-132 in nuclease-free water) and 
incubated on ice for at least 20 minutes prior to sonication. 
7. Sonication was done on a Misonix Sonic Dismembrator S-4000 using a 
1.6mm microtip adapter. Tube was positioned in an ice water bath such 
that the probe tip was a few millimeters from the bottom of the tube (clear 
tube is helpful here) and perfectly centered. Sonication program was as 
follows: 
a. 8 cycles, with 30 second rest periods between each cycle. 
b. Each cycle was 20 seconds total pulse time, oscillating between 1 
second “on” and 2 seconds “off”. 
8. Following sonication, an aliquot of lysate was taken and processed for 
DNA purification to verify by agarose gel that the median fragment size is 
approximately 400bp. Lysates were frozen until validation was completed. 
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Immunoprecipitation 
1. Once fragment size had been validated, lysates were thawed and 100µL 
10% v/v Triton X-100 was added to each tube and tubes were spun at full 
speed at 4°C for 20 minutes. Soluble fractions from all tubes (from same 
cell line / condition) were combined into one nuclease-free tube on ice. 
2. For each IP, approximately 10mL lysate was added to a nuclease-free 
15mL conical. 50µL of lysate was set aside as “input” and stored at 4°C.  
3. 50µg of each antibody was added to appropriate 15mL conical tubes, and 
tubes were placed on vertical rotator at 4°C for 16 hours. 
4. Invitrogen Protein A and Protein G Dynalbeads were thoroughly 
resuspended. 
5. 50µL each Protein A and Protein G Dynalbeads were added to each 15mL 
tube. Tubes were placed back on vertical rotator at 4°C and incubated for 
4 hours. 
6. 1 1.75mL nuclease-free tube per IP was placed on MagnaRack 
(Invitrogen). Lysates were added to tubes, when beads were fully adhered 
to magnet, cleared lysate was removed. This was repeated until all beads 
had adhered to magnets. 
7. Beads were gently washed with the following freshly-prepared ice-cold 
buffers in order: Low Salt Wash Buffer (0.1% w/v SDS, 1% v/v Triton X-
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100, 2mM EDTA, 150mM Sodium Chloride, 20mM Tris-HCl pH 8.0 in 
Nuclease-Free Water), High Salt Wash Buffer (0.1%w/v SDS, 1% v/v 
Triton X-100, 2mM EDTA, 500mM Sodium Chloride, 20mM Tris-HCl pH 
8.0 in Nuclease-Free Water), TEN (1mM ETDA, 10mM Tris-HCl pH 8.0, 
50mM Sodium Chloride). 
8. Beads were placed in 100uL freshly-prepared room temperature Elution 
Buffer (1% w/v SDS, 100mM Sodium Bicarbonate, 10mM EDTA in 
Nuclease Free Water) and tubes were placed on tube shaker for 30 
minutes at room temperature. Tubes were then moved to MangaRack, 
Cleared solution was transferred to fresh tube. These steps was repeated 
twice. 
9. 200µL TE Buffer was added to lysates to bring the final volume to 400uL. 
150µL Elution Buffer and 200µL TE Buffer was added to 50 µL Input 
sample set aside earlier. Genomic DNA isolation proceeds as described 
(Lee et al. 2006). 
 
ChIP-qPCR 
 
For ChIP-DNA isolated as above, ChIP-qPCR was performed as described (Ali et 
al. 2010, 2012). 
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ChIP-seq Library Preparation 
 
For ChIP-DNA isolated as above, libraries were prepared for paired-end 
multiplexed Illumina/Solexa sequencing using the Invitrogen TruSeq DNA 
Sample Prep v2.0 Kit according to manufacturer’s instructions. 
 
Read Mapping 
 
Reads were mapped to hg19 using Bowtie2 for paired-end reads (Langmead and 
Salzberg 2012). 
 
Peak Calling 
 
Peaks were called on aligned sequences using MACS (Zhang et al. 2008). 
 
Conversion of SAM to BED files 
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Mapped reads were converted to BED-format reads for analysis using SAMTools 
(Li et al. 2009) and BEDtools (Quinlan and Hall 2010). 
 
Discriminative Motif Discovery 
 
Homer (Heinz et al. 2010) motif discovery software was used to discover 
enriched motifs. For each set of test intervals, a GC/CpG/length-matched set of 
intervals was generated by Homer and used as background. 
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Background 
 
The advent of high-throughput sequencing technologies has allowed for the 
application of systems biology-type approaches to a wide range of cell biological 
models. Often, it is necessary to validate genome-wide findings at single gene or 
genomic locus resolution, and this is commonly done through the design of Real-
Time qPCR (quantitative polymerase chain reaction) primers for the amplification 
of either cDNA (complimentary DNA) or genomic DNA. We propose that the tools 
and methods used to design Real-Time qPCR primers should be both rigorous in 
design parameters and accommodate batch design. A major hurdle in the design 
of Real-Time qPCR primers is the investment of time required to make good 
primers. While there are many available programs to automate the design of 
primer pairs, they do not provide the user with enough information to decide 
which primers have the best chance of being efficient for qPCR. Further, we have 
not found a program that provides sufficient detail about the positions of primers 
to determine whether they can be used for a circumstance such as amplification 
of a specific isoform, or detection of cDNA in samples with genomic DNA 
contamination. To facilitate the process of designing qPCR primers in a rapid 
manner, we have designed the FoxPrimer suite of primer design algorithms. 
Through the use of a web interface, FoxPrimer mechanizes the design workflow 
via a number of robust command-line tools and stores the primer results in a 
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rapidly-searchable local database. These design choices provide a simple 
interface, which can be shared among a group of users. 
 
Purpose 
 
The design of Real Time qPCR primers is a critical step in any experimental 
approach where quantitative analysis is essential. Biological interpretation of 
results is often highly dependent on the use of primers that are specific, highly 
efficient, and well-annotated in position. In our experience, with the wealth of 
tools available to end-users for primer design, creating primers that fit the 
specificity requirement is generally successful. However, a single open-source 
program that meets all three requirements does not exist; instead users must rely 
on multiple programs to design and annotate primer pairs. FoxPrimer is designed 
to create and store Real-Time qPCR primers that meet all three of these 
requirements (specific, efficient, and well-annotated), while providing a simple 
web-based interface for the end-user. 
 
A non-experimental hurdle for primer design is the management of primer 
sequences within a research group or among collaborators. Commonly, 
researchers maintain a large spreadsheet of primers and their cognate 
information. While this may work well for individual use, this can easily become 
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quite unwieldy when a single document is shared among many users and may 
become a problem if all users are allowed to read and write to the same file. 
Further complicating the issue with spreadsheet-style storage is the implicit 
requirement that researchers must manually enter the primer information, which 
in many cases is very time-consuming. This is especially problematic when 
implementing a policy in which primer location is required for entry into the 
spreadsheet, as many primer design programs do not provide this information 
and would therefore become a barrier for users to easily store their primer 
information in a consistent format that is useful to others.  
 
FoxPrimer is designed to rapidly annotate primer pairs that have been 
experimentally validated, storing the primer information in a searchable 
database. To store validated primers, users only need to enter the sequences 
and a few other pieces of information, while FoxPrimer handles the annotation 
and storage into the primer databases. FoxPrimer therefore offers a solution for 
management of a database of primer information indexed with uniform 
information and with minimal time and effort requirements on the end-user for 
entry. 
 
Real Time qPCR Primer Design Rules 
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General considerations 
 
Primer pairs designed for Real Time qPCR typically have the following 
characteristics: primer oligo length between 18 and 24 nucleotides, melting 
temperature between 58°C and 62°C, and primer product size of approximately 
100bp. There are other considerations as well, such as no self-complementarity 
and low probability of recognizing repetitive sequences. Real-Time qPCR primers 
should amplify a single product as measured experimentally by a single band on 
a gel (after reaction) or a single sharp peak on a dissociation curve. One of the 
most critical, and often overlooked, aspects of Real Time qPCR primer usage is 
validation of primer efficiency by standard curve. Two common means of 
determining relative levels of a target sequence rely on the use of one or more 
internal controls or reference genes; both of these methods require all primer 
pairs (target and control) to amplify products at similar rates (Pfaffl 2001, 
Hellemans et al. 2007). Primer pair efficiency is measured by the rate at which 
the target is amplified in response to template concentration; across a wide range 
of concentrations, each time the concentration doubles, the detection value (Ct) 
should increase by one giving an efficiency of 100% (Bustin et al. 2009). Primer 
pairs that are not highly sensitive to template concentration are not suitable for 
quantitative use, and should therefore not be used for Real Time qPCR. While 
many algorithms are designed to give the best chance at having highly efficient 
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primer pairs, experimental validation of primer pair efficiency is absolutely 
required. 
 
cDNA Primer Design Considerations 
 
When designing Real Time qPCR primers with the intent of amplifying specific 
cDNA targets, there are several considerations that must be kept in mind. The 
first is the ability to recognize the mature mRNA sequence with greater efficiency 
than any genomic DNA contamination. The amount of contaminating genomic 
DNA in an RNA sample can be reduced by DNAse I digestion prior to cDNA 
amplification. Experimentally, taking an equal amount of RNA and performing the 
cDNA amplification reaction without the addition of reverse transcriptase creates 
a negative control template that can be used in the Real Time qPCR reaction to 
quantify the extent of genomic DNA contamination in the sample. 
 
In eukaryotes, intronic sequences that are part of the pre-mRNA are spliced out 
of the transcript to form the mature mRNA. The junction points at which the 
exons are joined represent sequences that are typically not found at the genomic 
level and are unique to the mature transcript. When designing Real Time qPCR 
primers for the amplification of specific cDNA templates, using primer pairs for 
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which one or both oligos span these exon-junction points should create a primer 
pair that is highly specific for the mature form of the mRNA. Alternatively, 
designing a primer pair for which the primers recognize different exons with a 
large intron between the exons creates a bias towards the mature mRNA, if the 
Real Time qPCR elongation time is quite short. Lastly, primer pairs within the 
same exon will have the same ability to amplify genomic DNA as cDNA. Often, a 
primer pair that falls within the same exon is the only primer pair that meets the 
requirements for efficiency, and it is therefore critical to include experimental 
controls as described above. This last consideration is especially important when 
designing primers for genes that do not contain introns. 
 
Manual Primer Design 
 
Before describing how FoxPrimer works, we describe our workflow for manual 
primer design, which has proven to be quite successful in meeting our three 
requirements for primer design. FoxPrimer mechanizes each of these steps, 
saving time and effort on the part of the researcher. 
 
cDNA Primer Design 
Our typical workflow for manual design of cDNA primers for a single transcript 
has been empirically defined to have a very high rate of success in terms of 
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target specificity and primer pair efficiency. The design and positional-annotation 
of Real-Time qPCR primers for the amplification of cDNA has two parts. First, the 
cDNA sequence is aligned to the reference genome to define intron-exon 
junctions and intron sizes. Then, primers are designed for the cDNA sequence 
and locations are manually annotated based on cDNA-genomic DNA alignment 
coordinates. To accomplish these tasks, we use two web-based tools: NCBI 
Splign <http://www.ncbi.nlm.nih.gov/sutils/splign/splign.cgi> (Kapustin et al. 
2008) to define transcript splice junctions and Primer3-Web 
<http://frodo.wi.mit.edu/> (Rozen and Skaletsky 2000) for primer design. We then 
manually determine the locations of primer pairs relative to exon/intron 
coordinates. Comparing this workflow to the one executed by FoxPrimer, we can 
see that while the underlying tools for this workflow are quite similar, FoxPrimer 
requires much less investment of time and effort from the user (Table 4.1). 
 
Genomic DNA (ChIP) Primer Design 
 
When designing primers for amplification of genomic DNA, we first determine the 
genomic region in which we would like the primers to be designed and then 
download the genomic sequence. FoxPrimer only requires a BED-format file of 
genomic coordinates, which is, conveniently, the type of file generated by many 
popular peak-calling algorithms (MACS (Zhang et al. 2008), SPP (Kharchenko et 
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al. 2008), PeakSeq (Rozowsky et al. 2009)). The next consideration is whether 
we want primers to amplify a defined sub-sequence such as a motif or whether 
the goal is to amplify a broader region. If the objective is to design primers 
flanking a specific motif, either TFSEARCH 
<http://www.cbrc.jp/research/db/TFSEARCH.html> (Heinemeyer et al. 1998) or 
FIMO (Find Individual Motif Occurences) <http://meme.nbcr.net/meme/cgi-
bin/fimo.cgi> (Grant et al. 2011) is used to define the location of the motif of 
interest in a genomic sequence. Primer3-Web <http://frodo.wi.mit.edu/> (Rozen 
and Skaletsky 2000) is then used for primer design (setting the subsequence 
string if making primers for a specific motif). The positions of the primers within 
the genomic sequence are then manually calculated primers relative to a gene of 
interest. Again, comparison of this workflow to the one executed by FoxPrimer, 
shows that while the underlying tools are quite similar, FoxPrimer requires much 
less investment of time and effort from the user and provides more information 
about the relative location of the primer pair (Table 4.2). 
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Table 4.1 cDNA Primer Design 
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Table 4.2 Genomic DNA (ChIP) Primer Design 
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Program Structure - Model, View, Controller 
 
FoxPrimer is written in Perl on the Catalyst web framework 
<http://www.catalystframework.org/>. The program is structured such that the 
Model, View and Controller (MVC) (GuangChun et al. 2003) architecture can be 
easily separated for future development of FoxPrimer. 
 
Model  
 
FoxPrimer is structured where the majority of program logic and execution occurs 
within the Model. The Perl modules that constitute the Model of the FoxPrimer 
MVC are self-contained and are capable of executing primer design functions 
independent of the Catalyst Controller module. This design approach allows for 
easier maintenance and testing of the FoxPrimer suite of primer design functions 
should interactions with external utilities become unstable in the future. 
 
Controller 
 
The FoxPrimer Controller module is only responsible for relaying information 
from the user to the Model where all of the business logic takes place. Then, the 
Controller returns error messages or final data to the View (in this case the web 
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page). The FoxPrimer controller ensures that the data entered by the user are 
valid and relays error messages as needed. 
 
View 
 
The FoxPrimer View module is the web page where the user can interact with the 
settings and view output from the program. All code related to the display of the 
web pages is separate from any code involved in the business logic of the 
program. This design allows editing of the aesthetics without affecting the Model 
and Controller elements of the program. The FoxPrimer View module uses 
Template Toolkit <http://www.template-toolkit.org/> to render HTML code, and 
allows the Controller to pass Perl data structures to the View and have the 
Template Toolkit iterate through the information and properly display data to the 
user. 
 
Program Function 
 
cDNA Primer Design 
 
Upon entering the program, the View module (or the web page) renders and 
presents the user with a prompt for a comma-delimited list of RefSeq  (Pruitt et 
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al. 2009) RNA accessions (Figure 4.1). By default, the fields for product size, 
minimum intron size, and number per type are already filled, but can be changed 
by the user. The number per type field determines how many of each type of 
cDNA primer type will be returned. Primer types are defined by the locations of 
the primer pairs relative to the intron-exon junctions of the transcript. There are 
four types of primers that are returned to the user: junction spanning primers 
(one or both olgios span the intron-exon junction), exon primer pair (primers 
target different exons that have one or more introns between the exons whose 
combined length is greater than the user-defined minimum intron size), smaller 
exon primer pair (primers target different exons that have one or more introns 
between the exons whose combined length is less than the user-defined 
minimum intron size), and intra-exon primers (primers that map to the same 
exon). Also by default, the mispriming library for Primer3 is set to 'human', but 
can be changed based on the organism for which the user is designing qPCR 
primers. Once the FoxPrimer Controller has determined that all of the fields are 
valid, it will begin to check the RefSeq accessions entered by the user. 
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Figure 4.1 cDNA primer design form 
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Gene2Accession Database 
 
FoxPrimer relies on RefSeq accession and NCBI "GenInfo Identifier" or GI to 
determine the location of the sequence on genomic DNA, and to rapidly fetch the 
cDNA and genomic sequences from GenBank. In order to implement this large 
database of information, FoxPrimer provides a helper script that interacts with the 
NCBI FTP server to download the gene2accession flat file 
<ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2accession.gz> containing the 
requisite information, parses the file, and then stores the relevant information in a 
local SQLite <www.sqlite.org> database. Storage in the SQLite database allows 
FoxPrimer to rapidly determine if a user-defined RefSeq accession is valid before 
attempting to interact with GenBank. 
 
FoxPrimer will design primers for each valid accession, while each accession 
that is not found by FoxPrimer in the gene2accession database will be returned 
to the user in an error message. If the user has not entered any valid accessions, 
then the program will exit and inform the user which accession(s) were not found 
in the gene2accession database in an error message. 
 
BioPerl 
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FoxPrimer uses BioPerl (Stajich et al. 2002) to interact with NCBI and fetch a 
sequence object for each cDNA and genomic DNA pair found in the 
gene2accession database. FoxPrimer stores in memory the GI for the cDNA, and 
the GI, start position, stop position and strand for the genomic DNA. Then, using 
the BioPerl Bio::DB::GenBank module FoxPrimer fetches sequence objects from 
NCBI and extracts a description of the mRNA from the cDNA object. Sequences 
from both cDNA and genomic DNA objects are written to temporary files in 
FASTA format. 
 
Sim4 
 
Once the sequences have been fetched from NCBI and written to file, FoxPrimer 
uses Sim4 (Florea et al. 1998) to align the cDNA sequence to the genomic DNA 
sequence to determine the coordinates of intron-exon junctions and lengths (if 
any) of each intron. Sim4 is an algorithm written to rapidly determine a best-fit 
alignment for a cDNA sequence to a genomic DNA sequence. Sometimes, 
multiple alignments are found, but this is rare. In such an instance, FoxPrimer will 
consider each alignment as valid, and proceed with primer design algorithm 
treating each alignment as a different pair of cDNA and genomic DNA. 
 
BioPerl provides an interface to call Sim4 from the FoxPrimer Model modules 
and fetches the results for each alignment determined by Sim4 (usually only one 
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per cDNA-gDNA pair). FoxPrimer then determines the coordinates of the 5' and 
3' end of each exon, as well as the length of each intron, and stores the 
information in memory.  
 
Updated_Primer3_Run 
 
FoxPrimer then uses Primer3 to design several hundred primers using the cDNA 
sequence as the template and the user-defined product size boundaries as the 
only constraint. BioPerl provides a module to interact with Primer3, however, this 
module was written for a previous release of Primer3. The algorithm for Primer3 
(current version is 2.2.3) has since been updated and so have the inputs for 
Primer3. Therefore, FoxPrimer features an updated version of 
BioPerl::Module:Bio::Tools::Run::Primer3, which we will submit to the BioPerl 
group when FoxPrimer is made public. 
 
Based on the constraints defined by the user for how many of each type of 
primer to be designed, FoxPrimer will iterate through the primers designed by 
Primer3 in increasing primer pair penalty score. For each primer pair, FoxPrimer 
defines the primer pair type. FoxPrimer will continue through the list of primers 
until the maximum number of each type of primer pair has been reached, or the 
primers designed by Primer3 have been exhausted. 
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Once FoxPrimer has finished designing primers for each accession entered by 
the user, the primers are stored in a local SQLite database for designed cDNA 
primer pairs. The primer information is then returned the user in a table via the 
FoxPrimer View module, together with any error messages (Figure 4.2). Once 
the primers have been stored in the created primers database, they can be 
searched and retrieved rapidly using the FoxPrimer search functions described 
later. 
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Figure 4.2 Example output from FoxPrimer for cDNA primer design 
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Figure 4.2 Example output from FoxPrimer for cDNA primer design 
 
Screenshot of example output from FoxPrimer cDNA primer design. Tables of 
primers for each transcript are ordered by ascending primer pair penalty score 
from Primer3. 
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Genomic DNA Primer Design 
 
For design of genomic DNA qPCR primers, the FoxPrimer View module renders 
a form for the user to complete, along with a widget allowing the user to upload a 
BED-file of genomic interval coordinates (Figure 4.3). FoxPrimer will check to 
ensure that a file has been uploaded, and if not, the Controller will inform the 
View to prompt the user to upload a BED file. By default, the View has entered a 
product size for the primer pairs to be created, and the drop down menus for the 
genome and motif have been set to hg19 and "no motif", respectively. Each of 
these parameters can be changed by the user. 
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Figure 4.3 Genomic DNA primer design form 
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Dynamic Genome Addition 
 
FoxPrimer is capable of designing genomic DNA qPCR primers for all RefSeq-
annotated genomes. To extract the genomic sequences for primer design, 
FoxPrimer requires large (hundreds of megabytes to several gigabytes, 
depending on genome size) UCSC 2bit-format files for each genome. It is 
unreasonable to expect users of FoxPrimer to need a sequence file for all 
RefSeq genomes or to have the requisite disk space to store these files. 
FoxPrimer therefore offers dynamic genome addition for each reference genome 
the user would like to design genomic DNA qPCR primers for. A helper script is 
provided, which interacts with the UCSC MySQL server 
<http://genome.ucsc.edu/goldenPath/help/mysql.html> to extract the necessary 
files and genomic coordinates for genomic DNA primer design. Once a genome 
has been installed using this helper script, the genome will appear in the 
dropdown menu on the website and users will be able to design genomic DNA 
primers for this genome. 
 
Available Motifs 
 
Often, users will want to design their genomic DNA primers so that they amplify a 
genomic region that matches the DNA-binding motif for a specific protein. To 
assist in the design of primers, which are targeted around motifs, FoxPrimer 
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provides a set of 454 motifs from the 2009 JASPAR/TRANSFAC position weight 
motif matrices (Bryne et al. 2008). FoxPrimer provides helper scripts to update 
the motif list or add custom position weight matrices. The FoxPrimer Controller 
makes a call to the FoxPrimer Model modules to dynamically fetch a list of motifs 
available to the user. This list is sent to the FoxPrimer View module and 
displayed in the form of a drop down menu.  
 
By default, FoxPrimer will only read and design primers for the first 10 lines of a 
BED file. This design limits the time between execution and results. This variable 
is clearly defined in the FoxPrimer Model modules, and can be changed by the 
administrator. 
 
If any interval in the uploaded BED-file is 30bp or less, FoxPrimer will assume 
the user is requesting primer pairs to flank this region and will mark them as 
such. FoxPrimer will extend the coordinates of such an interval in both the 5' and 
3' directions by twice the length of the maximum user-defined product size. The 
coordinates of the original interval are stored and defined as the target sequence 
for Primer3. This ensures that any short interval supplied by the user will be 
included in the product amplified by the designed primer pairs. 
 
TwoBitToFa 
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For each set of valid coordinates, FoxPrimer will use these coordinates to write 
the FASTA format sequence to a temporary file. TwoBitToFa is provided as part 
of the source code written by Jim Kent for the UCSC genome browser (Meyer et 
al. 2013). This program provides very rapid retrieval of genomic sequence from a 
highly compressed 2bit file containing all genomic sequences. A FASTA format 
file is needed to find motifs (if required) using FIMO, and to design primers using 
Primer3. 
 
FIMO 
 
If the user elects to search for a motif within the genomic intervals, FoxPrimer will 
search for the user-defined motif using FIMO (Find Individual Motif Occurences) 
from the MEME (Multiple Em for Motif Elicitation) suite of motif-oriented programs 
(Grant et al. 2011). FoxPrimer makes a call to FIMO, informing FIMO of the 
sequence to search and the motif for which to search. If the motif is not 
discovered in an interval, that interval is returned to the user in an error message 
after primers have been designed around all other motifs discovered. For each 
motif discovered, FoxPrimer will treat these short intervals as described above 
(coordinates are extended, and used as target sequence for primer design).  
 
For each motif found in the target sequences, FoxPrimer will use the 
aforementioned Updated_Primer3_Run Model module to create 5 primer pairs. 
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FoxPrimer will store the necessary information about the primer oligos, and then 
use the relative template coordinates to extrapolate these coordinates into 
genomic coordinates. 
 
Primer Position Determination 
 
Designing a pair of primers to amplify genomic DNA is not a difficult task. It is, 
however, time-consuming to determine where these primers are relative to 
nearby genes. This information is important and should be stored for each primer 
pair. For some users, simply knowing where the primers are in raw genomic 
coordinates will satisfy their research needs, and FoxPrimer provides this 
information for each primer pair. However, knowing where a primer pair is 
located relative to nearby genes is a critical piece of information. To define the 
positions of primers relative to nearby genes, FoxPrimer implements a version of 
the algorithm used in PeaksToGenes (see Chapter 5). FoxPrimer creates a 
temporary BED-file of coordinates using the 5'-end of each primer as the 
genomic start and genomic end of the positive and negative strand primers, 
respectively. Then, using intersectBed from the BEDTools suite of programs 
(Quinlan and Hall 2010), FoxPrimer defines a list of genes that are within 100Kb 
of the primer pair. FoxPrimer then iterates through the list of genes, and 
mathematically determines the relative positions of the primer pair to each gene 
in the list. 
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Once FoxPrimer has determined the relative locations of all designed primers, 
the information for each primer pair is entered into the created primers database 
for genomic DNA primers. Like the created cDNA primers database, this 
database allows all created primers to be rapidly searchable by the user. Finally, 
the primer information is sent from the FoxPrimer Controller to the FoxPrimer 
View, and a table of primer information as well as messages, describing any 
errors that that may have occurred during primer design, is returned to the user. 
 
Validated Primer Entry 
 
Given the investments of time and reagent cost to validate a primer pair, it is 
critical that validated primers be stored in a location where they are both secure 
and accessible.  By implementing an SQLite database for primer information 
storage, FoxPrimer accomplishes both of these goals. 
 
To facilitate rapid addition of validated primers to the SQLite database, 
FoxPrimer allows batch entry of primers. FoxPrimer requires the user to enter 
primer information in the form of a tab-delimited file containing the following 
information: “Primer Type”, “Left Primer Sequence”, “Right Primer Sequence”, 
“Accession”, “Your Name”. “Efficiency”, “Left Primer Location”, “Right Primer 
Location”, and “Genome”. The last three parameters are only required if the 
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primers are designed for genomic DNA amplification, and informs FoxPrimer 
about where it should make the template DNA for in silico validation. 
 
The FoxPrimer Controller will make calls to the FoxPrimer Model modules to 
ensure that the fields entered in the file are valid. The user will be informed of 
any errors via an error message from the FoxPrimer View. For each primer pair, 
FoxPrimer will use Primer3 to calculate the Tm and primer pair penalty, and use 
the aforementioned algorithms to determine exonic or genomic positions of the 
primers for cDNA and genomic primers, respectively. After these parameters 
have been defined, the primer pair is entered into the validated primer database, 
which can be searched by the user. 
 
Discussion 
 
FoxPrimer provides a simple interface to a series of robust programs for the 
design of Real Time qPCR primers that amplify either cDNA or genomic DNA 
sequences. For each primer pair designed, FoxPrimer provides detailed 
information about the location relative to either exons or nearby genes. Because 
FoxPrimer also reports the primer pair penalty score, the user can make 
informed decisions about which primer pairs should be experimentally tested. 
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FoxPrimer can be used to make primer pairs for a single mRNA or genomic 
interval quickly.  However, the real strength of this program lies in its ability to 
accomplish these tasks in batch. A limited version of FoxPrimer is available at 
<http://www.foxprimer.org>, and is running on a micro-instance of Amazon EC2, 
therefore, strict limits have been set to reduce compute cycles and costs. On 
more powerful private servers, FoxPrimer has been tested to design hundreds of 
primer pairs within a few minutes. High-throughput design of primers with a 
strong probability of meeting the requirements of Real Time qPCR will be a 
useful time-saving tool for the validation of next-generation sequencing projects. 
 
FoxPrimer has been a valuable tool for many researchers within our research 
group over the course of its development. It is our hope this program will see 
widespread adoption due to its simple interface and open source nature. 
 
Program Requirements 
 
• Perl >= 5.14.2 
• Perl module dependencies (see ‘INSTALL’ file for specifics) 
• Primer3 command-line version 
241 
 
• Sim4 
• twoBitToFa (Kent Source) 
• FIMO (From MEME) 
• BEDtools 
• SQLite3 
• MySQL 
• OS X or Linux 
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CHAPTER 5 PEAKSTOGENES: AVERAGE GENE PLOT GENERATION AND 
STATISTICAL TESTING 
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Introduction 
 
Gene expression is a highly regulated process that ultimately leads to the 
determination of cellular phenotype and functions. Characterization of the 
patterns and relationships in the regulatory networks controlling gene expression 
at the transcriptional level is much sought after information. This will allow for a 
greater understanding of the mechanism contributing to processes such as 
development, tissue turnover, response to external stimuli, and disease. 
 
Chromatin features including nucleosome positioning, histone modifications, 
hypersensitive regions, and DNA-binding proteins like transcription factors 
contribute to transcriptional regulation. Many of these epigenetic marks have 
been assigned a particular role in transcriptional regulation based on observed 
functions related to candidate genes. Approaches utilizing next-generation 
sequencing to experimentally understand the genome-wide functions of these 
chromatin features have allowed an unprecedented level of insight into and 
understanding of the regulatory roles of many proteins. 
 
Examination of the patterns of chromatin feature locations in relation to gene 
expression from next-generation sequencing data has dramatically increased our 
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understanding of chromatin-mediated regulation of transcription. However, a 
major hurdle in measuring and defining these relationships has been the 
researchers’ ability to manage the data according to their experimental needs. To 
assist in the process of defining patterns and relationships between chromatin 
features and gene expression, we will describe the programming framework 
PeaksToGenes. 
 
PeaksToGenes is designed to help the user identify patterns in sequencing 
results for the purpose of making predictions about the potential transcriptional 
functions of the chromatin features being investigated. A common means to 
begin identifying patterns in chromatin features is to construct an average gene 
profile of the mark across the entire genome. These average gene profiles show 
where a particular mark is most commonly found relative to gene bodies and can 
be used to perform statistical tests to determine how significant a given 
observation is. At the core, PeaksToGenes constructs these average gene 
profiles and then allows the user to query these profiles without manually 
designing scripts to create or extract information. 
 
PeaksToGenes is written in Modern Perl, and relies only on open-source 
dependencies. This design approach allows for a completely exposed API, 
allowing the user to easily write their own extensions for PeaksToGenes should 
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they have more specific experimentally-driven questions. Here, we describe the 
major functions and API of PeaksToGenes. 
 
Average Gene Profiles 
 
PeaksToGenes is designed to test whether the binding profile of a given protein 
is different near one subset of genes versus another subset of genes. These 
gene lists should be large enough so that the group sizes will be sufficient for 
robust statistical testing. Although there are many instances where proteins are 
known to bind distal to gene bodies and have enhancer-type functions, 
PeaksToGenes is focused on proximal binding and therefore focuses on 
genomic regions 10Kb upstream of the transcriptional start site (TSS), within the 
gene body, and 10Kb downstream of the transcriptional termination site (TTS). 
For each gene, PeaksToGenes stores either the number of peaks or the ratio of 
“IP” over “input” reads per relative genomic region (described below), making it 
relatively quick to contrast two lists of genes against one another. 
 
The 10Kb regions upstream of the TSS and downstream of the TTS are split into 
1Kb non-overlapping intervals. If used in “contrast” mode, PeaksToGenes will 
look in each one of these intervals and calculate the ratio of “IP” reads to “input” 
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reads. PeaksToGenes can optionally use a scaling factor, such as sequence 
enrichment scaling (SES) (Diaz et al. 2012) or RPKM (reads per kilobasepair per 
million reads) (Landt et al. 2012), which is multiplicatively applied to the number 
of “input” reads found in the interval. Alternatively, if PeaksToGenes is run in 
“annotate” mode, the number of peak regions will be counted for each relative 
genomic region. 
 
PeaksToGenes looks at the gene body in two ways: based on transcriptional 
regions and based on relative genomic coordinates. The transcriptional regions 
are defined by the function of the transcribed sequences, which fall into four 
categories: five prime untranslated regions (5’-UTRs), exons, introns, and three 
prime untranslated regions (3’-UTRs).  The genomic regions are defined by 
relative coordinates between the TSS and TTS and are divided into ten 
approximately equal length intervals, which we call “gene body deciles”. Because 
the relative coordinates within the gene bodies are not the same length as the 
relative genomic coordinates, the number of peaks or reads found in each 
coordinate are linearly scaled to 1Kb prior to applying the same ratio or counting 
functions described above for flanking regions. 
 
Once PeaksToGenes has defined either the number of peaks or the signal ratio 
for each relative genomic region for each gene in the given RefSeq genome, 
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these scalar numbers are stored in a local SQLite database indexed by genome, 
RefSeq mRNA accession and the name the user has chosen for the 
experimental sample. The user can then specify multiple gene lists to be utilized 
for statistical testing or just simple averaging of the signal ratios or numbers of 
peaks near the list of genes. 
 
Matrix Files 
 
The average genome profile (generated as described above) is stored in the 
local SQLite database. The data can be accessed by the user several ways. 
Often, users will want to create some kind of heat map, or manipulate the data 
using functions separate from the statistical contrast tests provided by 
PeaksToGenes. To that end PeaksToGenes provides the “matrix” function, which 
allows the user to specify a list of RefSeq accessions and a series of datasets 
(from the same genome) for which they would like a tab-delimited file of binding 
information printed to file. Each row represents a particular RefSeq gene, and 
each column represents a relative genomic region for a particular data set. The 
relative regions included in this matrix file are ordered from 10Kb 5’-TSS, gene 
body deciles, to 10Kb 3’-TTS for each dataset (protein) in the order (left to right) 
in which the datasets were defined as arguments for the “matrix” function. We 
often find that the files exported from this function are especially useful for the 
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creation of heat maps and for identifying patterns in protein binding using 
expectation maximization algorithms such as k-means clustering. 
 
Statistical Tests 
 
PeaksToGenes is designed to help the user test the hypothesis “is the binding of 
this protein different near one set of genes versus another?” By defining the 
binding profile of the protein in terms of peaks or signal ratios within gene bodies 
and in the flanking genomic regions, PeaksToGenes creates “populations” of 
scalar data points to which we can apply statistical approaches. In the current 
version of PeaksToGenes, the statistical tests are one-way tests contrasting the 
binding profile of a protein on one set of genes versus another set of genes 
within each relative genomic region. More specifically, PeaksToGenes will take 
two lists of genes and extract all of the binding data in the “1Kb upstream” region 
(or “promoter”) and determine whether the binding data within the two lists is 
significantly different. This is the repeated for each relative genomic region 
defined above.  
 
By default, PeaksToGenes will not run any statistical tests because it is important 
for the user to understand which tests are appropriate for their data. The two 
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tests included in this implementation of PeaksToGenes make very different 
assumptions about the nature of the data in each list, and ignoring these 
assumptions can lead to both false positive and false negative results; referred to 
as type I and type II statistical errors, respectively. Regardless of which 
combination of tests or no tests is chosen by the user, PeaksToGenes will create 
a tab-delimited file containing the sum, mean, and standard error of the mean 
(SEM) of binding data for each relative genomic region for each list of genes. 
 
Fisher-ANOVA 
 
The one-way parametric ANOVA test (Fisher ANOVA) provided by 
PeaksToGenes tests whether the means of two lists are different (Field 2007). 
This tests whether, on average, the binding profile is significantly different in a 
given genomic region near one set of genes versus another set of genes. This 
test may not be appropriate in all cases as it assumes that the data are normally 
distributed. In the case of data derived from peak intervals, this test is never 
appropriate as there are more values of zero than any other, and in the case of 
signal ratio data this must be examined on a case-by-case basis, as often the 
data are not normally distributed. 
 
251 
 
Wilcoxon Rank-Sum (Mann-Whitney U) 
 
The Wilcoxon Rank-Sum (or Mann-Whitney U) Test (Wilcoxon 1945) is used to 
determine whether the values in one list tend to be greater than the values in the 
other list. In the case of PeaksToGenes, this test determines whether the binding 
profiles in a particular relative genomic region near one set of genes tend to have 
higher values than the binding profiles near another set of genes. Instead of 
using the scalar value from the binding profile, this test assigns a rank to each 
value and then determines if the sum of the ranks in each list meet the expected 
values under the assumption that the lists have similar data. This test is most 
appropriate for binding profiles derived from signal ratios and can be used for 
binding profiles derived from peaks data. It should be noted that using binding 
profiles derived from peaks data can be computationally difficult as the number of 
genomic regions with zero peaks is quite high and the algorithm used to rank the 
data will take quite a long time dealing with all the ties found with a zero value. 
 
Implementation 
 
PeaksToGenes is written in Modern Perl, using objective-oriented program 
function encapsulation style. The objective-oriented set of Perl modules imported 
by Moose is used to provide the syntactic sugar for the creation of classes and 
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objects. User-defined experimental information and corresponding binding data is 
stored in a local SQLite database, using the Perl module DBIx::Class to form 
relationships between tables and form the interface between the database and 
the user. These design choices allow for additional Perl modules to be added by 
the user or in future development for the rapid addition of complementary 
functions. 
 
Interface 
 
The primary interface to PeaksToGenes is the script‘peaksToGenes.pl’. This 
script is a command-line interface, which allows the user to perform all the 
requisite functions described herein: installing databases, annotating datasets, 
deleting datasets, and performing statistical contrast tests. The 
‘peaksToGenes.pl’ script uses command-line arguments such as, “--
annotate”, “--contrast”, “--processors”, or “--test_genes”, which are used 
to define input files and settings.  
 
Each of the functions used by PeaksToGenes is encapsulated as an object class 
by Moose, allowing the user to write their own script or Perl module to utilize the 
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PeaksToGenes functions and database utilizing object-oriented programming 
paradigms. 
 
Input Files 
 
When using the “signal_ratio” function, PeaksToGenes expects BED-format files 
of reads for both the IP sample and the input sample. We use the following 
BASH pseudocode to generate these BED-format files from raw reads: 
for sample in IP Input 
do 
# Map to reference genome 
bowtie [bowtie options] [ebwt_files] –S 
${sample}.fastq > ${sample}.sam 
 
# Convert from SAM to BAM 
samtools view –bS ${sample}.sam > ${sample}.bam 
 
# Sort the BAM file 
samtools sort ${sample}.bam ${sample}_sorted 
 
# Remove the unsorted BAM file 
rm ${sample}.bam 
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# Convert the sorted BAM file to BED format 
bamToBed –i ${sample}_sorted.bam > ${sample}.bed 
 
# Remove the sorted BAM file 
Rm ${sample}_sorted.bam 
   
  done 
 
Alternatively, when using the “annotate” function, PeaksToGenes expects a 
BED-format file of intervals an external program or algorithm has defined as 
“peaks”. 
 
Error Handling 
 
There are a multitude of safeguards written into the current implementation of 
PeaksToGenes designed to prevent wasted time and unexpected program 
behavior. The first line of defense against these problems occurs in the main 
PeaksToGenes class ‘PeaksToGenes.pm’, which ensures that all required 
command-line arguments are defined for a given function and are properly 
formatted. If there any of these parameters are in error, PeaksToGenes will 
return an error message to the user, and terminate execution. The second error-
checking function occurs via checking the formatting of each peaks or reads file 
defined by the user to ensure the file adheres to proper BED-format 
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specifications. For each error found in a given file, PeaksToGenes informs the 
user of the type of error and the line at which the error(s) has occurred and will 
then cease execution. Another error-checking function implemented in 
PeaksToGenes is the checking of RefSeq accessions defined for contrast 
testing. If there is an invalid or deprecated accession for the given genome, 
PeaksToGenes returns these accessions to the user, and continues execution 
with the valid accessions found. If too many accessions are invalid, the user can 
choose to terminate execution; the program will still function correctly without 
user intervention. If there are no valid accessions entered, PeaksToGenes will 
exit before trying to extract genomic annotation data and run statistical contrast 
tests. 
 
Parallel Processing 
 
CPU manufacturers are beginning to hit limits in individual processor speeds and 
have begun pushing towards using many cores in parallel. PeaksToGenes is 
designed to take advantage of the ability to utilize multiple processors anywhere 
parallel operations were safe and tested to increase speed of operation. 
Parallelization is accomplished through the Perl module Parallel::ForkManager, 
which relies on the Unix fork operation to carry out instructions in parallel. The 
ability to utilize multiple processors in parallel is especially powerful when 
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PeaksToGenes is used on a computing cluster. Utilizing as many as 24 (a 
limitation of our cluster, not PeaksToGenes) processors in parallel allows for 
rapid execution of the PeaksToGenes functions. Many of the signal ratio 
annotation functions take quite a long time to complete, so parallelization of 
these functions allows for faster generation of results. 
 
Genomic Indexes 
 
In order to understand spatial relationships between the user's dataset and 
genes, a meta-gene profile must be created. To facilitate this process, 
PeaksToGenes uses a set of BED-format coordinate files, which contain 
genomic intervals whose positions are relative to a given RefSeq accession. 
PeaksToGenes does not come with any of these indexes installed, rather it 
provides a function to dynamically add genomic information based on the user's 
needs. This allows a great deal of flexibility, and at the time of writing 
PeaksToGenes is capable of dynamically adding 62 RefSeq genome definitions.  
 
To accomplish these functions, PeaksToGenes::Update::UCSC uses DBIx::Class 
to interact with the UCSC MySQL server to fetch the genomic coordinates of 
each RefSeq transcript as well as the sizes of each chromosome in the genome 
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of interest. These coordinates are then used to define 34 distinct genomic 
locations relative to RefSeq transcript genomic coordinates within the limits of the 
chromosome sizes. Each location is written in a separate BED-format file, and 
the full path to the file is stored in the PeaksToGenes SQLite database by 
PeaksToGenes::Update.  
 
For each relative location, PeaksToGenes creates a BED-format file with the 
coordinates for that relative location for every gene whose coordinates are valid. 
The path to these BED-format files are stored in the PeaksToGenes database, 
so that when the user chooses to annotate a dataset, the location of the files will 
be statically stored within the program and need not be known to the user. If for 
some reason, the user moves or deletes the BED-format relative location files, 
PeaksToGenes will quit during the annotation process, and inform the user that 
the files could not be found prompting the user to run the update function again. 
This will prevent unpredictable behavior and errors in interpretation downstream. 
 
Annotation / Average Gene Profile Creation 
 
With a set of genome-defined indexes in place, PeaksToGenes uses the 
intersectBed utility from the BedTools suite of command-line tools to assign 
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information from the user's dataset into the intervals defined by 
PeaksToGenes::Update. This operation is primarily performed on BED-formatted 
reads files (generated using the pseudocode above). Alternatively, 
PeaksToGenes can use BED-format files corresponding to externally defined 
“peak” intervals. 
 
For each relative genomic index, PeaksToGenes normalizes the number of 
peaks/peak scores/reads per 1Kb. This calculation is done as needed during the 
parsing of the results of the intersectBed command, and allows for bias to be 
reduced from larger sub-genomic regions such as gene body deciles or introns. 
This calculation further allows the raw values for each relative genomic region to 
be interpreted as the aggregate number of peaks/peak scores/reads per Kb. 
 
For each peak (or read interval) found within a particular relative genomic 
location, PeaksToGenes::Annotate::BedTools (for peaks) or 
PeaksToGenes::SignalRatio::BedTools (for reads) stores in memory both the 
number of peaks/reads as well as the aggregate peak scores (from MACS, SPP, 
etc.). These large hash references are then converted into a DBIx::Class insert 
statement by PeaksToGenes::Annotate::Database (for peaks) or 
PeaksToGenes::SignalRatio (for reads), and then inserted into the 
PeaksToGenes database using a bulk insert. 
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SQLite Database 
 
The process of generating an average gene profile is relatively quick. The issue 
is how to store this information in a way that is consistent, so that strict functions 
can be written to interpret and parse the files, and that is less prone to end-user 
tampering, so that PeaksToGenes will have an easier time recalling information 
from annotation/signal_ratio functions. We did not want to come up with an 
additional file format for the rapid storage and retrieval of this type of information, 
so we chose to use a local SQLite database to store the results of the meta-
genome profiles. 
 
Storing the data in a relational database management system (RDBMS) allows 
for strict data types in each field, adding an extra layer of error checking to 
ensure that data is properly handled and that results can be properly interpreted. 
Further, the use of an RDBMS allows for other means of extracting meta-genome 
information from PeaksToGenes database should a user decide to write their 
own implementation to access the database in another language (C++, Python, 
etc.) or through the SQLite command-line. 
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There are many different implementations of SQL-mediated control of RDBMS, 
however, we chose SQLite as we feel it the easiest to implement for end-users, 
especially those who do not have root/admin privileges (such as on a computing 
cluster). SQLite does, however, have some drawbacks in performance as 
compared to MySQL or PostgreSQL, which causes the time for insertion of the 
meta-genome profile data into the database to be quite long (SQLite, at this time, 
does not allow asynchronous transactions). However, we feel that the lack in 
performance is outweighed by the flexibility permitted by SQLite. 
 
Results 
 
Using PeaksToGenes to Identify Patterns in Chromatin Context Prior to Estrogen 
Stimulation in MCF-7 Breast Cancer Cells 
 
To demonstrate the functions of PeaksToGenes, we chose to examine the 
relationships between the chromatin context of MCF-7 breast cancer cells and 
their response to estrogen stimulation. Of particular interest are the positions of 
transcription factors such as ER-alpha and CTCF relative to genes responsive to 
estrogen stimulation. Positional binding of ER-alpha in relation to ER-alpha-
responsive genes has been investigated using other means (Carroll et al. 2006, 
Hurtado et al. 2011, Zwart et al. 2011) as well as the cooperative functions of 
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ER-alpha and CTCF on the promoters of ER-responsive genes (Ross-Innes et al. 
2011). To understand what role the chromatin context may be playing in ER-
response, the positions and binding intensities of the chromatin modifications 
histone 3 lysine 4 trimethylation (H3K4me3), histone 3 lysine 27 acetylation 
(H3K27ac), and histone 3 lysine 27 trimethylation (H3K27me3) were examined 
as well. Functional ER-alpha binding sites are associated with H3K4me3, slightly 
associated with H3K27ac and not significantly associated with H3K27me3 
(Joseph et al. 2010). Data for ER-responsive genes, ER binding, CTCF binding, 
and histone marks were extracted from publicly-available data for each of the 
aforementioned studies. 
 
Using PeaksToGenes, we find that genes responsive to ER-stimulation in MCF-7 
breast cancer cells are significantly enriched in binding of both ER-alpha and 
CTCF near the TSS. Further, we observe that the chromatin near the TSS of ER-
responsive genes is in a predominately open conformation, as H3K4me3 is 
highly enriched at these loci. PeaksToGenes provides a rapid means to perform 
a common form of epigenomics analysis, which produces results similar to those 
produced by home-grown scripting and code. 
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ER-responsive genes are significantly enriched in association with ER-alpha in 
proliferating MCF-7 cells 
 
The binding profile of ER-alpha in MCF-7 cells was defined using the 
PeaksToGenes “signal_ratio” function with input scaling using the sequence 
enrichment scaling algorithm. RefSeq mRNAs defined as responsive to ER-
stimulation after 3 hours were used as the list of “test_genes”, while the 
remaining RefSeq mRNAs on the Affymetrix HGU133A Plus 2 array were used 
as the “background_genes”. Here we observe that regions near the TSS of 
genes responsive to ER-stimulation are significantly enriched in binding of ER-
alpha (Figure 5.1). This is consistent with similar analyses done with ER-alpha 
(Carroll et al. 2006, Hurtado et al. 2011). 
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Figure 5.1 ER-responsive genes are significantly enriched in ER-alpha binding 
near the TSS 
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Figure 5.1 ER-responsive genes are significantly enriched in ER-alpha binding 
near the TSS 
 
PeaksToGenes average gene profile of the binding of ER-alpha as measured by 
the ratio of IP reads over input reads. Blue line is the mean ER-alpha signal ratio 
per relative genomic region near genes responsive to ER-stimulation, while the 
red line is the same data near genes defined as non-responsive to ER-
stimulation. Triangles represent the Wilcoxon Rank Sum p-value generated by 
using this test to compare the binding of ER for ER-responsive genes versus the 
non-responsive genes in each relative genomic region. Error bars are SEM. 
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Genes responsive to ER stimulation are enriched in CTCF binding near the TSS 
 
ER-alpha and CTCF bind many of the same genomic regions, and these co-
binding events are highly functional in response to ER stimulation (Ross-Innes et 
al. 2011). Using PeaksToGenes, we can observe that the same genes, which 
have significant binding of ER-alpha near the TSS are also significantly 
associated with CTCF binding near the TSS (Figure 5.2). It is interesting that 
some of the genes that are not responsive to ER stimulation (red line) show an 
increase in CTCF binding near the TSS, which suggests that CTCF may have 
TSS-centric functions independent of ER-alpha binding in MCF-7 cells. CTCF 
typically binds to open regions of chromatin that are DNAse I-sensitive, and it is 
thought that these CTCF binding events promote the interactions of distal 
enhancer regions with promoter regions (Sanyal et al. 2012, Merkenschlager and 
Odom 2013). Therefore, the ER-independent binding of CTCF within promoter 
regions is not unexpected. 
 
Genes Responsive to Estrogen Signaling are Associated with Open Chromatin 
Marks 
 
To further characterize the pre-estrogen-stimulation chromatin state of genes that 
are responsive to estrogen, we looked the chromatin modifications H3K4me3 
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and H3K27ac, which are associated with transcriptional activation, and 
H3K27me3, commonly associated with transcriptional repression. We used 
PeaksToGenes to address the extent to which more binding of these histones 
was differentially associated with genes responsive to estrogen signaling. 
Functional ER-alpha binding near the TSS of genes is associated with H3K4me3 
(Joseph et al. 2010); using PeaksToGenes, we observe the same association 
between H3K4me3 and genes responsive to ER-stimulation (which has strong 
ER-binding in near the TSS) (Figure 5.3). Because we have chosen to plot these 
three marks on the same scale, it is difficult to resolve some of the finer 
differences in H3K27ac and H3K27me3 binding between the ER-responsive and 
non-responsive genes. However, while the magnitudes of the mean differences 
are not great, we do observe statistically significantly increased levels of 
H3K27ac and reduced levels of H3K27me3 near the TSS of ER-responsive 
genes. These results, combined with the H3K4me3 results, suggest that ER-
responsive genes have an open chromatin configuration near the TSS. 
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Figure 5.2 Genes responsive to ER stimulation are strongly associated with 
CTCF binding near the TSS. 
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Figure 5.2 Genes responsive to ER stimulation are strongly associated with 
CTCF binding near the TSS. 
 
PeaksToGenes average gene profile of the binding of CTCF as measured by the 
ratio of IP reads over input reads. Blue line is the mean CTCF signal ratio per 
relative genomic region near genes responsive to ER stimulation, while the red 
line is the same data near genes defined as non-responsive to ER stimulation. 
Triangles represent the Wilcoxon Rank Sum p-value generated by using this test 
to compare the binding of ER for ER-responsive genes versus the non-
responsive genes in each relative genomic region. Error bars are SEM. 
 
 
 
  
269 
 
Figure 5.3 The TSS of genes responsive to ER stimulation are enriched in open 
chromatin marks 
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Figure 5.3 The TSS of genes responsive to ER stimulation are enriched in open 
chromatin marks 
 
PeaksToGenes average gene profile of the binding of (A) H3K4me3, (B) 
H3K27ac and (C) H3K27me3 as measured by the ratio of IP reads over input 
reads. Blue line is the mean histone mark signal ratio per relative genomic region 
near genes responsive to ER-stimulation, while the red line is the same data near 
genes defined as non-responsive to ER-stimulation. Triangles represent the 
Wilcoxon Rank Sum p-value generated by using this test to compare the binding 
of ER for ER-responsive genes versus the non-responsive genes in each relative 
genomic region. Error bars are SEM. 
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Discussion 
 
PeaksToGenes provides an open source framework for the analysis of 
epigenomic data in a gene-centric manner. The addition of statistical testing 
provides access to robust statistical methods without having to restructure the 
data. PeaksToGenes also provides convenient functions to write the average 
gene profiles to file so the user may perform their own analyses. We further 
demonstrate the ability of PeaksToGenes to reproduce previous results using ER 
stimulation in MCF-7 cells as a model. 
 
Using publicly available datasets we demonstrate a potential use case for 
PeaksToGenes. The analysis provided by PeaksToGenes allows for rapid insight 
into the binding events near a subset of genes. In this case, we examined the 
average profile of genes that are defined as responsive to ER-stimulation (Carroll 
et al. 2006). ER-alpha transcriptional activity occurs near the TSS of actively 
expressed genes marked by H3K4me3, and cooperatively functions with CTCF 
(Joseph et al. 2010, Ross-Innes et al. 2011). 
 
PeaksToGenes is not designed to be the only form of analysis done with 
epigenomic data; rather, PeaksToGenes can be considered as a complementary 
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analysis approach. In no way is PeaksToGenes a replacement for such 
approaches as chromosome segmentation or hidden Markov modeling (Ernst 
and Kellis 2012, Hoffman et al. 2012); however, PeaksToGenes requires minimal 
computational aptitude to find more general patterns and associations between 
protein binding and genes. 
 
Program Requirements 
 
• Perl >= 5.14.2 
• Perl Module dependencies (see ‘INSTALL’ file for details) 
• BEDtools 
• SQLite3 
• MySQL 
• OS X or Linux 
 
Data sources 
 
273 
 
ER-responsive genes 
 
ER-responsive genes in MCF-7 cells are genes defined as ER-responsive after 3 
hours of ER stimulation using Affymetrix arrays (Carroll et al. 2006). 
 
ER-alpha ChIP-seq 
 
ER-alpha binding profile in MCF-7 cells was extracted from (Hurtado et al. 2011). 
 
CTCF and H3K4me3 ChIP-seq 
 
CTCF and H3K4me3 binding profiles in MCF-7 cells were downloaded from 
ENCODE, and produced by the University of Washington ENCODE group 
(ENCODE Project Consortium 2011). 
 
H3K27ac and H3K27me3 ChIP-seq 
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H3K27ac and H3K27me3 binding profiles in MCF-7 cells were downloaded from 
ENCODE and produced by the Stanford / Yale / USC / Hardvard (SYDH) 
(ENCODE Project Consortium 2011).  
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CHAPTER 6: DISCUSSION 
 
Isolation of the in situ nuclear matrix 
 
The nuclear matrix and previous methods of biochemical fractionation has been 
quite a controversial concept, and has resulted in the nuclear matrix being 
maligned as “operationally defined”. Much of the scientific disagreement stems 
from the development of a myriad of protocols to isolate the nuclear matrix and 
thereby questions the functional relevance of this insoluble fraction. While 
compositions of the “matrix” isolated in most procedures are similar in terms of 
the relative amounts of RNA, DNA and proteins, the ultrastructural organization 
of the in situ nuclear matrix is only preserved under specific circumstances 
(Belgrader et al. 1991).  
 
The physical appearance of many nuclear bodies is largely tethered to functional 
activity, suggesting that organizational parameters are synergistically derived 
from physiological demands. Nuclear bodies form de novo, utilize RNA as a 
structural scaffold, and are self-organizing (reviewed in (Dundr and Misteli 
2010)). Given the dynamic relationship between functional demand and structural 
organization, it seems counterintuitive to expect that extracting these nuclear 
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bodies and the nuclear matrix while destroying native structure will result in a 
biochemically faithful isolate.  
 
The nuclear matrix is enriched in newly transcribed RNA, and in close physical 
proximity to open, active chromatin (Bachellerie et al. 1975, Fakan and Nobis 
1978, Fakan and Hughes 1989). The Laemli group developed a protocol to 
isolate matrix-associated DNA, which relies on LiS buffer for extraction 
(Mirkovitch et al. 1984, Izaurralde et al. 1988). Due to differences in the structural 
appearance of the residual structures from the “high salt” and “LiS” matrix 
preparations, DNA isolated from these preparations were defined as matrix 
associated regions “MARs” and scaffold associated regions “SARs” respectively 
(Belgrader et al. 1991). This marked one of the major splits in the nuclear matrix 
field in terms of the functional characterization of NM-DNA. 
 
For both “high salt” and “LiS” matrix preparations, without some form of 
stabilization, many matrix-DNA interactions are lost. Somehow, the experiments 
demonstrating loss of matrix-DNA attachments were not considered in the 
majority of attempts to understand the role of NM-DNA in gene expression 
regulation; most of these protocols are reliant upon methods that destabilize 
matrix-DNA interactions in the preparation of non-stabilized “nuclear halos” prior 
to nuclease digestion and NM-DNA isolation (Maya-Mendoza and Aranda-
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Anzaldo 2003, Linnemann et al. 2008, Keaton et al. 2011). Given the 
functionally-derived organizational properties of nuclear bodies, and the dynamic 
matrix-DNA interactions (Misteli 2010, Dundr and Misteli 2010), the question is 
then, how can native DNA-matrix interactions be extracted using a protocol that 
does not preserve structural integrity or matrix-DNA interactions? As we are 
interested in understanding how malignant nuclear disorganization and nuclear 
matrix transcriptional functions are related, we realized how critical it would be to 
ensure that the methods used to isolate matrix-associated DNA would preserve 
the structural integrity of the nuclear matrix and associated nuclear bodies. 
 
As mentioned above, there are two approaches that are commonly used to 
isolate matrix DNA, both of which rely on the intermediate “nuclear halo” 
preparation prior to nuclease digestion. Using the high salt extraction protocol, 
MARs are enriched, which are experimentally defined as transcriptionally 
repressive (Maya-Mendoza and Aranda-Anzaldo 2003, Rivera-Mulia and Aranda-
Anzaldo 2010, Trevilla-García and Aranda-Anzaldo 2011). In contrast, using the 
“LiS” extraction method, SARs are enriched, which are associated with 
transcriptionally-active genes (Heng et al. 2004, Keaton et al. 2011). One study 
has shown that using both methods side-by-side in the same cell line to extract 
MARs and SARs results in the isolation of DNA sequences enriched near 
transcriptionally silent or active genes respectively (Linnemann et al. 2008). The 
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aforementioned studies used either tiling-PCR or hybridization arrays of a subset 
of the genome to measure the positional enrichment of DNA isolated from the 
nuclear matrix; however, we wanted to generate completely unbiased, genome-
wide measurements of matrix-associated DNA positional enrichment. The 
investment of time, energy, and money to perform a genome-wide screen using 
both the high salt and LiS methods in parallel seemed excessive, and the 
intermediate “nuclear halo” step seemed antithetical to our goal of preserving the 
ultrastructural organization of the in situ nuclear matrix. We therefore began 
looking at alternative approaches to isolating DNA associated with the nuclear 
matrix. 
 
Two approaches became immediately attractive to us in terms of their ability to 
preserve nuclear integrity. One is the use of agarose-suspended digestion and 
electroelution-mediated extraction developed by Jackson and Cook (Jackson and 
Cook 1988). The other uses formaldehyde to stabilize matrix-DNA interactions 
prior to nuclease digestion and salt extraction (Nickerson et al. 1997). The 
formaldehyde-stabilized method was more practical in terms of our ability to 
execute this procedure on a large enough scale to collect sufficient material for 
deep-sequencing library preparation, so we used this approach as a starting 
point for the optimization of the methods described above. This method of matrix 
isolation results in the isolation of a fibrogranular network of RNPs that is 
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structurally indistinguishable from the that which is observed in an intact nucleus 
via regressive EDTA staining and electron microscopy (Nickerson et al. 1997). 
This level of structural preservation, combined with reversibly cross-linked 
stabilization, satisfied our requirements for an experimental approach to isolate 
native DNA-matrix interactions. 
 
Roles of RUNX1 and RUNX2 in recruitment of DNA to the nuclear matrix 
 
RUNX proteins have a conserved amino acid sequence in the C-terminal 
domain, the nuclear matrix targeting signal (NMTS), which is required for 
interaction with the nuclear matrix and transcriptional activities (Zeng et al. 1997, 
1998, Zaidi et al. 2001, 2006). The DNA-binding domain of RUNX proteins is 
located in the N-terminal half of the protein and is not required for interaction with 
the nuclear matrix (Zeng et al. 1997, van Wijnen et al. 2004). It is not known 
whether RUNX proteins recruit genomic DNA to the nuclear matrix, however, it 
has been hypothesized that this is a function of RUNX proteins. 
 
Given that RUNX transcriptional activity was observed to be coupled to 
association with the nuclear matrix, and the strong associations we observed 
between actively expressed gene promoters and RUNX1 binding, we expect to 
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see cooperative enrichment of matrix-associated DNA and RUNX1 in the MDA-
MB-231 cells. However, we did not see any relationships between the two 
datasets nor with RUNX2 and NM-DNA (data not shown), which would lead us to 
believe that RUNX proteins are not involved in the recruitment of DNA to the 
nuclear matrix in MDA-MB-231 cells.  
 
The MDA-MB-231 cells are perhaps not the best cell line to try to understand 
whether RUNX proteins recruit DNA to the nuclear matrix, as the normal 
associations between transcriptional activity and matrix-association are not well 
represented in the malignant MDA-MB-231 cells. This may, in part, explain why 
RUNX functions in breast cancer cells are so different from what is observed in 
hematopoietic and osteoblastic cells. It would be interesting to execute a similar 
study in the context of a blood or bone cell line to understand how related NM-
DNA and RUNX binding are, as a normal organizational context may be more 
representative of RUNX-matrix functions. 
 
Computational tools for analysis of nuclear organization 
 
In this dissertation, we describe the development and application of FoxPrimer 
and PeaksToGenes, which are used to interrogate experimentally derived 
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nuclear organization data. While the specific applications of these tools may 
differ, FoxPrimer and PeaksToGenes are designed to provide results to the user 
in a rapid yet thorough manner and are open source software packages. We 
suggest that the shared design philosophy of FoxPrimer and PeaksToGenes will 
allow groups utilizing next-generation type sequencing approaches a means to 
address some of their specific questions using free, well-documented software. 
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CHAPTER A1 HSA-MIR-30C PROMOTES THE INVASIVE PHENOTYPE OF 
MDA-MB-231 CELLS 
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Introduction 
 
Breast cancer is the most commonly diagnosed disease among women.  
Aggressive breast cancers have high potential to become metastatic, a transition 
that makes clinical intervention very difficult. Therefore, understanding the 
molecular mechanisms that have the potential to facilitate a more invasive or 
metastatic state are critical to understand the progression to metastatic breast 
cancer. 
 
A frequent site of breast cancer metastasis is bone. Upon metastasizing to bone, 
breast cancer cells typically participate in what is known as the "vicious cycle" of 
osteolysis. During this process, breast cancer cells push the normally 
homeostatic signals of bone resorption and bone mineralization towards a more 
resorptive state, thereby causing osteolysis, bone density loss and ultimately 
pathological fractures (Guise et al. 2006). At a molecular level, many of the 
genes upregulated in bone metastatic breast cancer cells are typically involved in 
the process of bone differentiation, such as MMP9, MMP13, VEGF, and PTHLH 
(Pratap et al. 2006). High expression of these genes is clinically associated with 
poor outcome and prognosis for patients (Kingsley et al. 2007). 
 
Runx2 is a transcription factor required for the development of ossified bone 
(Komori et al. 1997). In breast cancer cell lines, Runx2 transcriptionally regulates 
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the expression of many genes known to be important for breast cancer 
metastasis and bone osteolysis and is involved in promoting the osteolytic 
properties of MDA-MB-231 cells as observed in intra-tibial orthotopic injection 
studies (Barnes et al. 2004, Javed et al. 2005, Pratap et al. 2008). 
 
During osteoblast differentiation, a number of small non-coding RNAs, 
microRNAs (including mir30c), have been characterized to target the 3'-UTR of 
the Runx2 transcript as a mechanism of lineage specification. When osteoblast 
progenitor cells commit to the osteoblast lineage, the levels of these Runx2-
targeting miRNAs are significantly reduced, thereby facilitating the developmental 
requirement for increased Runx2 levels as a function of osteoblast differentiation 
(Zhang et al. 2011). 
 
One of the many challenges in cancer is discovering intervention therapies that 
will more specifically target the cancer cells rather than normal cells. As has been 
previously described, mir30c is highly capable to target the Runx2 mRNA and 
reduce Runx2 protein levels (Zhang et al. 2011). We investigated the extent to 
which mir30c down-regulation of RUNX2 protein could reduce the invasive 
phenotype of MDA-MB-231 breast cancer cells. We observed that while mir30c 
does reduce the levels of RUNX2 protein, mir30c significantly increases the 
invasiveness of MDA-MB-231 cells. We used a qPCR screen of in silico 
predicted targets of mir30c whose ontological associations are related to the 
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invasive phenotype. We identify NOV as the target of mir30c, which is likely 
playing a role in the increased invasiveness of MDA-MB-231 cells. The functional 
consequences of altering NOV through siRNA are consistent with the predicted 
function of repressing the invasiveness of MDA-MB-231 cells. These studies 
demonstrate the potential for miRNAs to have quite undesirable effects in vivo 
due to the multiplicity of potential targets and affected pathways. 
 
 
 
Results 
 
hsa-mir-30c promotes the invasiveness of MDA-MB-231 breast cancer cells 
 
In vitro, MCF-7 breast cancer cells are much less invasive than MDA-MB-231 
cells (Morini et al. 2000). We observed statistically significant higher levels of 
endogenous hsa-mir-30c in the more invasive breast cancer cell line MDA-MB-
231 compared to the MCF7 cell line (Figure A.1 A). 
 
In osteoblasts, mmu-mir-30c post-transcriptionally regulates the levels of Runx2 
(Zhang et al. 2011). In the MDA-MB-231 cell line, trans-expression of hsa-mir-
30c or an anti-mir sequence designed to inhibit the function of endogenous hsa-
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mir-30c causes the expected changes in the RUNX2 proteins levels (Figure A.1 
B). Therefore, as in osteoblasts (Zhang et al. 2011), RUNX2 is regulated by hsa-
mir-30c.  
 
To assess the effect of hsa-mir-30c or the anti-mir on the invasive potential of 
MDA-MB-231 cells, we transfected the cells for 48 hours and then loaded the 
cells into transwell culture plates with or without a layer of MatriGel. Cells were 
placed in the top of the transwell, while conditioned osteoblast media was placed 
in the bottom well as a chemoattractant for the cells to mimic a bone 
environment. After the cells were permitted to either migrate or invade towards 
the osteoblastic medium, cells were fixed and stained with HEMA3 (Figure A.1 
C). We observe that hsa-mir-30c expression levels are linked with the invasive 
potential of MDA-MB-231 breast cancer cells. We observe that the anti-mir 
control affects the endogenous levels of RUNX2, so the anti-mir reagents were 
not used for the rest of this study as we were concerned about off-target effects. 
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Figure A.1 hsa-mir-30c promotes the invasiveness of MDA-MB-231 cells and 
regulates RUNX2 levels 
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Figure A.1 hsa-mir-30c promotes the invasiveness of MDA-MB-231 cells and 
regulates RUNX2 levels 
 
(A) qPCR for hsa-mir-30c in MCF-7 and MDA-MB-231 cells, normalized to U6 
RNA. Mean and SEM (error bars) for two technical replicates of two biological 
replicates. * = Student’s t-test p-value < 0.05. (B) Representative Western blots 
of lysates of MDA-MB-231 following 48 hours of transient transfection of non-
targeting miRNA (NT), hsa-mir-30c (30c), non-targeting anti-miRNA (A-NT) and 
anti-hsa-mir-30c (A-30c). Top blot: RUNX2, bottom blot: α-Tubulin.(C) 
Representative Matrigel invasion assay in MDA-MB-231 cells following 48 hours 
of transient transfection of non-targeting miRNA (NT), hsa-mir-30c (30c) and anti-
hsa-mir-30c (A-30c), cells are stained with HEMA3.  
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The canonical 5-prime end of hsa-mir-30c, not the "star" or 3-prime end of hsa-
mir-30c, promotes the invasiveness of MDA-MB-231 cells 
 
During normal miRNA biogenesis, the stem-loop structure that is termed the pre-
miRNA is cleaved and only one end of the longer pre-miRNA is integrated into 
the Dicer complex (Kim 2005). In the case of hsa-mir-30c, the 5'-end of the stem-
loop is most commonly detected as the mature form of the miRNA (Griffiths-
Jones et al. 2006). When the "star" strand or in the case of hsa-mir-30c the 3'-
end of the stem-loop is utilized, a unique set of mRNAs can be targeted by the 
Dicer complex. The phenomenon of alternate utilization of the non-canonical part 
of the pre-miRNA has been observed in leukemic cells (Kuchenbauer et al. 
2011), and we investigated the extent to which this kind of transformation may be 
occurring in MDA-MB-231 metastatic breast cancer cells. 
 
To test whether the hsa-mir-30c-mediated effect on the invasiveness of MDA-
MB-231 cells was due to the canonical miRNA strand, we transfected either hsa-
mir-30c-5p (canonical) or hsa-mir-30c-3p (star) to evaluate potential changes in 
the invasive properties of MDA-MB-231 cells. While hsa-mir-30c-3p does inhibit 
the migration of MDA-MB-231 cells, it does not affect the invasiveness (Figure 
A.2 A-C]. Further, using primers specifically designed to detect either the 5'- or 
3'-form of hsa-mir-30c, we observe that the ratio of the endogenous levels of 5'-
form are several hundred fold higher than the 3'-form in both MDA-MB-231 and 
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MCF-7 breast cancer cells (Figure A.2 D). These results suggest that the 
phenomenon of “star”-strand miRNA activity does not have a major contribution 
to the invasiveness of MDA-MB-231 cells. 
  
294 
 
Figure A.2 The 5'-end of the hsa-mir-30c hairpin is the predominant mature 
miRNA detected in and promoting the invasiveness of MDA-MB-231 cells 
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Figure A.2 The 5'-end of the hsa-mir-30c hairpin is the predominant mature 
miRNA detected in and promoting the invasiveness of MDA-MB-231 cells 
 
(A) Representative images Matrigel invasion assay following 48 hours of 
transient transfection of siRNA of cells stained with HEMA3. (B) Percent of cells 
that migrated through the control inserts, defined by count of stained cells on the 
bottom of the inserts as a percent of cells loaded into inserts. Mean and SEM 
(error bars) for four technical replicates each of two biological replicates. * = p-
value from one-way ANOVA followed by paired t-tests < 0.05. (C) Percent of cells 
that invaded through the Matrigel inserts, normalized to the number of cells that 
migrated through the control inserts. Mean with SEM (error bars) for four 
technical replicates each of two biological replicates. ** = p-value from ANOVA 
with paired follow-up t-tests < 0.01.  (A-C) NT = non-targeting miRNA, 30c = hsa-
mir-30c, and 30c* = hsa-mir-30c-3p. (D) qPCR detection of endogenous hsa-mir-
30c (hsa-mir-30c-5p) and hsa-mir-30c* (hsa-mir-30c-3p) in MCF-7 and MDA-MB-
231 cells. Mean with SEM (error bars) for two technical replicates each of two 
biological replicates normalized to U6 snRNA using the delta-Ct method. * = p-
value from Student’s t-test comparing hsa-mir-30c (hsa-mir-30c-5p) and hsa-mir-
30c* (hsa-mir-30c-3p) in MDA-MB-231 cells < 0.05.  
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Screening via ontological terms and qPCR reveals Nov to be a target of hsa-mir-
30c in MDA-MB-231 breast cancer cells 
 
To identify potential targets of hsa-mir-30c participating in the invasive phenotype 
associated with hsa-mir-30c expression in MDA-MB-231 cells, we performed a 
screen in three steps: 1) generate a list of potential targets based on seed 
sequence targeting potential using the top 300 human mRNA targets from 
microRNA.org; 2) Filter the list based on known functions and ontological terms 
for mRNAs that code for proteins associated with invasion, adhesion, or 
migration, as well as mRNAs that code for transcription factors (Figure A.3 A); 3) 
qPCR screen for functional targets measuring the relative mRNA levels in MDA-
MB-231 cells after being transfected with either non-targeting miRNA or hsa-mir-
30c. We observe NOV to be the most downregulated upon transfection of hsa-
mir-30c (Figure A.3 B). Furthermore, the protein levels of NOV were reduced by 
hsa-mir-30c transfection (Figure A.3 C). The observation that NOV mRNA is 
reduced upon transfection of hsa-mir-30c is highly reproducible as observed in 
multiple biological replicates (Figure A.3 D). Aligning the sequence of hsa-mir-
30c with the sequence of the NOV 3’-UTR, mirSVR predicts three potential 
binding sites for hsa-mir-30c (Figure A.3 E). Further, hsa-mir-30c is unique 
among the mir-30 family members, as a unique site is predicted for hsa-mir-30c 
that is not shared by the other family members (Figure A.4). Based on 
ontological terms associated with Nov, and the reduction of NOV protein levels in 
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response to hsa-mir-30c levels, we hypothesize that NOV may be involved in the 
regulation of MDA-MB-231 invasiveness. 
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Figure A.3 Predictive, ontological, and qPCR screen for hsa-mir-30c reveals 
NOV as a target of hsa-mir-30c 
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Figure A.3 Predictive, ontological, and qPCR screen for hsa-mir-30c reveals 
NOV as a target of hsa-mir-30c 
 
(A) Summary table of genes chosen for qPCR screen based on: mirSVR score 
<http://www.microrna.org> (Betel et al. 2008), NCBI GeneRIF, and ontological 
terms. (B) The log2 of the fold change in mean with SEM detection levels (hsa-
mir-30c / non-targeting miRNA) is plotted for each set of primers for each 
transcript normalized to HPRT using delta-delta Ct method. (C) Representative 
Western blots for lysates of MDA-MB-231 cells following 48 hours of transient 
transfection with non-targeting miRNA (NT) or hsa-mir-30c (30c). Top blot: NOV, 
bottom blot: Lamin C. (D) qPCR for NOV levels for two technical replicates each 
for three biological replicates following 48 hour transient transfections of non-
targeting miRNA (NT) and hsa-mir-30c (30c) normalized to HPRT using delta-
delta Ct method. Mean with SEM. ** = p-value from Student’s t-test < 0.01. (E) 
Alignment of hsa-mir-30c (top sequences) with the 3’-UTR of NOV (bottom 
sequences) with the 5’-positions within the NOV 3’-UTR being relative to the 5’-
start of the 3’-UTR for each of the three predicted targeting sites. Target scores 
are provided by mirSVR. Uppercase letters linked with a “|” character indicates a 
perfect match, while uppercase letters linked with a “:” character indicates a 
wobble pair.  
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Figure A.4 Alignment of mir-30 family members on the NOV 3’-UTR 
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Figure A.4 Alignment of mir-30 family members on the NOV 3’-UTR 
 
For each of the predicted sites of targeting by hsa-mir-30c on the NOV 3’-UTR 
(A-C), if an alignment is possible, the alignment of each mir-30 member is 
presented. Alignment of hsa-mir-30 family members (top sequences) with the 3’-
UTR of NOV (bottom sequences); the 5’-positions within the NOV 3’-UTR are 
relative to the 5’-start of the 3’-UTR for each of the three predicted targeting sites. 
Target scores are provided by mirSVR. Uppercase letters linked with a “|” 
character indicates a perfect match, while uppercase letters linked with a “:” 
indicate a wobble pair. 
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hsa-mir-30c regulation of NOV and invasion is independent of RUNX2 
 
To understand whether there is cross-talk between RUNX2/hsa-mir-30c/NOV, we 
modulated RUNX2 levels in MDA-MB-231 cells using lentivirus-mediated stable 
cell lines expressing either empty vector, wild-type Mus musculus Runx2 or a 
subnuclear-targeting-deficient mutant form of Mus musculus Runx2, which 
inhibits the invasiveness of MDA-MB-231(Barnes et al. 2004, Javed et al. 2005). 
In overexpression conditions, we observe that neither Runx2 nor the RY-mutant 
form of Runx2 altered the protein levels of Nov (Figure A.5 A) or the levels of 
hsa-mir-30c (Figure A.5 B). Further, we tested whether a reduction in the 
endogenous levels of RUNX2 in MDA-MB-231 cells via siRNA, which reduces 
invasiveness of MDA-MB-231 cells (Pratap et al. 2008), affects the levels of NOV 
protein or hsa-mir-30c. Here, we observe that Nov protein levels are not affected 
by RUNX2 knockdown (Figure A.5 C), and that hsa-mir-30c levels, while slightly 
reduced, are not statistically significantly changed by RUNX2 siRNA (Figure A.5 
D). These results suggest that hsa-mir-30c/NOV-mediated regulation of the 
invasiveness of MDA-MB-231 cells is occurring through a RUNX2-independent 
pathway. 
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Figure A.5 RUNX2 does not significantly regulate the expression levels of either 
hsa-mir-30c or NOV 
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Figure A.5 RUNX2 does not significantly regulate the expression levels of either 
hsa-mir-30c or NOV 
 
(A & B) Detection of NOV and hsa-mir-30c levels in MDA-MB-231 stably 
expressing empty vector (EV), wild-type Runx2 (WT), or R398A/Y428A mutant 
Runx2 (RY). (A) Representative Western blots of MDA-MB-231 stable cell 
lysates. Top blot: Runx2 (top band: transgenic murine Runx2, lower band: 
endogenous human RUNX2). Middle blot: NOV. Lower blot: Lamin C. B) qPCR 
detection for hsa-mir-30c in consecutive (N=2) passages of stable MDA-MB-231 
cells normalized to U6 snRNA. (C & D) Detection of Nov and hsa-mir-30c 
following 48 hours of transient transfection of non-targeting siRNA (NS) and 
RUNX2 siRNA (siR2). (C) Representative Western blots of MDA-MB-231 lysates 
following 48 hours of siRNA transfection. Vertical dashed line indicates that the 
image of the blot was cut for figure. Top blot: RUNX2. Middle blot: NOV. Lower 
Blot: α-Tubulin. (D) qPCR detection of hsa-mir-30c levels of two technical 
replicates each of four biological replicates following 48 hour transfection of 
siRNA. p-value from Student’s t-test: approaching statistical significance. B,D) 
Bars equal mean, error bars equal SEM. 
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NOV inhibits the invasiveness of MDA-MB-231 cells 
 
To determine the involvement of NOV in the invasive phenotype of MDA-MB-231 
cells, we used siRNA specific for Nov to knock down the protein (Figure A.6 A) 
and observed the effects of reduced NOV on MDA-MB-231 invasiveness. When 
NOV protein is significantly reduced, similar to hsa-mir-30c overexpression, the 
invasiveness of MDA-MB-231 cells is significantly increased (Figure A.6 B-D). 
These results suggest that the targeting of NOV by hsa-mir-30c is a contributing 
factor in the invasive phenotype imparted to the MDA-MB-231 cells by hsa-mir-
30c. 
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Figure A.6 NOV inhibits the invasiveness of MDA-MB-231 cells 
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Figure A.6 NOV inhibits the invasiveness of MDA-MB-231 cells. 
 
(A) Representative Western blot for NOV (upper blot) and tubulin (lower blot) 48 
hours post-transfection with siRNA. Vertical dashed line indicates where image of 
gel was cut for figure. (B) Representative image of HEMA-3 stained cells, which 
migrated through either the control inserts (upper row) or Matrigel inserts (lower 
row) after 48 hours of transfection with siRNA. (C) Quantification of 4 technical 
replicates of 2 biological replicates measuring the percent of cells that migrated 
through the control inserts (100% being the number of cells loaded into the 
inserts). (D) Quantification of 4 technical replicates of 2 biological replicates 
measuring the percent of cells that invaded through the Matrigel normalized by 
the number of cells migrated through the control inserts. (A-D) NS = Non-
silencing siRNA, siNOV = NOV siRNA. (C & D) Bars equal mean, error bars 
equal SEM. ** = Student’s t-test p-value < 0.01. 
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Discussion 
 
Here we identify a novel pathway by which hsa-mir-30c promotes the 
invasiveness of the MDA-MB-231 cell line through targeting of NOV. 
Concomitant reductions in the levels of both NOV and RUNX2 upon increased 
levels of hsa-mir-30c causes increased invasiveness of the MDA-MB-231 cells. 
Demonstrating the specificity of NOV’s involvement in the invasive phenotype 
observed, transfection of siRNA targeting NOV results in significant increases in 
the invasiveness of MDA-MB-231 cells. 
 
While it is clear that RUNX2 plays a major role in promoting the osteomimetic 
and osteolytic properties of MDA-MB-231 cells (Barnes et al. 2004, Javed et al. 
2005, Pratap et al. 2008), it remains unclear how RUNX2 levels are regulated at 
both the transcriptional and post-transcriptional levels in breast cancer cells. mir-
30c targets Runx2 in osteoblasts, and during osteoblast differentiation hsa-mir-
30c levels are reduced in concert with increased levels of Runx2, a process that 
is required for proper mineralization of osteoblasts (Zhang et al. 2011).  
 
The mir-30 family shares a conserved seed sequence. However, our in silico 
research suggests that seed sequence differences may give rise to selectivity of 
targeting among mir-30 members. This is particularly interesting taking into 
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account a recent study showing that hsa-mir-30a targets the 3’-UTR of VIM, 
causing reduced VIM protein levels and invasiveness of MDA-MB-231 cells 
(Cheng et al. 2012). While levels of VIM and hsa-mir-30a were outside the scope 
of this study, we do observe that hsa-mir-30a does not appear to be a strong in 
silico-predicted target of NOV, whereas hsa-mir-30c both in silico and in vitro 
appears likely to target NOV. We did not examine the extent to which hsa-mir-
30c may be targeting VIM in our system; however, the functional consequence of 
increased invasiveness of MDA-MB-231 cells following the reduction of NOV 
through either hsa-mir-30c or NOV-siRNA suggests that the invasiveness of 
MDA-MB-231 cells is quite sensitive to NOV levels. It is also quite interesting that 
these mir-30 miRNAs appear on many chromosomes rather than co-regulated in 
a cluster, and are involved in the regulation of a myriad of pathways such as 
tumor suppression (p53) (Li et al. 2010), apoptosis (BCL) (Jia et al. 2011), and 
epithelial to mesenchymal transition (VIM) (Cheng et al. 2012). Individual 
members of the mir-30 family have been implicated in both tumor suppression 
and oncogenesis; it is therefore difficult to define the family as a “tumor 
suppressive” or “oncogenic”. This ambiguity makes studying the functions of the 
mir30 family members on a case-by-case basis critical for understanding the 
basis of post-transcriptional molecular mechanisms of disease. The relative 
levels of the mir-30 family members and their temporal expression may play a 
critical role in disease progression. 
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NOV appears to play a context-sensitive role in oncogenesis/tumor suppression 
(Brigstock 2003). In several cancers that develop from mesenchymal tissues, 
NOV has been shown to promote tumor growth and metastasis (Manara et al. 
2002, Benini et al. 2005, Vallacchi et al. 2008). By contrast, in the context of 
brain cancer NOV appears to inhibit tumor progression (Fu et al. 2004, Sin et al. 
2008). While it is unclear what the function of NOV is when looking at breast 
cancer cell line data (Ghayad et al. 2009, Sin et al. 2009), NOV expression in 
human tissue samples of breast cancer shows a clear negative association 
between NOV expression and late-stage and metastatic disease (Jiang et al. 
2004). These histological results strongly suggest that in breast cancer, a 
disease that develops from epithelial tissue, NOV functions to inhibit disease 
progression.  We demonstrate that a major function of NOV is inhibition of the 
invasive phenotype of a metastatic breast cancer cell line (MDA-MB-231), similar 
to the associations of NOV expression with disease progression and metastasis 
in patients. 
 
Materials and Methods 
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RNA isolation 
RNA was isolated using Qiagen miRNAeasy Mini Kit (217004) following the 
manufacturer's recommended protocol with optional in-column DNAse I digestion 
of genomic DNA (Qiagen RNase-Free DNase Set 79254). 
 
miRNA amplification and detection 
Complimentary miRNA-specific cDNA was amplified and detected using Applied 
Biosystems TaqMan MicroRNA Assays for hsa-mir-30c (#4427975) hsa-mir-30c-
2* (#4427975) and RNU6B (#4427975). 
 
cDNA amplification and detection  
cDNA was amplified from equal quantities of total cellular RNA for each 
treatment or cell line. cDNA was amplified using the Invitrogen SuperScript First-
Strand Synthesis System for RT-PCR (#11904-018) according to the 
manufacturer's protocol. Reactions were volumetrically diluted, and reaction 
products were used as templates for Real Time qPCR using Bio-Rad iQ SYBR 
Green Supermix (#170-8880). 
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cDNA qPCR primers 
Real Time qPCR primers were designed using FoxPrimer (www.foxprimer.org) 
and validated for efficiency by standard curve using cDNA amplified from 
untreated MDA-MB-231 cells. 
 
 
Protein isolation and Western blotting 
Cells grown on tissue culture plates were placed directly on ice, and washed 
twice with PBS supplemented with Roche cOmplete, EDTA-free Protease 
Inhibitor Cocktail (#11873580001) and 25μM MG132 (Calbiochem (EMD 
Millipore) CAS 133407-82-6). Cells were scraped into screw-top microcentrifuge 
tubes, gently spun down to pellet cells and excess PBS was aspirated and 
discarded. Cells were snap-frozen in liquid nitrogen. Protein lysates were 
prepared by the addition of RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 2mM 
EDTA, 1% v/v NP-40, 0.1% w/v SDS, 1x Roche cOmplete, EDTA-free Protease 
Inhibitor Cocktail and 25μM MG132) and placing tubes on a 100°C heat block for 
10 minutes. Protein lysates were quantified using Pierce BCA Protein Assay Kit 
(#23225) according to manufacturer's instructions. 50μg protein per sample was 
loaded onto an SDS-PAGE gel. SDS-PAGE was performed as described (Jitesh 
Cancer Research Paper). Briefly, lysates were run through an 8.5% acrylamide 
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gel, and then transferred to a PVDF Transfer Membrane (Thermo Scientific 
#88518). 
Membranes were blocked with 5% (w/v) milk (BioRad #170-6404XTU) in PBS 
and then subjected to immunodetection using the following primary antibodies 
and dilution factors in 1% (w/v) milk in PBS: Nov (Santa Cruz Biotechnology H-71 
sc-50304 1:1000), Lamin A/C (Santa Cruz Biotechnology N-18 sc-6215 1:5000), 
α-Tubulin (Santa Cruz Biotechnology H-300 sc-5546 1:2000), Runx2 (Lab 
hybridoma clone 8G5 1:1000). Secondary antibodies used were from Santa Cruz 
Biotechnology and were diluted 1:5000 in 1% (w/v) milk in PBS: donkey anti-goat 
IgG-HRP (sc-2020), goat anti-mouse IgG-HRP (sc-2005), and goat anti-rabbit 
IgG-HRP (sc-2004). After incubation with primary and secondary antibodies, the 
membranes were washed three times for thirty minutes each with 0.1% (v/v) 
Tween-20 in PBS. HRP reaction was achieved by one minute incubation with 
Perkin Elmer Western Lightning ECL (NEL102001EA). Membranes were 
exposed to Kodak BioMax Light File for Chemiluminescent Imaging (#868-9358) 
in serial exposure times to empirically determine the exposure time at which 
signal is most linear. 
 
Matrigel invasion and migration assays 
Proliferating MDA-MB-231 cells were trypsinized and counted using Cellometer 
Auto T4 Cell Counter. A cell suspension of 100,000 cells/mL in growth medium 
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was prepared and 100μL of the suspension was loaded into each BD Matrigel 
24-well 8.0 µm PET Membrane Invasion Chamber (#354483). Matrigel coated 
plates, and control insert plates had 500μL NIH3T3-conditioned medium loaded 
in the bottom as the chemoattractant. Plates and chemoattractant medium were 
incubated at 37°C for 3-4 hours prior to loading MDA-MB-231 cells. Cells were 
incubated for 16 hours at 37°C in 5% CO2 and then fixed and stained using the 
Fisher HealthCare PROTOCOL Hema 3 Manual Staining System (#22-122-911) 
according to the manufacturer's instructions. Cotton swabs were used to 
eliminate cells which did not migrate/invade as well as Matrigel. Cells were 
counted using an inverted light microscope. 
 
Transient transfection 
Proliferating MDA-MB-231 cells were transfected with 50nM of siRNA/miRNA 
using Oligofectamine (Invitrogen #12252-011) accoding to the Oligofectamine 
protocol. 
 
siRNAs 
Dharmacon SMARTpool: ON-TARGETplus RUNX2 siRNA (L-012665-00-0005) 
Dharmacon SMARTpool: ON-TARGETplus NOV siRNA (L-010527-00-0005) 
Dharmacon ON-TARGETplus Non-targeting Pool (D-001810-10-05) 
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miRNAs and anti-miRNAs 
Dharmacon miRIDIAN microRNA hsa-mir-30c-1 mimic (C-300542-03-0005) 
Dharmacon miRIDIAN microRNA hsa-mir-30c-1* mimic (C-301199-01-0005) 
Dharmacon miRIDIAN microRNA hsa-mir-30c-1 haripin inhibitor (IH-300542-07-
0005) 
Dharmacon miRIDIAN microRNA Mimic Negative Control #1 (CN-001000-01-05) 
Dharmacon miRIDIAN microRNA Hairpin Inhibitor Negative Control #1 (IN-
001005-01-05) 
 
Screen for hsa-mir-30c targets 
The top 300 targets of hsa-mir-30c based on mirSVR were downloaded from 
microrna.org in January, 2011. Gene symbols were used to access gene 
ontology (GO) terms from DAVID (http://david.abcc.ncifcrf.gov/) and gene 
reference into function (GeneRIF) from NCBI 
(http://www.ncbi.nlm.nih.gov/gene/about-generif). Genes whose GO terms or 
GeneRIFs were associated with invasion, migration, extracellular matrix, or 
transcription factors were selected and qPCR primers were designed. After 48 
hours of transfection, RNA was isolated, cDNA was amplified and Real Time 
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qPCR was carried out to detect the relative levels of mRNAs following 
transfection with hsa-mir-30c. 
 
Cell lines 
Cell lines were grown and maintained as previously described (Jitesh Cancer 
Research paper). 
 
Stable cell lines 
Constructs and stable cell lines were generated as previously described (Pande 
et al. 2013). 
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Global genomic analysis of AML1-ETO and transcriptional co-regulators in 
t(8;21) leukemia 
Trombly, D.J., Whitfield, T.W., Padmanabahn, S., Dobson, J.R., Gordon, J.A., 
Lian, J.B., van Wijnen, A.J., Stein, J.L., and Stein, G.S.* 
 
Abstract 
 
The acute myeloid leukemia-related t(8;21) fusion protein AML1-ETO impairs the 
function of AML1 and other myeloid transcription factors, which results in 
differentiation arrest and increased self-renewal properties. The oncogenic 
phenotype caused by AML1-ETO has been primarily studied at single gene 
resolution, therefore we utilized chromatin immunoprecipitation-sequencing 
(ChIP-seq) to understand the global contributions of AML1-ETO and associated 
co-regulatory proteins to the leukemic properties of the t(8;21) model cell line 
Kasumi-1. We find that both AML1 and AML1-ETO are more associated with the 
nuclear co-repressor protein (N-CoR) as compared to the histone 
acetyltransferase p300, which indicates a bias towards transcriptional repression 
as a mechanism for self-renewal and differentiation arrest. Terms identified by 
independent gene ontology analyses show significant overlap between the 
AML1, AML1-ETO, and N-CoR, datasets but not for p300, further suggesting that 
these proteins function cooperatively. To understand the alternative functions of 
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AML1-ETO, de novo motif discovery was used to identify potential co-regulatory 
DNA-binding proteins. Genomic regions co-occupied by AML1-ETO and N-CoR 
in Kasumi-1 cells are enriched in PU.1, RUNX1 and CEBPβ motifs indicating that 
PU.1 may be important for the repressive functions of AML1-ETO and N-CoR. In 
summary, our study identified a RUNX1/AML1-ETO/N-CoR gene regulatory 
network that can be used to interrogate the molecular mechanisms of 
differentiation arrest in t(8;21) leukemia. 
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Genomic occupancy of RUNX2 with global expression profiling identifies 
novel mechanisms regulating osteoblastogenesis 
Wu, H., Whitfield, T.W., Gordon, J.A., Dobson, J.R., Moore, J., van Wijnen, A.J., 
Stein, J.L., Lian, J.B., and Stein, G.S.* 
 
Abstract 
 
Proliferation and differentiation of osteoblasts are highly regulated during bone 
development and formation, as well as normal turnover and repair in the adult 
skeleton. Runx2, the master regulator of osteoblastogenesis, directs a 
transcription program necessary for bone formation through both transcriptional 
and epigenetic mechanisms. While individual Runx2 gene targets have been 
identified, insight into the broad spectrum of Runx2 functions is obtainable by 
global analysis of Runx2 binding. Here, we performed genome-wide 
characterization of Runx2 occupancy at three major stages of osteoblast 
differentiation: proliferation, matrix deposition and mineralization. Novel findings 
include: 1) distinct patterns of Runx2 distribution in genomic regions including 
upstream, proximal promoters, introns, and exons, and intergenic regions; 2) 
greater than 80% of all Runx2 binding occurs in non-proximal promoter regions 
indicating that Runx2 function extends beyond classical transcriptional control; 3) 
Runx2 binding profiles during osteoblast differentiation that result in functional 
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changes in gene expression; and 4) novel biological targets and validated 
functional cis-elements regulated by Runx2.  These data comprise a 
comprehensive map of Runx2 interactions with chromatin revealing gene 
regulatory roles, as well as potential involvement in other nuclear functions and 
chromatin organization in developing osteoblast. 
  
322 
 
Disruption of the RUNX2 response to SMAD signaling affects bone 
turnover in adult mice 
Lou, Y., Dobson, J.R., Wu, H., Frederick, D., Hussain, S., van Wijnen, A.J., 
Stein, G.S., Lian, J.B., Stein, J.L.* 
 
Abstract 
 
Bone morphogenetic protein (BMP) and transforming growth factor-β (TGFβ) are 
required for bone formation and bone turnover in vivo. Previous studies have 
shown that three critical residues (HTY426-428) of the transcription factor 
RUNX2 are required for its interaction with SMAD proteins. Mutation of HTY426-
428 to AAA426-428 can abolish the activity of RUNX2 to execute and complete 
BMP2/ TGFβ signaling for osteoblasogenesis in vitro. Here, we describe a 
mouse model with this triple amino acid mutation inserted into the endogenous 
RUNX2 locus to test the consequences of disruption of a Runx2-Smad 
transcriptional complex in vivo. The RUNX2HTY426-428AAA mice have grossly 
normal skeleton at the birth. Histological and µCT imaging analysis of 
RUNX2HTY426-428AAA mice beyond three months of age revealed similar bone 
lengths but extended lengths of trabecular area of tibiae and femurs (P<0.01) as 
compared to wild-type mice of matched ages. To define pathways affected by the 
HTY mutation that may be causing the observed trabecular phenotype, genome-
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wide transcriptome analysis was performed. Proliferating primary osteoblasts 
isolated from newborn RUNX2HTY426-428AAA mice or wild-type mice were 
cultured with or without BMP2 treatment and gene expression was measured 
using Affymetrix GeneChip Mouse Genome 2.0 arrays. The analyzed result has 
revealed that disruption of Runx2-Smad interaction can alter 860 genes’ 
response to the BMP2 signaling pathway. Ontological terms associated with 
these genes were examined to identify biological themes associated with each 
group of genes. This analysis revealed an increase in proliferation-related and 
bone-related genes combined with reduced expression of genes involved in 
adipocyte and chondrocyte differentiation. Thus, coordinated changes in the 
expression of these genes can cause a cell autonomous defect. By ex vivo and 
in vivo studies, we have also found that the RUNX2HTY426-428AAA mice 
exhibited a slightly enhanced osteogenesis differentiation of calvarial osteoblast 
and bone marrow stromal cells (BMSCs), an inhibition of osteoclast and 
adipocyte lineage differentiation of BMSCs, and accelerated bone fracture-
healing process. These observations were mirrored in our analysis of 
proliferating primary osteoblasts. These findings indicate that the bone resorption 
is compromised by the Runx2HTY mutation, while bone formation is slightly 
increased in RUNX2HTY426-428AAA mice, which caused increased trabecular 
bone in our RUNX2HTY426-428AAA knock-in mice. Taken together, our findings 
suggest that a RUNX2-SMAD functional complex may be dispensable for normal 
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skeletal development, but is required for the balance between bone formation 
and bone resorption in vivo. 
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Regulation of breast cancer cell proliferation and metabolism by SWI/SNF 
chromatin remodeling enzyme ATPases 
Wu, Q., Madany, P., Akech, J., Dobson, J.R., Douthwright, S., Underwood, J.M., 
Colby, J.L., van Wijnen, A.J., Stein, J.L., Chiosea, S., Lian, J.B., Stein, G.S., 
Imbalzano, A.N., Nickerson, J.A.* 
 
Abstract 
 
The mammalian SWI/SNF complexes mediate ATP-dependent chromatin 
remodeling that functions as a master regulator of gene expression in a broad 
range of biological function. Dysregulation of this process has been shown to 
play an important role in oncogenic transformation. Human SWI/SNF consists of 
at least nine subunits, including one of two mutual exclusive ATPases hBRM 
(human Brahma) and BRG1 (Brahma-Related Gene 1). Several subunits of this 
complex, SNF5, BAF57 and BAF180, have been documented as tumor 
suppressors in human and mice BRG1 is commonly considered as a tumor 
suppressor based on the observations that it is frequently deleted in lung cancer, 
and that ~10% of Brg1 heterozygous mice developed mammary tumors. 
However, there is an increasing body of evidences indicated that BRG1 may 
function differently in melanoma, prostate cancer and glioma. BRG1 and BRM 
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are expressed in nearly all breast cancer cell lines, and their role in breast cancer 
has yet not been fully characterized.  
 
We reported here that BRG1 and BRM expression is up-regulated in primary 
human breast cancers. Knockdown of these enzymes in metastatic human 
breast cancer MDA-MB-231 cells decreased cell proliferation by extending cell 
cycle without cell cycle arrest in a specific phase. Loss of BRG1/BRM had a 
more profound effect on anchorage-independent growth and tumor-initiation 
progenitor population. When injected into mammary fat pad, those knockdown 
cells were unable to or formed much smaller tumors. We link the proliferation 
defect to the observation that BRG1/BRM regulates fatty acid synthesis by 
binding to the promoters of and controlling expression of key metabolic enzymes 
controlling fatty acid synthesis such as ACC and FASN.  An additional 
mechanism of regulation occurs via BRG1/BRM directly interacting with AMPK to 
sequester it from inactivate ACC.  As a consequence, inhibition of BRG1/BRM 
expression sensitized cancer cells to chemotherapeutic agents, suggesting that 
the SWI/SNF ATPases may have potential as a therapeutic target for malignant 
breast cancer. 
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Runx2 transcriptional activation of Indian Hedgehog and a downstream 
bone metastatic pathway in breast cancer cells. 
Pratap, J., Wixted, J.J., Gaur, T., Zaidi, S.K., Dobson, J.R., Gokul, K., Hussain, 
S., van Wijnen AJ., Stein, J.L., Stein, G.S., Lian, J.B. Cancer Res. 2008 October; 
68(19): 7795. 
 
Abstract 
 
Runx2, required for bone formation, is ectopically expressed in breast cancer 
cells. To address the mechanism by which Runx2 contributes to the osteolytic 
disease induced by MDA-MB-231 cells, we investigated the effect of Runx2 on 
key components of the "vicious cycle" of transforming growth factor beta 
(TGFbeta)-mediated tumor growth and osteolysis. We find that Runx2 directly 
up-regulates Indian Hedgehog (IHH) and colocalizes with Gli2, a Hedgehog 
signaling molecule. These events further activate parathyroid hormone-related 
protein (PTHrP). Furthermore, Runx2 directly regulates the TGFbeta-induced 
PTHrP levels. A subnuclear targeting deficient mutant Runx2, which disrupts 
TGFbeta-induced Runx2-Smad interactions, failed to induce IHH and 
downstream events. In addition, Runx2 knockdown in MDA-MB-231 inhibited IHH 
and PTHrP expression in the presence of TGFbeta. In vivo blockade of the 
Runx2-IHH pathway in MDA-MB-231 cells by Runx2 short hairpin RNA inhibition 
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prevented the osteolytic disease. Thus, our studies define a novel role of Runx2 
in up-regulating the vicious cycle of metastatic bone disease, in addition to 
Runx2 regulation of genes related to progression of tumor metastasis. 
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Transcriptional corepressor TLE1 functions with Runx2 in epigenetic 
repression of ribosomal RNA genes. 
Ali, S.A., Zaidi, S.K., Dobson, J.R., Shakoori, A.R., Lian, J.B., Stein, J.L., van 
Wijnen, A.J., Stein, G.S.* Proc. Natl. Acad. Sci. U.S.A. 2010 March; 107(9): 
4165. 
 
Abstract 
 
Epigenetic control of ribosomal RNA (rRNA) gene transcription by cell type-
specific regulators, such as the osteogenic transcription factor Runx2, conveys 
cellular memory of growth and differentiation to progeny cells during mitosis. 
Here, we examined whether coregulatory proteins contribute to epigenetic 
functions that are mitotically transmitted by Runx2 in osteoblastic cells. We show 
that the transcriptional corepressor Transducin Like Enhancer-1 (TLE1) 
associates with rRNA genes during mitosis and interphase through interaction 
with Runx2. Mechanistically, depletion of TLE1 relieves Runx2-mediated 
repression of rRNA genes transcription and selectively increases histone 
modifications linked to active transcription. Biologically, loss of TLE-dependent 
rRNA gene repression coincides with increased global protein synthesis and 
enhanced cell proliferation. Our findings reinforce the epigenetic marking target 
genes by phenotypic transcription factors in mitosis and demonstrate a 
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requirement for retention of coregulatory factors to sustain physiological control 
of gene expression during proliferation of lineage committed cells. 
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Cancer-related ectopic expression of the bone-related transcription factor 
RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation 
and motility. 
Leong, D.T.*, Lim, J., Goh, X., Pratap, J., Pereira, B.P., Kwok, H., Nathan, S., 
Dobson, J.R., Lian, J.B., Ito, Y., Voorhoeve, P.M., Stein, G.S., Salto-Tellez, M., 
Cool, S.M., van Wijnen, A.J.* Breast Cancer Res. 2010 October; 12(5):R89. 
 
Abstract 
 
INTRODUCTION: 
Metastatic breast cancer cells frequently and ectopically express the transcription 
factor RUNX2, which normally attenuates proliferation and promotes maturation 
of osteoblasts. RUNX2 expression is inversely regulated with respect to cell 
growth in osteoblasts and deregulated in osteosarcoma cells. 
METHODS: 
Here, we addressed whether the functional relationship between cell growth and 
RUNX2 gene expression is maintained in breast cancer cells. We also 
investigated whether the aberrant expression of RUNX2 is linked to phenotypic 
parameters that could provide a selective advantage to cells during breast cancer 
progression. 
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RESULTS: 
We find that, similar to its regulation in osteoblasts, RUNX2 expression in MDA-
MB-231 breast adenocarcinoma cells is enhanced upon growth factor 
deprivation, as well as upon deactivation of the mitogen-dependent MEK-Erk 
pathway or EGFR signaling. Reduction of RUNX2 levels by RNAi has only 
marginal effects on cell growth and expression of proliferation markers in MDA-
MB-231 breast cancer cells. Thus, RUNX2 is not a critical regulator of cell 
proliferation in this cell type. However, siRNA depletion of RUNX2 in MDA-MB-
231 cells reduces cell motility, while forced exogenous expression of RUNX2 in 
MCF7 cells increases cell motility. 
CONCLUSIONS: 
Our results support the emerging concept that the osteogenic transcription factor 
RUNX2 functions as a metastasis-related oncoprotein in non-osseous cancer 
cells. 
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A RUNX2-HDAC1 co-repressor complex regulates rRNA gene expression 
by modulating UBF acetylation. 
Ali, S.A., Dobson, J.R., Lian, J.B., Stein, J.L, van Wijnen, A.J., Zaidi, S.K., Stein, 
G.S.* J. Cell Sci. June 2012; 125(Pt 11): 2732. 
 
Abstract 
 
The osteogenic and oncogenic transcription factor RUNX2 downregulates the 
RNA polymerase I (RNA Pol I)-mediated transcription of rRNAs and changes 
histone modifications associated with the rDNA repeat. However, the 
mechanisms by which RUNX2 suppresses rRNA transcription are not well 
understood. RUNX2 cofactors such as histone deacetylases (HDACs) play a key 
role in chromatin remodeling and regulation of gene transcription. Here, we show 
that RUNX2 recruits HDAC1 to the rDNA repeats in osseous cells. This 
recruitment alters the histone modifications associated with active rRNA-
encoding genes and causes deacetylation of the protein upstream binding factor 
(UBF, also known as UBTF). Downregulation of RUNX2 expression reduces the 
localization of HDAC1 to the nucleolar periphery and also decreases the 
association between HDAC1 and UBF. Functionally, depletion of HDAC1 relieves 
the RUNX2-mediated repression of rRNA-encoding genes and concomitantly 
increases cell proliferation and global protein synthesis in osseous cells. Our 
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findings collectively identify a RUNX2-HDAC1-dependent mechanism for the 
regulation of rRNA-encoding genes and suggest that there is plasticity to 
RUNX2-mediated epigenetic control, which is mediated through selective mitotic 
exclusion of co-regulatory factors. 
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